












The Global Burden Attributable to Low Bone 
Mineral Density 
 







Aquesta tesi doctoral està subjecta a la llicència Reconeixement 3.0. Espanya de Creative 
Commons. 
 
Esta tesis doctoral está sujeta a la licencia  Reconocimiento 3.0.  España de Creative 
Commons. 
 




The Global Burden 
Attributable to Low Bone 
Mineral Density 
 
Lídia Sànchez Riera1,2 
PhD Supervisors:  
Prof Joan Miquel Nolla Solé1 
Prof Lyn March2 
 
1 Institut d’Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge-
Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain 
2 Northern Clinical School, Institute of Bone and Joint Research, Royal North Shore 
Hospital, University of Sydney, St Leonards, New South Wales, Australia. 
 























    
 










Let this PhD be an 
acknowledgement of the many 
steps you took towards the 
improvement of people’s health. 
The memory of you both and your 





The first acknowledgements go for my thesis directors Professor Lyn March, from 
Sydney University, and Professor Joan Miquel Nolla, from Universitat de Barcelona.  
This thesis and all the transversal experience acquired with it would have never 
happened without them.  
 
Thank you, Joan Miquel, for being such an open-minded leader, genuinely fond of 
international exchanges in both directions. Your encouragement to chase excellence 
and your love for the good job have been key to follow this path, and even when 
times were tough, you have always been there in the other side, maintaining the 
bridge between universities, holding my hand. Some of your attitudes and ideas 
have had a great impact in my life, and now, I hope you feel very proud of our 
achievements together.  
 
For Lyn March I have, no doubt, the most important acknowledgements to make. 
Lyn, you opened me the doors to a life-changing experience and for that I will be 
eternally grateful. I deeply admire you as a professional and as a human being. Your 
generosity to mentor me and to take me in your life is one of the most amazing 
experiences I will ever have. Your dedication and vocation into your work, as well as 
the care for your love ones, it is inspiring to me. Mentor, colleague, friend and 
mummy. You have a unique place in my heart. I love you, and love my Australian 
family with my dad Steve and my little brothers Sean, Ben and Sam.     
 5 
I want to thank Philip Sambrook and the Institute of Bone and Joint Research (IBJR) 
to adopt me under their wings. The outstanding work done by Philip during his career 
was the initial magnet to contact the IBJR. It is an honor for me to see my name 
sharing authorship with Philip in my first two articles written with the IBJR.  I 
remember the words of Philip during my first farewell in Australia, after a short period 
of three months, “we receive lots of visiting fellows but rarely someone fitting so well 
as you did”…he made my day.   
 
I have numerous acknowledgments to make within the IBJR. I am particularly 
grateful to Charles (Jian Sheng) Chen, who was consistently supportive in all my 
projects and had a great patience to help me with the statistics, and who also gladly 
accepted to be part of the osteoporosis review team for the Global Burden of 
Diseases (GBD) 2010 study.  I also want to dedicate a special thank for Emma 
Smith, one of the coordinators of the musculoskeletal expert group of the GBD 2010 
study. Her dedication to the project was enormous, and always had time to give me 
light when I was lost. Thank you Cindy, Monique and Nicholas for taking me to the 
age care facilities in the FREEDOM study and show me the field work, and thank 
you as well for taking part in the review team for the GBD 2010 study. All the staff in 
the IBJR were always warm and welcoming; thank you Marita, Lindall, Tania, Joana, 
Shane, Michelle, Annica (and forgive me, please, if I leave anybody out) for making 
me feel part of the family and invite me to all the birthday cake parties.  
 
Special thanks for the different generations of rheumatology registrars from Royal 
North Shore Hospital (Anna, Jason, Peter and Beth), who were so friendly to me. 
You all were top level rheumatology fellows, and represented well the high standards 
 6 
of your institution. Anna stayed in my apartment in Barcelona, and with Jason, we 
have been in each other’s weddings in Australia, and that leaves such nice 
memories.  
 
I also want to thank the rheumatology fellows in Hospital Universitari de Bellvitge 
working in 2007, Ivan, Marc, Valeria and Diana, who had to work harder when I first 
went to Sydney during the last year of my fellowship, and never lost their smile, 
particularly Ivan, who had to run my clinics and was an excellent buddy during the 
whole fellowship. Thank you as well to César and Berta for breaking the ice of the 
external rotations within the department and smoothing the path for the future 
generations.   
 
I want to say a big thank you to all the members of the Osteoporosis Working Group 
for the GBD study for their different contributions, very often dedicating their personal 
time. The work done by Lennert, Veerman, Rosana Norman and Damian Hoy, Public 
Health experts from the University of Queensland, as well as from Theo Vos, Steve 
Lim and Emily Carnahan from the University of Washington, has been very important 
for the development of this thesis and for my understanding of many epidemiology 
concepts. Their support and contribution to all the scientific productions related to 
this thesis has been consistent over the years and I am particularly grateful to Theo 
for keeping me in the loop of the GBD initiative in this current 2013 update. Also, my 
acknowledgments to the international expert leaders Philip Sambrook, Cyrus 
Cooper, John Kanis, and Anthony Woolf, who were happy to provide feedback on 
the suitability of our methodology. Thank you to all of them for the time dedicated in 
 7 
the many emails, phone calls, and teleconferences we have exchanged over the 
years.    
 
My thanks are also for those institutions that recognized the value of my research 
career through their awards: the Spanish Society of Rheumatology (Sociedad 
Española de Reumatología), the Catalan Society of Rheumatology (Societat 
Catalana de Reumatologia), the International Osteoporosis Foundation (IOF) and the 
European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis (ESCEO). Besides the importance of their economic contribution, their 
recognition meant a lot to me, and helped me keep going when I was faced with 
challenges. Thank you to Loreto Carmona, who kindly reviewed the draft for my 
scholarship applications to the Sociedad Española de Reumatología.      
 
Thank you as well to all my family for being so happy with the idea of me studying 
overseas. Thank you Mum and Dad for being modern and generous parents who 
always encourage me to undertake “all you did not have the opportunity to do”. The 
honest satisfaction and pride of my family about my career is one of the warmest 
rewards.    
 
My last and most special acknowledgement is for my partner in life, Nicholas 
“Roosty” Wilson. Your endless support in everything I do in life, including this PhD, 
has no pair. Thank you, Roosty, for your great help in the review process, and for 
your skillful touch in all those technical aspects I sometimes struggle a bit. Working 
and living beside you over all these years has been an authentic pleasure, and I feel 
grateful to keep chasing our professional and personal dreams together. Thank you 
 8 
for your understanding and generosity, always putting me first before anything else. I 
could not dream of a better colleague or a better husband. How lucky I feel to have 
both in you! I love you.  
 
I feel privileged of having the best supporting professionals and human beings 
beside me. I know they will be as happy as me to see this thesis coming to see the 




 SUMMARY IN CATALAN (RESUM EN CATALÀ)….……10 
 ORIGINAL THESIS ………………………………………....59 
 10 
 
LA CÀRREGA EN SALUT MUNDIAL 
ATRIBUÏBLE A LA BAIXA DENSITAT 
MINERAL ÒSSIA 
(THE GLOBAL BURDEN 
ATTRIBUTABLE  TO LOW BONE 
MINERAL DENSITY) 
 
Resum en català de la memòria presentada per Lídia Sànchez Riera 
per optar al títol de Doctor en Medicina 
 
 
Nota: Referències bibliogràfiques, taules, figures, apèndixs, llista d’abreviacions i 
produccions científiques relacionades amb aquesta memòria es trobaran formant 




1 Introducció ..................................................................... 14 
1.1 Osteoporosi i fractures osteoporòtiques ................................. 14 
1.2 Impacte en salut de les fractures  osteoporòtiques ................ 15 
1.3 Epidemiologia de l’osteoporosi i de les fractures 
osteoporòtiques ............................................................................... 17 
1.4 Cost econòmic de les fractures osteoporòtiques .................... 19 
1.5 Factors de risc d’osteoporosi i fractura osteoporòtica. Paper 
de la densitat mineral òssia i dels factors de risc clínic ................... 20 
1.6 Diagnòstic i maneig de l’osteoporosi ...................................... 24 
1.7 Osteoporosi en el món real: infradiagnosticada i 
infratractada ..................................................................................... 27 
1.8 Context d’aquesta tesi doctoral: “The Global Burden of 
Diseases 2010 Study” ...................................................................... 28 
2 Hipòtesis i Objectius ..................................................... 30 
2.1 Hipòtesis: ................................................................................. 30 
2.2 Objectius:................................................................................. 30 
3 Mètodes .......................................................................... 32 
 12 
3.1 Introducció a l‘Anàlisi de Risc Comparatiu (“Comparative 
Risk Assessment methodology”) ..................................................... 32 
3.2 Constitució del grup de treball per Osteoporosi en l’ estudi 
GBD 2010 ........................................................................................ 33 
3.3 Definició de la variable d’exposició al factor de risc. 
Extracció i gestió de dades .............................................................. 34 
3.4 Avaluació de la relació de risc entre baixa DMO i fractura ..... 36 
3.5 Càrrega en salut mundial degut a les caigudes atribuïbles a 
la baixa densitat mineral òssia......................................................... 37 
4 Resultats ........................................................................ 40 
4.1 Resultats de la revisió sistemàtica .......................................... 40 
4.2 Resultats de la variable d’exposició al factor de risc: 
Distribució de la densitat mineral òssia ........................................... 41 
4.3 Fracció de la càrrega en salut mundial degut a caigudes 
atribuïble a la baixa densitat mineral òssia ..................................... 41 
4.4 Càrrega en salut mundial degut a la baixa densitat mineral 
òssia: DALYs, YLDs, YLLs i morts .................................................. 42 
4.5 Comparació de l’impacte en salut de la baixa densitat 
mineral òssia comparat amb altres factors de risc en l’estudi GBD 
2010. ................................................................................................ 44 
5 Discussió........................................................................ 45 
 13 
6 Conclusions ................................................................... 54 





1  Introducció 
 
1.1 Osteoporosi i fractures osteoporòtiques  
L’osteoporosi es defineix com una malaltia sistèmica del sistema esquelètic 
caracteritzada per una baixa massa òssia i un deteriorament de la microarquitectura 
de l’òs, amb el conseqüent augment de la fragilitat òssia i de la susceptibilitat a 
fractura (NIH Consensus Development Panel on Osteoporosis Prevention 2001). Es 
comporta com una malaltia silent; un alt percentatge de la gent afectada ignoren que 
pateixen la condició. Com a resultat, les conseqüències de l’osteoporosi  són millor 
estudiades quan es mesura l’impacte de la seva conseqüència clínica, les fractures 
osteoporòtiques (també conegudes com “fractures per fragilitat), les quals 
acostumen a tenir lloc després d’un traumatisme de baix impacte, com per exemple, 
una caiguda casual.  Les localitzacions més habituals i millor caracteritzades  són, 
per ordre del seu impacte ens salut, maluc, vèrtebra, i canell.  Existeixen altres 
fractures en localitzacions perifèriques considerades com osteoporòtiques, com 
húmer proximal, pelvis, costella, tíbia proximal, clavícula, mà i peu (Seeley, Browner 
et al. 1991). 
 
Durant les dues darreres dècades, la definició operativa d’ osteoporosi s’ha basat en 
els valors de densitat mineral òssia (DMO, o BMD de l’anglès bone mineral density): 
en dones postmenopàusiques i en homes a partir de 50 anys d’edat, el diagnòstic 
d’osteoporosi es realitza quan la DMO mesurada per DXA (dual-energy-X-ray 
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absorptiometry o dual-X-ray absorptiometry) a columna lumbar, maluc total o coll 
femoral (en ocasions el terç distal de radi també es pot utilitzar) es troba a -2.5 
desviacions estàndard (DE, o SD de l’anglès standard deviation) o per sota de la 
mitja del valor de DMO en dones joves (T score ≤ -2.5) (WHO 1994; Kanis 2008) 
(Figure 1.1). En dones premenopàusiques i en homes més joves de 50 anys,  el 
diagnòstic es defineix per factors de risc clínic (fractura o altres factors de risc) en 
presència d’ una massa òssia inferior al rang esperat pel gènere i el grup d’edat (Z 
score ≤ -2.0) (Binkley, Bilezikian et al. 2006; Watts, Leslie et al. 2013).  En aquesta 
subpoblació, l’osteoporosi és menys comú, i el cribratge de causes subjacents 
relacionades amb la seva aparició cal que sigui exhaustiu, donat l’alta freqüència de 
causes secundàries d’osteoporosi (Khosla, Lufkin et al. 1994). 
 
Malgrat el consens en les definicions anteriors pel diagnòstic d’osteoporosi i 
l’evidència existent del paper de la DMO en el risc de fractura, la sensibilitat de la 
DMO per predir una fractura és limitada, i el seu valor predictiu millora quan els 
factors clínics es tenen en compte. Des d’un punt de vista epidemiològic, mesures 
com la probabilitat de fractura a 10 anys es consideren més adequades per definir el 
risc de fractura, l’autèntica càrrega en salut de l’osteoporosi (Genant, Cooper et al. 
1999; Kanis and Gluer 2000). 
 
1.2 Impacte en salut de les fractures osteoporòtiques 
Els resultats derivats de les fractures osteoporòtiques poden anar des del dolor 
crònic,  la pèrdua de mobilitat i la independència, fins a la institucionalització i la mort 
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(Johnell and Kanis 2004; Johnell and Kanis 2006; Bliuc, Nguyen et al. 2009; 
Bertram, Norman et al. 2011).  
 
La fractura de maluc constitueix el tipus de fractura osteoporòtica amb les pitjors 
conseqüències per la salut, en part perquè el seu pic d’incidència, clàssicament,  
succeeix en població d’edat avançada, entre el 70 i els 79 anys d’edat (Johnell and 
Kanis 2004). Dins de l’any posterior a una fractura de maluc, la mortalitat acumulada 
arriba fins el 37% en homes i el 25% en dones, i és considerablement més elevada 
que en la població general de la mateixa edat (Kanis, Oden et al. 2003; Kannegaard, 
van der Mark et al. 2010). Aproximadament la meitat d’individus perden el seu nivell 
de funció física habitual, i molts requereixen assistència a llarg termini (Magaziner, 
Simonsick et al. 1990; Sernbo and Johnell 1993; Melton 2003).  
  
Les fractures vertebrals són les segones en ordre d’impacte en salut. Poden causar 
dolor i limitació del moviment espinal i afecten considerablement la qualitat de vida 
(Naves Diaz, Diaz Lopez et al. 2001). La seva incidència i prevalença augmenten de 
forma constant des dels 50 fins al 80 anys d’edat (O'Neill, Felsenberg et al. 1996; 
Jansson, Blomqvist et al. 2010). Una cinquena part dels afectats requereix 
hospitalització, i en ocasions, assistència a llarg termini (Silverman 1992; Ross 
1997). Aproximadament només un terç dels col·lapses vertebrals osteoporòtics 
provoquen dolor agut, (Cooper, Atkinson et al. 1992), però també són causa de 
discapacitat (Silverman 1992; Ross 1997). Conseqüències a llarg termini com la 
cifosi, la malaltia pulmonar restrictiva i l’estenosi espinal contribueixen igualment a la 
pèrdua de qualitat de vida i a la mortalitat (Kado, Browner et al. 1999), la qual es 
troba clarament augmentada respecte la població general i és proporcional al 
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número de fractures prevalents (Kado, Browner et al. 1999; Kanis, Oden et al. 
2004). 
    
Les fractures de canell tendeixen a ocórrer en edats més precoces, amb un pic 
d’incidència entre els 40 i els 65 anys. Al voltant d’una cinquena part de les fractures 
de Colles (fractures del radi distal amb desplaçament dorsal del radi, amb o sense 
fractura de cúbit) en països desenvolupats resulten en hospitalització (O'Neill, 
Cooper et al. 2001). Nomes un 50% dels afectats refereix una bona recuperació 
funcional als 6 mesos (Kaukonen, Karaharju et al. 1988).  
 
La mortalitat prematura després d’una fractura persisteix significativament més 
elevada que en la població general no només durant el primer any post-fractura, 
sinó també fins a un període de 5-15 anys, depenent del grup d’edat i la localització 
de la fractura (Bliuc, Nguyen et al. 2009; Melton, Achenbach et al. 2013).  
 
1.3 Epidemiologia de l’osteoporosi i de les fractures 
osteoporòtiques 
En una revisió molt recent, la prevalença de l’osteoporosi en quatre cinquenes parts 
de la població mundial s’ha estimat en un  3% en homes i un 10% en dones de 50 a 
59 anys (Oden, McCloskey et al. 2013). Aquest percentatge incrementa al 6% i al 
19%, respectivament, en poblacions entre els 60 i els 69 anys, seguit d’una 
prevalença del 9% i del 35%, respectivament, en aquells amb edat compreses entre 
els 70 i els 79 anys, i finalment, del 19% i del 51%, respectivament, en població a 
partir dels 80 anys d’edat. Els autors han calculat que al voltant de 2,7 milions de 
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fractures de maluc van tenir lloc en el 2010 a la població mundial, de les quals la 
meitat eren atribuïbles a osteoporosi  (264.000 en homes i 1,10 milions en dones), i 
per tant, evitables. 
 
Treballs previs en la iniciativa the global burden of diseases (GBD, en català la 
“càrrega mundial de les malalties”) han estimat que un total de 9 milions de fractures 
osteoporòtiques van tenir lloc en el món durant el 2000, de les quals 1,6 milions eren 
de maluc (70% dones), 1,7 milions eren de canell (80% dones) i 1,4 milions eren 
fractures vertebral clíniques (58% dones) (Johnell and Kanis 2006). Malgrat que les 
fractures de maluc representaven solament un 18,2% de totes les fractures, 
constituïen un 40% de tot l’impacte en salut mundial degut a fractures. El nombre 
més gran de fractures succeí a Europa, seguit del Pacífic occidental, el sud-est d’ 
Àsia i les Amèriques, contribuint col·lectivament al 97% de totes les fractures al 
món, subratllant la influència del creixement de la població amb edat avançada. En 
combinar mortalitat i morbiditat en una mateixa mesura estàndard coneguda com 
DALYs (de l’angles disability-adjusted life years), les fractures osteropòtiques eren 
causa de més DALYs perduts en comparació amb l’artritis reumatoide i tots els tipus 
de càncer, amb excepció del càncer de pulmó  (Johnell and Kanis 2006).  
 
Considerant l’envelliment progressiu de la població mundial, s’ha projectat un 
augment del 300% en la incidència mundial de fractura de maluc el 2050 comparat 
amb el 1990 (Gullberg, Johnell et al. 1997).  
 
Un aspecte important en l’epidemiologia de les fractures osteoporòtiques és que la 
incidència de fractura és país-depenent (Kanis, Johnell et al. 2002; Roy, Pye et al. 
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2002) (Table 1.1), així com també ho són els nivells poblacionals de DMO (Sanchez-
Riera, Wilson et al. 2010). Aquesta variabilitat va més enllà de les diferències en 
l’expectativa de vida i la proporció de població senil, i probablement reflecteixen el 
paper de múltiples factors genètics, culturals i mediambientals.    
  
1.4 Cost econòmic de les fractures osteoporòtiques 
El cost econòmic de l’osteoporosi i de les fractures osteoporòtiques prové de les 
conseqüències a curt termini (hospitalització i cirurgia, per exemple), i de les 
conseqüències a llarg termini, com la incapacitat crònica, les intervencions 
farmacològiques i la institucionalització.   
  
A la Unió Europea, el cost de l’osteoporosi el 2010 es va calcular en 37.000 milions 
d’euros, dels quals, un 66 % corresponien al tractament de fractures agudes, un 5% 
al tractament farmacològic, i el 29% restant a l’assistència sòcio-sanitària a llarg 
termini. La meitat d’aquests costos eren resultat de fractures de maluc. Els costos 
derivats de les fractures per fragilitat superaven altres condicions amb gran potencial 
de discapacitat, com els accidents cerebrovasculars, el Parkinson i l’artritis 
reumatoide (Hernlund, Svedbom et al. 2013; Strom, Borgstrom et al. 2013).  
 
Degut als canvis demogràfics de la població, els costos derivats de les fractures 
osteoporòtiques a Europa augmentaran en un 22% del 2010 al 2025 (Hernlund, 
Svedbom et al. 2013). Aquest increment en la incidència de les fractures i el 
conseqüent cost també s’ha predit per Nord-Amèrica, Llatino-Amèrica, Australàsia, 
Orient Mitjà, Nord-Àfrica i Àsia (Cooper, Campion et al. 1992; Gullberg, Johnell et al. 
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1997). De fet, l’ increment progressiu de l’esperança de vida i de la població general 
a Àsia i Llatino-Amèrica està provocant un viratge de l’impacte de l’osteoporosi cap 
a aquestes regions del món. Pels volts del 2050, es calcula que la meitat de les 
fractures de maluc tindran lloc a Àsia (Cooper, Campion et al. 1992).  
 
1.5 Factors de risc d’osteoporosi i fractura osteoporòtica. Paper 
de la densitat mineral òssia i dels factors de risc clínic 
La resistència òssia reflecteix principalment la integració entre DMO i qualitat òssia. 
La darrera pot esdevenir complicada de mesurar de forma generalitzada a la 
pràctica clínica, sobretot des d’un punt de vista poblacional. La DMO, d’altra banda, 
és un factor de risc de fractura ben definit (Marshall, Johnell et al. 1996; Johnell, 
Kanis et al. 2005), i pot ser mesurada amb tècniques estandarditzades que són 
objectives, reproduïbles, no invasives, ràpides i relativament econòmiques. A més a 
més, el potencial modificador d’una gran varietat de mesures farmacològiques i no 
farmacològiques sobre la DMO es troba ben caracteritzat. Per tant, la DMO ofereix 
un escenari excel·lent pel maneig i el seguiment dels individus amb alt risc de 
fractura.  
  
L’ ús de la DXA central (columna i maluc) roman com la tècnica per mesurar DMO 
més àmpliament utilitzada i validada, i és el mètode d’elecció segons les 
recomanacions dels organismes internacionals experts (WHO 1994; 2007). Tot i 
l’existència d’un llindar establert pel diagnòstic d’osteoporosi amb l’ús de DXA (T 
score ≤ -2.5), el risc de fractura degut a una baixa DMO és continu més que no pas  
categòric, i de fet, la major part de les fractures osteoporòtiques succeeixen en 
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individus amb osteopènia (es a dir, amb T scores entre -1 i -2.5) (Siris, Chen et al. 
2004). Per tant, la definició d’osteoporosi amb DXA, d’alguna manera arbitrària, té 
una baixa sensibilitat per detectar individus amb alt risc de fractura.   
 
L’anomenat gradient de risc de fractura (en anglès, gradient of risk, GR) s’ha definit 
com el risc relatiu (relative risk, RR) de fractura per cada unitat de DMO disminuïda. 
Una important metanàlisi del 1996 (Marshall, Johnell et al. 1996) va trobar que les 
mesures de DMO a maluc, columna lumbar i canell podien predir conjuntament 
l’esdeveniment d’una fractura amb un GR d’aproximadament 1,5 per cada 
disminució en una DE de la DMO. El valor del RR millorava quan les mesures eren 
específiques per cada localització, de manera que la precisió predictiva de la 
fractura de maluc, per exemple, millorava amb mesures de la DMO realitzades a 
maluc (Table 1.2), amb un GR de 2,6. Això volia dir que un individu amb un T score 
de −3 DE a maluc tindria una probabilitat de fractura de 2.63 (o aproximadament 17 
vegades més) que un altre individu amb un T score de 0 DE. Gairebé 10 anys més 
tard, una nova metanàlisi basada en 12 cohorts poblacionals prospectives d’Europa 
occidental, Estats Units, Canadà, Japó i Austràlia, va trobar resultats similars 
(Johnell, Kanis et al. 2005). En aquest darrer estudi, es va trobar que la DMO a coll 
femoral (en anglès femoral neck bone mineral density, FNBMD) posseïa un bon 
valor predictiu per fractura de maluc, per qualsevol fractura osteoporòtica, i per 
qualsevol fractura en general. Tot que l’esdeveniment d’una fractura tenia lloc més 
sovint en dones, el GR per cada unitat de FNBMD era equivalent entre els dos 
gèneres, la qual cosa significa que l’excés de risc degut solament a la DMO era 
comparable entre dones i homes.  
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El valor predictiu de la DMO per calcular el risc de fractura pot millorar molt amb la 
incorporació de factors independents de risc clínic (Kanis, Oden et al. 2007). El 
Fracture Risk Assessment Tool (FRAX®), és una iniciativa promoguda per 
l’Organització Mundial de la Salut (OMS, i en anglès, World Health Organization, 
WHO) i validada per diversos països (http://www.shef.ac.uk/FRAX). Aquesta eina de 
predicció de fractura és un algoritme dinàmic que integra el GR de FNBMD derivat 
de la metanàlisi de Johnell i Kanis (Johnell, Kanis et al. 2005) amb 12 factors de risc 
clínic (Table 1.3), i permet el càlcul d’una probabilitat a 10 anys per fractures de 
maluc i per qualsevol fractura osteoporòtica, fins i tot en absència de informació de 
la DMO. Existeixen altres algoritmes per la predicció de fractures, tot i que la seva 
validació i acceptació per part de la comunitat científica internacional encara esta 
lluny del FRAX®.    
 
El factor de risc clínic més rellevant per sofrir una fractura és clarament l’edat (Kanis, 
Johnell et al. 2001), seguit del gènere femení (Johnell and Kanis 2006; Oden, 
McCloskey et al. 2013), i la història de fractura prèvia (Kanis, Johnell et al. 2004). El 
paper del pes i l’índex de massa corporal (en anglès body mass index, BMI) també 
es troba ben caracteritzat tant en homes com en dones en diverses parts del món 
(Cauley, Fullman et al. 2005; De Laet, Kanis et al. 2005; Kaptoge, Reid et al. 2007; 
Beck, Petit et al. 2009; Kim, Oh et al. 2009; Orito, Kuroda et al. 2009; Genaro, 
Pereira et al. 2010; Langsetmo, Poliquin et al. 2010; Sheng, Xu et al. 2010). Pel que 
fa a l’activitat física, la seva influència sobre el risc de fractura és doble: d’una 
banda, augmenta la qualitat i quantitat d’òs trabecular i cortical, i per tant millora la 
resistència òssia (Cousins, Petit et al. 2010; Janz, Letuchy et al. 2014); d’una altra 
banda, l’exercici pot tenir un efecte positiu en la força muscular, l’equilibri i la marxa, 
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tots components importants en el risc de caigudes en la gent gran (Nevitt, 
Cummings et al. 1991; Ensrud, Ewing et al. 2007; Wilson, Hilmer et al. 2011; Cauley, 
Harrison et al. 2013), les quals són un dels factors de risc més important de fractura 
a la pràctica clínica (Roy, Pye et al. 2002; Ensrud, Ewing et al. 2007; Deprey 2009). 
Cal tenir en compte que aquesta és una de les limitacions més importants de l’eina 
FRAX®, la qual, de moment, no incorpora la probabilitat de caiguda en l’algoritme.  
 
Altres factors de risc de fractura inclouen el tabaquisme, l’alcohol i diverses 
condicions clíniques que s’han identificat com factors independents de baixa DMO i 
de fractura (Table 1.3, Table 1.4) (Kanis, Borgstrom et al. 2005; Kanis 2008; Kanis, 
Johansson et al. 2009). Entre les múltiples causes farmacològiques, el tractament 
corticoideu és clarament el factor de més pes, pel seu gran impacte i prevalença, 
constituint sovint la primera causa d’osteroporosi secundària en països 
desenvolupats (Allport 2008; Civitelli and Ziambaras 2008). La deficiència en vitamin 
D provoca hiperparatiroïdisme secundari i també s’ha associat a l’aparició 
d’osteoporosi (Holick 2007), i fractures (LeBoff, Kohlmeier et al. 1999; Bischoff-
Ferrari, Can et al. 2008; Cauley, Parimi et al. 2009; Nakamura, Saito et al. 2010). Pel 
que fa als suplements de calci, una de les recomanacions clàssiques generals en el 
maneig de l’osteoporosi, l’evidència científica recent mostra que la seva influència 
en la DMO i el risc de fractura és força mínima (Shea, Wells et al. 2004) . No 
obstant, les guies de maneig clínic recomanen en general complir amb els 
requeriments diaris de calci, específics per cada període de la vida, preferentment a 
través de la dieta.  
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Finalment, diferents ètnies presenten divergències en els nivells poblacionals de 
DMO (clàssicament, per exemple, la raça negra presenta nivells de DMO més 
elevats que caucàsics o asiàtics) (Nam, Shin et al. 2010; Yang, Lu et al. 2013) i en 
l’estructura òssia (relacionades, per exemple, amb  diferents paràmetres geomètrics 
del coll femoral) (Faulkner, Cummings et al. 1993; Pulkkinen, Partanen et al. 2004; 
Gnudi, Sitta et al. 2007) que igualment influencien en el risc de fractura.  És 
important remarcar que tot i aquestes diferències, el GR de fractura per unitat de 
DMO a coll femoral (FNBMD) és comparable entre diferent races (Broussard and 
Magnus 2004; Looker, Melton et al. 2009). Així mateix, l’existència de gens 
determinants en l’estructura i densitat òssies s’ha demostrat en estudis amb 
bessons (Slemenda, Christian et al. 1991; Arden and Spector 1997; Harris, Nguyen 
et al. 1998), i pel fet que la història paterna o materna de fractura de maluc familiar 
ha demostrat ser un factor de risc consolidat de fractura (Kanis, Johansson et al. 
2004).   
 
1.6 Diagnòstic i maneig de l’osteoporosi 
Tant la DMO com la microarquitectura i la qualitat òssies juguen un paper important 
en la resistència òssia i la susceptibilitat de sofrir una fractura. Tot i així, des d’un 
punt de vista clínic, el diagnòstic d’osteoporosi es basa en la DMO, segons les 
categories diagnòstiques de l’OMS (WHO) (Table 1.6). És important, però, 
diferenciar la definició operativa d’osteoporosi establerta d’aquest manera, de 
l’avaluació del risc de fractura i del llindar de tractament.   
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Actualment, no existeix cap guia universalment acceptada pel cribratge poblacional 
dels individus amb alt risc de fractura, essent la majoria identificats 
oportunísticament en presència d’una fractura per fragilitat o altres factors de risc. 
Quan  la probabilitat de fractura basada en els factors de risc clínic és elevada, es 
recomana tractament independentment del valor de la DMO, mentre que l’estudi de 
la mateixa esdevé més decisiu en aquells casos on la probabilitat de fractura és 
intermitja.  Finalment, els individus categoritzats de baix risc, no requeririen 
avaluació amb DMO o intervenció farmacològica (Figure 1.4). Algoritmes de 
predicció de fractura com el FRAX® poden facilitar aquesta presa de decisions. En 
darrer terme, caldrà tenir en compte factors geogràfics (com l’accés a aparells de 
DXA i el cost-benefici de les intervencions) i individuals (comorbiditats, adherència al 
tractament, etc).    
 
Un cop identificats aquells subjectes candidats a intervenció farmacològica, caldrà 
també fer un cribratge inicial de causes secundàries d’osteoporosi i una anàlisi de 
l’estat de salut general prèviament a l’inici del tractament (Table 1.7).  
 
La immobilització prolongada (com les esdevenides en llargues hospitalitzacions) 
constitueix una causa important de deteriorament de l’òs i cal que s’eviti en la 
mesura del possible, així com el risc de caigudes, que cal evaluar sistemàticament 
en cada subjecte (Table 1.8).  
 
Un bon nivell d’activitat física,  a més d’una ingesta adequada de calci, vitamina D 
(un mínim de 800 UI diàries en dones postmenopàusiques) i proteïnes, es 
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necessària per evitar la sarcopènia i l’osteoporosi relacionades amb l’edat (Rizzoli, 
Stevenson et al. 2014) .  
 
Diversos agents farmacològics han estat aprovats pel tractament de l’osteoporosi. 
Tots ells han demostrat el seu efecte positiu sobre la DMO i la reducció en el risc de 
fractura (Table 1.9). Reduccions en el risc de fractura s’han demostrat entre un 30% 
i un 70 % per fractures vertebrals,  al voltant d’un 15-20 % per fractures no 
vertebrals i fins a un 40% en fractures de maluc (Kanis, McCloskey et al. 2013). La 
reducció en la mortalitat s’ha estimat en un 11% a nivell mundial en una metanàlisi 
recent (Bolland, Grey et al. 2010). El cost-efectivitat ha estat ben establert de forma 
individual per tots aquests tractaments, així com també per estratègies de cribratge 
d’osteoporosi seguides d’ intervenció farmacològica (Schousboe, Ensrud et al. 2005; 
Mobley, Hoerger et al. 2006; Hiligsmann, Gathon et al. 2010; Nayak, Roberts et al. 
2011).  
 
L’objectiu del tractament farmacològic és millorar la resistència òssia i 
conseqüentment reduir el risc de fractura. És possible que l’eficàcia anti-fracturària a 
llarg termini sigui només parcialment depenent de l’extensió en què augmenten o 
mantenen la DMO (Rabenda, Bruyere et al. 2011). De tota manera, com ja s’ha 
esmentat prèviament, la DMO és un dels majors predictors de resistència òssia, i 
constitueix una mesura objectiva, no invasiva i fàcilment reproduïble per monitoritzar 
els canvis amb el tractament. A més a més, existeix evidència científica de la 
correlació entre canvis en la DMO i reducció en el risc de fractura (Hochberg, 
Greenspan et al. 2002; Delmas, Li et al. 2004).  
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1.7 Osteoporosi en el món real: infradiagnosticada i infratractada 
Els costos econòmics derivats de les fractures per fragilitat, tal com s’ha explicat 
prèviament, són enormes, i les projeccions basades en l’envelliment global de la 
població preveuen grans increments en la factura que les societats hauran d’afrontar 
en les properes dècades.   
 
El cribratge i tractament dels pacients amb alt risc de fractura ha demostrat ésser 
cost-efectiu per diverses intervencions relativament senzilles (Strom, Borgstrom et 
al. 2007; Zethraeus, Borgstrom et al. 2007; Nayak, Roberts et al. 2012; Strom, 
Borgstrom et al. 2013). Com a factor de risc, la baixa DMO té un valor predictiu 
comparable al de la hipertensió arterial pels accidents cerebrovasculars o la 
hipercolesterolèmia per l’infart agut de miocardi (Marshall, Johnell et al. 1996). La 
intervenció terapèutica de tots tres factors de risc ha demostrat ser cost-efectiva a 
nivell poblacional, però el que és més important, el cost-efectivitat del tractament de 
l’osteoporosi millora clarament amb l’edat, la qual cosa no esdevé tan constant en el 
cas de la hipertensió o la hipercolesterolèmia (Zethraeus, Strom et al. 2008). 
 
Aquestes observacions contrasten significativament amb la manca de cribratge de l’ 
osteoporosi en la població general i la gran insuficiència de tractament després de la 
fase aguda d’una fractura per fragilitat (Strom, Borgstrom et al. 2013), amb menys 
d’un 20% de pacients rebent cap tipus d’intervenció farmacològica per prevenció 
secundària d’osteoporosi en el moment de l’alta hospitalària (Elliot-Gibson, Bogoch 
et al. 2004; Giangregorio, Papaioannou et al. 2006). Molt diferent és el cas, per 
exemple, de la gent gran amb infart agut de miocardi, 75% dels quals reben 
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betablocadors a l’alta com part de la prevenció secundària de cardiopatia isquèmica 
(Austin, Tu et al. 2008), i que il·lustra el gran recorregut en estratègies de prevenció i 
salut pública que l’osteoporosi ha de realitzar en comparació, per exemple, amb els 
factors de risc cardiovascular. Un paradigma d’aquest fet és la no menció de 
l’osteoporosi o les fractures per fragilitat entre les prioritats recentment establertes 
per l’OMS en malalties no comunicables (www.who.int).  
 
1.8 Context d’aquesta tesi doctoral: “The Global Burden of 
Diseases 2010 Study”  
El treball d’aquesta tesi constitueix part de les tasques realitzades pel grup expert en 
malalties musculoequelètiques (Musculoskeletal Expert Group, MSK EG) (Figure 
1.9) (Cross M, Smith E et al. 2014; Driscoll, Jacklyn et al. 2014; Hoy D, March L et 
al. 2014; Hoy D, March L et al. 2014; Hoy D, Smith E et al. 2014; Hoy D, Smith E et 
al. 2014; Sanchez-Riera L, Carnahan E et al. 2014; Smith E, Hoy D et al. 2014; 
Smith, Hoy et al. 2014) dins la gran iniciativa en epidemiologia mundial coneguda 
com el Global Burden of Disease (GBD) 2010 Study (Vos, Flaxman et al. 2012; Lim, 
Vos et al. 2012; Murray, Vos et al. 2012; Salomon, Vos et al. 2012). Aquesta 
iniciativa es va iniciar el 1990 com un projecte de l’OMS per calcular la càrrega en 
salut mundial (global) de les principals malalties i condicions patològiques. El 
projecte GBD utilitza una eina d’ estadística bayesiana (DisMod-MR, de l’anglès 
Disease Modelling Meta-Regression tool) especialment dissenyada pels propòsits 
del projecte i que permet comparar els paràmetres de mesura d’impacte (càrrega en 
salut) entre diferents malalties, regions del món, edats, i gèneres, així com analitzar 
tendències temporals. Les dues mesures principals de la càrrega en salut són les 
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morts i els anys de vida ajustats per discapacitat (Disability-Adjusted Life Years, 
DALYs), que combinen en una mateixa mesura els anys viscuts amb discapacitat 
(Years Lived with Disability, YLDs) i els anys de vida perduts degut a una mort 
prematura (Years of Life Lost due to premature mortality, YLLs) (Figure 1.8) (Murray, 
Vos et al. 2012). En l’edició 2010, múltiples millores en la metodologia de l’estudi 
GBD es van optimitzar respecte edicions prèvies, i el ventall de condicions es va 
ampliar significativament, abastant 291 malalties i lesions i 67 factors de risc 
(Murray, Vos et al. 2012).  
 
L’osteoporosi, per si mateixa, no es trobà inclosa com a malaltia en l’estudi GBD 
2010, i per primer cop, la baixa DMO (low bone mineral density, low BMD) s’inclogué 
en l’anàlisi de la càrrega en salut mundial com a factor de risc de fractures, que al 
seu torn, formaren part de la càrrega degut a les caigudes com a una de les 291 
condicions estudiades en l’estudi GBD (Figure 1.11). Aquest treball descriu els 
mètodes utilitzats per calcular la contribució de la baixa DMO en la càrrega en salut 
mundial degut a les caigudes i presenta els resultat obtinguts per grups d’edat, 
gènere, i regió mundial, amb les estimacions obtingudes pel 1990 i pel 2010. La 
metodologia es basa en l’anàlisi de risc comparatiu (Comparative risk assessment, 
CRA), seguint la metodologia general per l’anàlisi de factors de risc dins l’estudi 
GBD 2010 (Lim, Vos et al. 2012).  
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2  Hipòtesis i Objectius 
 
 
2.1 Hipòtesis:  
 
1) Un percentatge important de la càrrega en salut mundial degut a les caigudes 
és potencialment evitable en un escenari hipotètic on la població d’edat 
avançada presenta un nivell de DMO ideal.   
2) La càrrega en salut mundial degut a la baixa DMO ha augmentat 
probablement en els darrers 20 anys, degut particularment a l’envelliment de 
la població. La càrrega en salut de la baixa DMO pot variar en funció de la 
regió del món, el grup d’edat i el gènere.  
 
 
2.2 Objectius:  
 
1) Calcular els valors de DMO mesurats per DXA a coll femoral en la població 
mundial a partir dels 50 anys com la variable de risc d’exposició pel 1990 i pel 
2010. 
2) Calcular la fracció de la càrrega en salut mundial degut a les caigudes 
atribuïble a la baixa DMO pel 1990 i pel 2010.  
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3) Calcular el percentatge de la càrrega mundial en salut atribuïble a la baixa 
DMO pel 1990 i pel 2010.  
4) Calcular el nombre total de morts arreu del món degudes a una baixa DMO 
pel  1990 i pel 2010. 
5) Calcular el número de DALYs al món deguts a la baixa DMO pel 1990 i pel 
2010. 
6) Comparar la càrrega en salut mundial de la baixa DMO amb l’impacte derivat 
d’altres factors de risc dins l’estudi GBD 2010.  
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3  Mètodes 
 
3.1 Introducció a l‘Anàlisi de Risc Comparatiu (“Comparative Risk 
Assessment methodology”)  
En l’anàlisi de risc comparatiu (Comparative Risk Assessment, CRA) (Ezzati, Hoorn 
et al. 2011; Lim, Vos et al. 2012), l’impacte en salut degut a un factor de risc es 
compara a l’impacte hipotètic que resultaria si la distribució en la població del factor 
de risc es trobés a un nivell òptim (exposició “contrafactual”). Aquesta distribució 
“ideal” és el que es coneix com la distribució de risc teorèticament mínim 
(theoretical-minimum-risk exposure Distribution, TMRED), la qual ha de ser 
hipotèticament possible segons l’evidència científica disponible (Figure 3.1): 
 
 
Seguint la fòrmula anterior, es calcula la fracció poblacional atribuïble (Population 
Attributable Fraction, PAF), on RR(x) és el risc relatiu segons l’exposició al factor de 
risc  x, P(x) és la distribució poblacional de l’exposició al factor de risc, P’(x) és la 
distribució contrafactual de l’exposició al factor de risc, i m es el nivell d’exposició 
màxima al factor de risc. Utilitzant aquesta metodologia, s’ha estimat quina proporció 
de la càrrega en salut mundial degut a les caigudes en la població mundial es 
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atribuïble a la baixa DMO, seguint els passos metodològics que es detallen a 
continuació.   
 
3.2 Constitució del grup de treball per Osteoporosi en l’ estudi 
GBD 2010  
Aquest treball s’ha dut a terme amb la contribució d’una xarxa de professionals 
internacionals que han treballat en equip amb diversos graus d’involucrament. El 
projecte es nodreix d’aquesta xarxa de col·laboració per tal de produir una 
metodologia i analitzar els resultats de la manera més adequada possible, amb la 
guia d’experts en epidemiologia de l’osteoporosi i en salut pública mundial. Així, es 
va crear el grup de treball en osteoporosis (Osteoporosis Working Group, OWG), el 
qual es trobava dividit en l’equip revisor (Review Team, RT) i el grup de líders 
experts (Expert Leaders Group, ELG). Aquest darrer es trobava format tant per 
experts en salut publica implicats directament en l’estudi GBD 2010 com per líders 
d’opinió mundial en epidemiologia de l’osteoporosi. Tots els passos en la 
metodologia així com els resultats provisionals foren supervisats per coordinadors 
generals en el grup d’experts de malalties musculoesquelètiques (MSK EG group) i 
membres de l’equip central (core team, CT) de l’estudi GBD 2010 a la Universitat de 
Washington, per tal de proporcionar resposta a les dificultats i assegurar 
l’homogeneïtat dins l’estudi (Table 3.1). 
 
La líder del OWG, (main project officer, MPO) realitzà el cribratge dels resultats 
obtinguts de la SR per obtenir el número final d’estudis seleccionats per ser 
inclosos, liderà el procés d’extracció de dades, proporcionà evidencia científica a 
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l’ELG per facilitar les discussions de grup quan fou necessari, coordinà reunions i 
comunicacions dins de cada grup i entre grups, liderà l’escriptura de manuscrits 
científics, i presentà comunicacions en congressos internacionals (Figure 3.2).  
 
3.3 Definició de la variable d’exposició al factor de risc. Extracció 
i gestió de dades  
Es va realitzar una revisió sistemàtica (systematic review, SR) a través de les bases 
de dades Medline, Embase, CAB Abstracts, CINHAL, WHOLIS, i SIGLE, cercant 
estudis poblacionals publicats entre el 1980 i el 2010 amb valors de DMO en g/cm2 
mesurats amb DXA a coll femoral (femoral neck bone mineral density, FNBMD). En 
regions amb molta escassetat de dades també es van incloure altre tipus d’estudis 
(no poblacionals) sempre i que la mostra es considerés mínimament representativa 
de la població nacional. La DXA central es la tècnica mes validada per mesurar la 
DMO. La localització concreta a coll femoral (FNBMD) es va justificar per l’evidència 
existent de que la predicció de la morbiditat i mortalitat relacionades amb la fractura 
de maluc (la fractura osteoporòtica amb les conseqüències més nocives per la salut) 
és òptima quan la DMO és mesurada a coll femoral enlloc de columna o radi distal 
(Johnell, Kanis et al. 2005). El que és més, les mesures de FNBMD es troben molt 
ben correlacionades amb el risc de fractura vertebral, amb altres fractures 
osteoporòtiques i amb qualsevol fractura en general (Johnell, Kanis et al. 2005). 
 
La MPO va dissenyar una base de dades en MS Excel que, després de la seva 
revisió dins el OWG, va ser implementada per extraure les dades dels estudis 
seleccionats a la SR, i que incloïa els següents paràmetres: regió mundial, país, any 
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de publicació, tipus d’estudi, tamany de la mostra, descripció de la població d’estudi, 
cobertura (rural, urbana o ambdues), any d’inici i final de col·lecció de dades, edat 
dels participants, raça, marca del fabricant de la DXA, coeficient de variació (CV) de 
la mesura de la DMO a coll femoral (FNBMD), mitja dels valors de FNBMD en g/cm2 
i DE (SD). Tots els estudis inclosos es van sotmetre a una avaluació de qualitat amb 
una eina per mesurar el risc de biaix (risk of bias tool, RoB tool) validada 
anteriorment per estudis de prevalença (Hoy, Brooks et al. 2012) i modificada a 
traves d’exercicis Delphi pels propòsits de la revisió en baixa DMO (Sanchez Riera, 
Wilson et al. 2010). Tots els valors de les mitges i SD de FNBMD provinents de 
diferents fabricants de DXA (Hologic®, Norland® i Lunar®) foren estandarditzats a 
través d’ equacions de conversió internacionalment reconegudes (Table 3.2) (Lu, 
Fuerst et al. 2001) a sFNBMD i sSD, respectivament. Finalment, es va realitzar un 
cribatge sistemàtic de les dades per identificar duplicats i inconsistències en els 
valors.  
 
Les mitges de sFNBMD i sSD per cada regió, país i any es van calcular fent servir 
DisMod-MR, una eina d’estadística bayesiana dissenyada específicament pels 
propòsits de l’estudi GBD 2010 (Vos, Flaxman et al.). El model incloïa efectes fixos 
per co-variables dependents de l’estudi, i efectes aleatoris segons la regió mundial i 
el país.  
 
Amb l’ús de DisMod-MR, covariables a nivell nacional de les quals es disposés 
àmplia informació a la major part de països del món, es podien utilitzar per predir 
valors aproximats de DMO en aquelles regions amb una manca important de dades. 
Així, es van utilitzar els ingressos lag-distribuït per habitant, l’índex de massa 
 36 
corporal (body mass index, BMI), i la disponibilitat de llet basada en dades de la 
Food and Agriculture Organization de les Nacions Unides com les covariables 
nacionals. Altres estratègies per obtenir dades en regions amb manca d’informació 
sobre nivells poblacionals de DMO va incloure el contacte directe amb alguns dels 
autors dels estudis inclosos i professionals relacionats amb el món de l’osteoporosi 
per tal d’obtenir informació no publicada.   
 
3.4 Avaluació de la relació de risc entre baixa DMO i fractura 
Les nostres estimacions del risc relatiu (RR) entre DMO i fractures es basen en una 
metanàlisi publicada el 2005 de 12 estudis poblacionals prospectius d’Europa 
occidental, Estats Units, Canadà, Japó i Austràlia (Johnell, Kanis et al. 2005). El 
nostre SR també incloïa una cerca dissenyada per identificar estudis d’alta qualitat 
en risc relatiu entre DMO i fractura. (Figure 4.1). Es van identificar molts pocs 
estudis poblacionals prospectius publicats després de la metanàlisi del 2005 (Table 
4.2), els quals presentaven valors de RR comparables als obtinguts prèviament, 
amb una mostra total poc significativa comparat amb la metanàlisi anterior, i per 
tant, es va considerar com no necessària l’actualització de la metanàlisi del 2005.  
 
Pels objectius del nostre treball, els valors originals de RR expressats en RR/SD del 
Z score, es van transformar a valors absoluts de RR/0,1g/cm2 de FNBMD (Table 
3.3), amb la col·laboració d’un dels autors de la metanàlisi, que era un dels 
membres components de l’ELG, i de l’ús de DisMod-MR, que en va derivar 
estimacions de risc per homes i dones per cada grup d’edat, tant per fractures de 
maluc, com per la resta de fractures en el seu conjunt.  
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Per establir el TMRED (el nivell òptim de DMO), es va escollir una referència 
internacional que permetés realitzar comparacions, provinent de la mostra 
poblacional del National Health and Nutritional Examination Survey (NHANES) III 
(Looker, Wahner et al. 1998). Després d’analitzar el resultat provisional de diversos 
escenaris de TMRED (Figure 3.3 i Figure 3.4), es va decidir finalment per l’ús del 
percentil 90 específic per edat i gènere de caucàsics d’aquest estudi (Table 3.4).    
 
3.5 Càrrega en salut mundial degut a les caigudes atribuïbles a la 
baixa densitat mineral òssia 
La mortalitat i la morbiditat associades a la baixa DMO es van calcular, només, per 
poblacions a partir dels 50 anys. Els principals motius foren la relativa baixa 
prevalença de la condició en poblacions més joves, i sobretot, la manca d’una 
evidència epidemiològica sòlida de la relació DMO-fractura en poblacions més joves.  
 
La informació en mortalitat en l’estudi GBD 2010 es va obtenir de diverses fonts, de 
les quals les més importants foren els registres vitals nacionals i les morts intra-
hospitalàries (Lozano, Naghavi et al. 2012). Per atribuir les morts degudes a baixa 
DMO, la dificultat estrebava en que les morts es trobaven categoritzades segons la 
causa de la lesió (caigudes), enlloc de la naturalesa de la lesió (fractura). Al seu 
torn, les fractures es poden trobar com a conseqüència de moltes lesions segons el 
sistema internacional de classificació de malalties (International Diseases 
Classification System and other health problems, ICD), com ara accidents de trànsit, 
assalts, o desastres naturals. Degut als objectius de la nostra anàlisi, les 
estimacions de les PAFs es van restringir a aquelles fractures degudes a caigudes 
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“casuals” o accidentals”, on s’esperava trobar-hi la major part de les fractures 
degudes a osteoporosi o baixa DMO. Amb aquest propòsit, es van utilitzar registres 
nacionals de dades hospitalàries de Brazil (Ministry of Health (Brazil). 2006-2009), 
Canadà (Canadian Institute for Health Information. 1994-2009), Mèxic (Ministry of 
Health (Mexico). 2000-2009), i els Estats Units (National Center for Health Statistics, 
Centers for Disease Control and Prevention, US Census Bureau. 1979-2009) amb 
doble codificació (causa i naturalesa de la lesió) per calcular la proporció de morts 
intra-hospitalàries degudes a caigudes que involucressin fractures de maluc o 
fractures vertebrals. Aquelles caigudes amb menció concomitant de dany cerebral o 
lesió interna (sagnat abdominal, hemotòrax, etc) es van excloure de l’anàlisi.  Altres 
tipus de fractura (no-maluc-no-vertebral) es van excloure dels càlculs, ja que es van 
considerar com menys probables de causar mortalitat, decisió recolzada per una 
anàlisi de la base nacional de dades australiana 
(http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3303.0Main+Features12003?
OpenDocument). Atès que aquesta era l’única font per determinar la fracció de les 
morts secundàries a caigudes degudes a fractures de maluc o vèrtebra, fou 
necessari aplicar les proporcions obtingudes a tots els països.  
 
Pel que fa al càlcul de la discapacitat, els YLDs es van calcular segons la 
localització de la fractura en totes aquelles fractures resultants de caigudes 
accidentals, amb dades d’incidència provinent fonamentalment d’altes hospitalàries 
de planta i urgències. D’aquesta manera, els RRs per unitat de FNBMD relacionats 
amb fractura de maluc (Table 3.3) es van aplicar a totes les fractures de maluc, 
mentre que el RRs de fractures diferents del maluc es van aplicar a la resta de 
fractures (Table 3.3). Pel càlcul dels YLDs es van utilitzar els pesos relatius de 
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discapacitat (Disability Weights, DW) originats en l’estudi GBD 2010 per cada 
localització de fractura(Table 3.6) (Salomon, Vos et al. 2012). 
 
El resultat de les PAFs de baixa DMO per fractures foren aplicats als càlculs de 
YLDs de les fractures dins la càrrega global degut a les caigudes. Pels càlculs de 
mortalitat, les PAFs per fractures foren aplicades a les proporcions de morts 
relacionades amb caigudes per fractures de maluc i fractures vertebrals sense 
fractura de maluc (Table 3.5). 
 
Finalment, per obtenir el número de DALYs finals deguts a baixa DMO es van 
aplicar les fòrmules generals relacionades amb el GBD:  
 
DALY= YLL + YLD 
on: 
YLL=years of life lost to premature mortality ; YLD=years lived with disability  
i:  
YLL = N x L  
on  N = number of deaths; L = standard life expectancy at age of death in years  
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4  Resultats 
 
4.1 Resultats de la revisió sistemàtica  
El procés de revisió sistemàtica (SR) es mostra a la Figure 4.1. Es van seleccionar 
130 estudis (Appendix 5) per la variable d’exposició de risc (FNBMD), amb un total 
de 860 punts d’informació provinent de 49 països de 17 de les 21 regions en què es 
va dividir el món en l‘estudi GBD 2010 (Figure 4.2), amb una heterogeneïtat 
important en quant a la quantitat d’informació segons la regió. La dades sobre els 
nivells poblacionals de DMO foren més robustes pel 2010, ja que el nombre de 
publicacions va augmentar progressivament des del 1980 fins el 2010 (Figure 4.3). 
 
Cap de les variables nacionals utilitzades (ingressos per habitant, índex de massa 
corporal, i disponibilitat de llet) va demostrar cap millora significativa en l’habilitat 
predictiva de DisMod-MR, i per tant, no foren incloses en el model de predicció.  
 
L’eina per valorar la qualitat dels estudis inclosos (RoB tool) tampoc no va provar ser 
predictiva del valor de DMO (Table 4.1), i per tant, no es va introduir cap co-variant 
en l’anàlisi depenent del risc de biaix basat en els resultats del RoB tool.   
 
Pel que fa a la segona estratègia de cerca (risk factor-disease relationship) (Figure 
4.1), com s’ha esmentat anteriorment, es van identificar molts pocs estudis 
poblacionals prospectius publicats després de la metanàlisi del 2005 (Table 4.2). 
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Aquests estudis presentaven valors de RR comparables als obtinguts prèviament, 
amb una mostra total poc significativa comparat amb la metanàlisi anterior, i per 
tant, es va considerar com no necessària l’actualització del metanàlisi del 2005.  
 
4.2 Resultats de la variable d’exposició al factor de risc: 
Distribució de la densitat mineral òssia 
La distribució mundial dels valors poblacionals de la DMO (expressat en sFNBMD) a 
partir dels 50 anys d’edat pel 1990 i pel 2010 es mostra en la Figure 4.6. Àsia i 
Àfrica foren les regions amb nivells més baixos de DMO, mentre que Nord-Amèrica, 
la regió del Carib i Europa de l’est mostraren els valors més elevats de DMO tant per 
homes com per dones. Malgrat que els valors de DMO ajustats per edat havien 
mostrat una tendència a la millora entre 1990 i 2010 en anàlisis descriptives 
preliminars (Sanchez-Riera, Wilson et al. 2010), particularment a Àsia i Europa 
occidental, la DMO a nivell poblacional disminuí en algunes regions degut a 
l’envelliment de la població. 
 
4.3 Fracció de la càrrega en salut mundial degut a caigudes 
atribuïble a la baixa densitat mineral òssia 
La fracció de l’impacte degut a caigudes atribuïble a la baixa DMO (PAFs) resultà en 
general més elevada en dones que en homes, tant per les estimacions del 1990 
com per les del 2010.  En general, les PAFs més altes s’observaren en regions 
pobres (Àsia est, Àsia sud-est, Àfrica sub-sahariana est i oest), amb l’excepció de 
l’Europa de l’est. No obstant, gran diversitat de PAFs s’observà entre els països rics, 
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fins i tot dins la mateixa regió geogràfica (els països escandinaus, per exemple, 
comparats amb el Regne Unit) (Figure 4.7). 
 
Pels càlculs de 1990, un 12,1% de tots els DALYs deguts a caigudes i un 29,6% de 
totes les morts degudes a les caigudes foren atribuïbles a la baixa DMO. Aquests 
percentatges augmentaren al 14,8% i al 34,7%, respectivament, per les estimacions 
del 2010. La contribució en la càrrega mundial entre totes les causes de salut 
s’incrementà en totes les regions mundials excepte el Carib i Oceania (Table 4.3).   
  
4.4 Càrrega en salut mundial degut a la baixa densitat mineral 
òssia: DALYs, YLDs, YLLs i morts 
A nivell mundial, el número de morts i de DALYs atribuïbles a la baixa DMO pel 
1990 augmentà des de 103.000 i 3.125.000, respectivament, a 188.000 i 5.216.000, 
respectivament, pel 2010. La contribució de la baixa DMO en la càrrega en salut 
mundial resultant de totes les causes analitzades gairebé es duplicà des del 1990 
(0,12%) fins al 2010 (0,21%), amb augments significatius tant dels YLLs com dels 
YLDs en ambdós sexes (Table 4.4). En el grup d’edat de 50-69 anys, aquests 
percentatges incrementaren al 0,41% pel 1990 i al 0,5% pel 2010, i esdevingueren 
encara més elevats en la població a partir dels 70 anys d’edat (0,64% i 0,79%, 
respectivament) (http://www.healthdata.org/gbd). Àsia est i Àsia sud foren les 
regions que més van contribuir a l’increment mundial de l’impacte en salut de la 
baixa DMO. Les tasses de DALYs mundials per 100.000 habitants augmentaren 
significativament des 1990 al 2010, però l’augment fou més discret amb 
l’estandardització per edat (Table 4.3), la qual cosa reflecteix el creixement i 
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envelliment de la població. Les tasses foren més altes a Europa occidental, Europa 
central, i la regió Àsia-Pacífic, mentre que les tasses estandarditzades per edat 
foren més altes, en general, en regions en vies de desenvolupament o 
subdesenvolupades, tals com Àfrica subsahariana est i oest, Oceania, Àsia est, i 
Àsia sud (Table 4.4 i Figure 4.8). La mortalitat prematura (YLLs) contribuí a la 
càrrega mundial en salut lleugerament més que la discapacitat (YLDs). Així, els 
YLLs representaren el 51% i el 53% de tots els DALYs atribuïbles a la baixa DMO 
pel 1990 i pel 2010, respectivament (Table 4.4).  
 
L’anàlisi per gèneres rebel·là que els homes obtingueren més DALYs que les dones 
tant pel 1990 com pel 2010, amb una bretxa entre els dos gèneres que augmentà 
entre els dos períodes, corresponent un 56% i un 60% de tots els DALYs als homes 
pel 1990 i el 2010, respectivament (Table 4.4). La bretxa entre gèneres augmentà 
amb el càlcul de la tassa de DALYs per 100.000 habitants tant pel 1990 com pel 
2010, i en el subgrups de 50-69 anys i ≥ 70 anys. Les diferències entre sexes foren 
més destacables en els YLLs que en els YLDs. Les morts atribuïbles a la baixa 
DMO gairebé es doblaren en homes des del 1990 (52.816) al 2010 (103.440), 
mentre que en dones l’increment fou d’aproximadament un 60% entre el 1990 
(50.455) i el 2010 (84.146) (http://www.healthdata.org/gbd). 
 
Per totes les malalties, lesions i factors de risc analitzats en l’estudi GBD 2010, els 
detalls sobre els resultats dels DALYs, YLDs, YLLs i morts es poden visualitzar a la 
web de l’Institute for Health Metrics and Evaluation (IHME) de forma gratuïta per 
regió, país, gènere, grup d’edat i any (http://www.healthdata.org/gbd). 
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4.5 Comparació de la càrrega en salut de la baixa densitat mineral 
òssia comparat amb altres factors de risc en l’estudi GBD 2010.   
La baixa DMO obtingué un rang més aviat baix en termes del total de DALYs que en 
foren atribuïbles en comparació amb altres factors de risc analitzats en l’estudi GBD 
2010, com els factors dietètics, la pressió arterial elevada, el tabaquisme, l’ús de 
l’alcohol, la glucosa sèrica en dejú, l’alt IMC, l’alt colesterol i la baixa activitat física 
(Figure 4.9) (Lim, Vos et al. 2012).  
 
En agrupar tots els factors dietètics i tots els factors ocupacionals en una categoria 
conjunta per cadascun, la classificació de la baixa DMO es trobà en la posició 20 
entre 21 categories de factors de risc analitzats en les estimacions mundials pel 
1990, i en la posició 23 entre 25 categories pel 2010. Per algunes regions del món, 
la baixa DMO ocupà posicions més elevades: la posició 12 a Europa Occidental, la 
13 a Àsia-Pacífic, la 15 a Europa central, Australàsia i Nord-Amèrica, i la 16 a Àsia 
est. Una millora en la classificació mundial dels factors de risc s’observà en 
seleccionar els subgrups d’edat avançada (Figures 4.10-4.17). Així, per exemple, la 
baixa DMO fou l’11è factor de risc (d’entre 17 categories) amb el màxim nombre de 
DALYs al món pel 1990, i el 13è (entre 21 categories) pel 2010 (Figure 4.11) en 
població ≥ 70 anys. Els resultats foren similar per homes i dones, amb canvis 
màxims d’una posició en les classificacions per grups de gènere 
(http://www.healthdata.org/gbd). 
 45 
5  Discussió 
Les conseqüències en salut de les fractures osteoporòtiques van des del dolor 
crònic fins a la institucionalització i la mort, ocasionant una factura social i 
econòmica enormes, amb projeccions d’augmentar ràpidament en les properes 
dècades arreu del món. Atesa l’evidència de que el cribratge i tractament de 
l’osteoporosi és cost-efectiu, i la manca actual de reconeixement de la seva 
importància, iniciatives en salut pública són requerides urgentment per tal de 
promoure’n el diagnòstic precoç i el tractament. 
 
Per primer cop, la baixa DMO, un bon predictor d’osteoporosi i risc de fractura, ha 
estat analitzada com a factor de risc dins l’estudi d’epidemiologia d’abast mundial 
GBD 2010. La càrrega en salut atribuïble a la DMO s’ha realitzat analitzant el seu 
impacte en les fractures, que al seu torn, han format part de la càrrega en salut 
deguda a les caigudes.      
 
Els resultats han mostrat que, tot i que els valors de la DMO ajustats per edat 
mostraren una tendència a la millora a nivell mundial a través del temps, l’impacte 
absolut en salut de la baixa DMO augmentà del 1990 al 2010, probablement 
relacionat al creixement global de la població d’edat avançada. Les tasses de 
DALYs estandarditzades per edat i les PAFs més elevades en regions mundials 
pobres probablement reflecteixen el paper important de determinants de la DMO 
potencialment modificables, com els factors nutricionals i l’accés a l’assistència 
sanitària. La mortalitat prematura (YLLs) contribuí lleugerament més que la 
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discapacitat (YLDs) en el conjunt global de DALYs atribuïbles a baixa DMO. Aquest 
fet s’explica, al menys parcialment, per l’alta mortalitat associada, ja que la baixa 
DMO podria ésser responsable de fins a un terç de totes les morts atribuïbles a les 
caigudes accidentals, les quals ocuparen la tercera posició entre les lesions amb 
més càrrega en salut mundial en el GBD 2010 (la segona posició en el grup de 50-
69 anys i la primera posició en el grup a partir de 70 anys) (Murray, Vos et al. 2012).  
 
Per tots els paràmetres de mesura de l’impacte en salut, els homes mostraren valors 
més elevats que les dones malgrat les PAFs foren superiors en les darreres. Raons 
que expliquen aquesta troballa són la incidència més alta de fractures en el conjunt 
d’homes, i la tassa de mortalitat més elevada en homes seguint la fractura, 
particularment en els grups d’edat més joves. Aquesta darrera observació és 
compatible amb estudis longitudinals  (Center, Nguyen et al. 1999, Kannegaard, van 
der Mark et al. 2010, Melton, Achenbach et al. 2013). La inclusió de totes les 
localitzacions de fractures, incloent aquelles no clarament relacionades amb 
l’osteoporosi (cara, crani, mà) i el ventall ampli de codis de caigudes utilitzats 
(incloent lesions per traumatismes d’alta energia) es l’explicació més raonable 
darrera de la superioritat de la càrrega en salut atribuïble a la baixa DMO en homes 
comparat amb dones, conjuntament amb la utilització d’un TMRED per l’anàlisi de 
risc comparatiu que pretenia eliminar l’efecte de l’edat i el gènere en el risc de 
fractura.  
 
Tot i que el pes relatiu de la baixa DMO comparat amb la resta de factors de risc 
augmentava en grups d’edat avançada i en regions desenvolupades, en global, 
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l’impacte de la baixa DMO en el total de la salut mundial esdevingué inferior a molts 
altres factors de risc, i és possible que el pes relatiu de la DMO en el panorama de 
la salut mundial hagi estat infravalorat per diverses raons.   
 
Primer, l’elecció d’un nivell òptim de DMO (TMRED) per l’anàlisi de risc comparatiu 
(CRA) utilitzant una referència ajustada per edat i gènere, emmascarà l’important 
paper de l’edat i el gènere en el risc de fractura (Kanis, Johnell et al. 2001), i pot ser 
que expliqui una gran part del pes relativament baix que la baixa DMO obtingué en 
comparació a altres factors de risc dins l’impacte en salut mundial. Tanmateix, la 
iniciativa GBD té com a objectiu principal la de proporcionar una fotografia útil per tal 
d’ajudar a establir prioritats en estratègies de salut pública; es centra sobretot en 
condicions “modificables”. En conseqüència, l’edat i el gènere havien de ser 
exclosos de l’anàlisi atès el seu paper clar com factors de risc independents de 
baixa DMO. D’altra banda, l’elecció d’una referència caucàsica americana (Looker, 
Wahner et al. 1998) per dibuixar l’escenari ideal de DMO pot haver conduït a una 
sobreestimació o una infraestimació, segons la regió, del paper de la baixa DMO en 
l’impacte en salut. En aquest sentit, l’ús de diversos TMREDs regionals foren 
considerats. No obstant, es va seleccionar una referència única, l’actualment 
recomanada pels organismes científics internacionals (Kanis 2008; Kanis, 
McCloskey et al. 2008; Internaional Society of Clinical Densitometry 2013) per tal de 
facilitar l’anàlisi comparatiu entre diferents regions del món. A més a més, no existia 
una referència poblacional d’alta qualitat per cada regió del món. A banda de totes 
aquestes consideracions en relació al TMRED per la nostra anàlisi de risc 
comparatiu, el que és important de remarcar és que la relació de risc entre DMO i 
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fractures sembla ser constant entre diverses ètnies (Leslie 2012; Shin, Zmuda et al. 
2014). 
 
Separar les morts degudes a fractures del global de morts relacionades amb les 
caigudes no fou una tasca fàcil. Va ser necessari recórrer a les poques fonts que 
informaven tant de la causa de la lesió com de la naturalesa de la lesió a través de 
dades hospitalàries que incloïen la doble codificació segons els sistemes ICD9 i ICD 
10. Tampoc fou gens fàcil atribuir morts com a conseqüència de fractures a la baixa 
DMO, ja que rarament els diagnòstics d’osteoporosi, osteopènia o baixa massa  
òssia apareixien en els certificats de defunció. Per resoldre aquests conflictes, es 
van incloure totes aquells codis de caigudes potencialment relacionats amb 
“fractures per fragilitat”, segons la definició de les quals, succeeixen de forma 
inintencionada com a conseqüència d’un succés intrínsec no major (Gibson M 
1987). Tot i que alguns pocs codis podien incloure caigudes potencialment d’alt 
impacte, i per tant, no considerades clàssicament com caigudes relacionades amb 
“fractures per fragilitat”, es considerà que també compartien en tot cas una relació 
amb la baixa DMO. Una altra estratègia rellevant per identificar aquelles morts 
potencialment relacionades amb la fractura i la baixa DMO fou excloure aquells 
traumatismes amb codis concomitants corresponents a lesió cerebral o interna, per 
facilitar l’anàlisi de mortalitat degut únicament al succés de la fractura.  
 
Assumir que només les fractures associades a caigudes accidentals es trobaven 
relacionades amb la baixa DMO ben segur fou una causa de pèrdua de l’impacte 
estimat per la baixa DMO en la salut global, atesa l’evidència prèvia del paper 
rellevant de la DMO tant en traumatismes de baixa com d’alta energia (Karlsson, 
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Hasserius et al. 1993; Sanders, Pasco et al. 1998; Mackey, Lui et al. 2007), inclús 
en població jove. Si es consideren, per exemple, totes les fractures relacionades 
amb accidents de trànsit i les autolesions (primera i segona causes d’impacte en 
salut mundial pel que fa al grup de lesions en l’estudi GBD 2010), el percentatge 
potencial de l’impacte en salut degut a la baixa DMO que s’ometé és immens.  
 
D’altra banda, només les fractures clíniques (aquelles que resulten de caigudes) es 
tingueren en compte en les estimacions de l’impacte de la baixa DMO, mentre que 
és ben reconegut que només al voltant d’un terç de les fractures vertebrals són 
clíniques (Ross 1997). Les fractures vertebrals prevalents, inclús si tenen lloc sense 
símptomes aguts, comporten freqüentment conseqüències a llarg termini, com dolor 
crònic, cifosis i patologia pulmonar restrictiva (Silverman 1992; Ross 1997). Per bé 
que és d’esperar que la càrrega en salut d’aquest tipus de fractura fou recollit en 
part dins el ventall de condicions subjacents a la lumbàlgia (low back pain, primera 
causa de discapacitat mundial en l’estudi GBD 2010), cal admetre la seva exclusió 
dins l’impacte en salut degut a les caigudes, i per tant, la reducció en el paper 
atribuïble de la DMO.  
 
La troballa de més YLLs que YLDs en els resultats d’aquest treball és contrària a la 
noció que la major part de l’impacte en salut provinent de les fractures prové, 
precisament, de la discapacitat a llarg termini (ja que la major part d’inidividus no 
moren després de patir una fractura). Una explicació plausible darrera d’aquests 
resultats és el poc pes relatiu de la fractura de maluc en la seva descripció de 
seqüela a llarg termini (Table 3.6). És molt possible que el mot “fixed” (“arreglat”) de 
la descripció utilitzada per generar-ne el DW corresponent indugués falsament a una 
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valoració excessivament optimista de la discapacitat a llarg termini de la fractura de 
maluc. Una altra possible font de pèrdua de YLDs és la utilització predominant de 
dades hospitalàries per detectar aquelles fractures relacionades amb caigudes, ja 
que és probable que algunes fractures menors en països no desenvolupats no 
acabin en consulta hospitalària.   
 
L’exclusió de totes aquelles fractures diferents de la localització en maluc i vèrtebra 
de l’anàlisi de mortalitat relacionat a les fractures per caigudes fou probablement un 
altre factor contribuent a la infraestimació del paper de la baixa DMO en salut. Com 
s’explicà en la secció de mètodes, la inclusió exclusiva de les fractures de maluc i 
les fractures vertebrals es recolzà en un anàlisi prèvia de la base de dades 
nacionals de mortalitat australiana (http://www.abs.gov.au/ AUSSTATS/abs@.nsf/ 
Lookup/3303.0Main+Features12003?OpenDocument). Importants estudis 
epidemiològics longitudinals han trobat resultats similars (Cauley, Thompson et al. 
2000; Ioannidis, Papaioannou et al. 2009). Per bé que les fractures de maluc i de 
vèrtebra han demostrat ser la primera i la segona causa de mortalitat, 
respectivament, degut a fractures osteoporòtiques (Browner, Pressman et al. 1996; 
Bliuc, Nguyen et al. 2009; Ioannidis, Papaioannou et al. 2009), alguns autors han 
demostrat la participació d’altres localitzacions de fractura en el risc de mortalitat a 
llarg termini en estudis prospectius (Bliuc, Nguyen et al. 2009; Morin, Lix et al. 2011; 
Melton, Achenbach et al. 2013; Bliuc, Nguyen et al. 2014). Malgrat això, bona part 
d’aquest excés de mortalitat es atribuïble al risc de subseqüents fractures amb alt 
impacte en salut, com la fractura de maluc. De fet, la mortalitat a llarg termini 
relacionada amb les fractures es un fenomen tediós d’interpretar en el marc de 
l’estudi GBD, ja que la mortalitat ha de trobar-se intrínsecament associada a la 
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fractura. Això pot resultar difícil d’interpretar, sobretot tenint en compte que la 
mortalitat relacionada a les fractures osteoporòtiques es troba molt íntimament 
relacionada als nivell basals de fragilitat (Cawthon, Marshall et al. 2007; Ensrud, 
Ewing et al. 2007; Tosteson, Gottlieb et al. 2007; Patel, Brennan et al. 2014), i per 
tant, esdevé complicat establir quina fracció d’aquesta mortalitat a llarg termini és 
realment atribuïble al succés de la fractura.   
 
Pel que fa al mètode de mesura de la variable d’exposició al factor de risc, la DXA, 
cal acceptar un possible biaix de selecció envers a països amb més àmplia 
disponibilitat d’aquesta tècnica (International Osteoporosis Foundation 2008). A 
més, l’aplicació d’equacions d’estandardització entre diferents fabricants de DXA 
resulta probablement incompleta per eliminar totes la diferències de mesura entre 
aparells, especialment entre diferents models del mateix fabricant (Barthe, Braillon 
et al. 1997; Henzell, Dhaliwal et al. 2003). D’altra banda, la selecció del coll femoral 
com a única localització de la mesura de la DMO també pot haver infraestimat la 
prevalença de la baixa DMO, davant l’observació que els nivells de DMO a columna 
lumbar solen ser en general més baixos que a maluc, sovint presentant discordança 
diagnòstica (Woodson 2000; O'Gradaigh, Debiram et al. 2003; Looker, Melton et al. 
2012). Ara bé, les mesures de la DMO a columna lumbar tenen més risc d’ésser 
artefactades (sobretot per canvis artròsics o calcificacions vasculars) que no pas a 
coll femoral (Paggiosi, Glueer et al. 2011). El que és més, fins al moment, l’evidència 
epidemiològica més robusta en relació al risc relatiu DMO-fractures utilitza la DMO a 
coll femoral (FNBMD) com a variable d’exposició al risc (Johnell, Kanis et al. 2005).  
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En tant a la qualitat dels estudis que finalment es van incloure de la revisió 
sistemàtica, no es trobà cap diferència en els valors de DMO entre diferents grups 
de risc de biaix. Eren esperables, per exemple, les divergències entre diferents 
grups de risc de biaix de selecció, ja que gran part dels estudis excloïen individus 
amb història de fractura prèvia, però els models de regressió lineal no van 
aconseguir de demostrar aquesta hipòtesi. Les raons darrera d’aquest resultats són 
desconegudes, però és possible que tingui relació amb la disparitat en número 
d’estudis en cada grup de biaix, i l’heterogeneïtat entre els estudis en general.  
 
Finalment, cal tenir en compte les limitacions intrínseques d’aquest treball. D’una 
banda, cal recordar que, malgrat la baixa DMO és un bon predictor del risc de 
fractura, té una baixa sensibilitat com a factor de risc aïllat (Siris, Chen et al. 2004). 
És possible que estudis futurs puguin utilitzar mesures compostes de la resistència 
òssia, incloent paràmetres de geometria de maluc, grossor cortical i trabecular, etc, 
a més a més de la DMO. Per ara, això no és possible d’aplicar a un nivell 
poblacional, i menys encara, en un estudi d’àmbit mundial, degut a una manca clara 
de la disponibilitat àmplia de la tecnologia necessària i de l’excés de radiació que 
aquestes tecnologies impliquen. Tot i així, la DMO constitueix encara una mesura 
fàcil i objectiva de mesurar la resistència òssia i que permet realitzar comparacions a 
molts nivells (entre edats, regions, etc). Ara bé, aquest treball boga per una anàlisi 
del risc de fractura basada en la DMO com una variable contínua, i no basada en les 
categories diagnòstiques establertes per l’OMS.         
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Per acabar, cal recordar les limitacions intrínseques relacionades amb l’abast de la 
l’estudi GBD. Aquesta iniciativa no té en consideració els costos socials i econòmics 
derivats de cada condició estudiada. Tal com s’ha explicat prèviament, les millores 
en l’expectativa de vida i l’envelliment mundial de la població estant conduint les 
fractures osteoporòtiques a provocar una factura enorme per gairebé totes les 
societats del món, amb projeccions de créixer ràpidament en les següents dècades i 
convertir-se en una de les verdaderes epidèmies de les societats futures. El 
cribratge i el tractament farmacològic de l’osteoporosi ha demostrat ser cost-efectiu 
per reduir-ne les fractures i la mortalitat derivades. Tot i així, la manca de 
reconeixement de la magnitud del problema és encara molt insuficient per part de la 
població general, els professionals en salut i les institucions científiques. Per tant, 
les autoritats en salut pública han de considerar tots aquests factors de gran 
rellevància en establir prioritats en prevenció de malalties i decidir on destinar els 
recursos.   
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6  Conclusions 
Aquest treball constitueix el primer estudi mai realitzat en mesurar la càrrega en 
salut mundial que seria teòricament evitable en l’absència de baixa DMO a la 
població mundial, considerant la DMO com una variable contínua i utilitzant una 
metodologia única que permet comparar estimacions entre gèneres, grups d’edat i 
regions del món, i analitzar tendències amb el temps. El resultats obtinguts ens 
permeten arribar a les següents conclusions:   
 
 
1. En la població a partir dels 50 anys d’edat, Àsia i Àfrica foren les regions del 
món amb valors més baixos de DMO a coll femoral (FNBMD), mentre que 
Nord-Amèrica, el Carib i Europa de l’est mostraren els valors de FNBMD més 
elevats, tant per homes com per dones. Tot i que els valors de FNBMD 
ajustats per edat mostraren una millora entre el 1990 i el 2010, sobretot a 
Àsia i Europa occidental, la distribució dels nivells poblacionals de FNBMD 
varen disminuir entre els dos períodes degut a un envelliment global de la 
població. Els nivells poblacionals de FNBMD foren superiors en homes que 
en dones per totes les regions mundials i per tots els períodes de temps.  
2. La fracció poblacional atribuïble (PAFs) de la baixa DMO per les caigudes fou 
generalment més elevada per dones que per homes tant el 1990 com el 
2010. En general, les PAFs més altes s’observaren en regions pobres (Àsia 
est i Àsia sud-est, Àfrica subsahariana sud-est, Àfrica subsahariana est i 
Àfrica subsahariana oest). Les PAFs mundials degudes a la baixa DMO van 
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augmentar des de 1990 al 2010 tant per homes com per dones. El nombre 
total de DALYs atribuïbles a la baixa DMO pel 1990 representaren un 12,1% i 
un 29,6%, respectivament, de tots els DALYs deguts a caigudes. Aquests 
percentatges augmentaren al 14,8% i al 34,7%, respectivament, per les 
estimacions del 2010.  
3. El percentatge de la baixa DMO en la càrrega en salut mundial gairebé es 
doblà des del 1990 (0,12%) al 2010 (0,21%). En la població de 50-69 anys, 
aquests percentatges augmentaren al 0,41% pel 1990 i al 0,5% pel 2010, i 
foren encara més elevats en la població a partir dels 70 anys d’edat (0,64% i 
0,79% pel 1990 i el 2010, respectivament). La fracció de la DMO en el total 
de la càrrega en salut regional augmentà en gairebé totes les regions del 
món.   
 
4. A nivell mundial, el número de morts atribuïbles a la baixa DMO augmentà 
des de 103.000 pel 1990 a 188.000 pel 2010. Les morts atribuïbles a la baixa 
DMO gairebé es doblaren en homes des del 1990 (52.816) al 2010 (103.440), 
mentre que en dones l’increment fou d’aproximadament un 60% entre el 1990 
(50.455) i el 2010 (84.146).  
 
5. A nivell mundial, el número de DALYs atribuïbles a la baixa DMO augmentà 
des de 3.125.000 pel 1990 a 5.216.000 pel 2010. Àsia est i Àsia sud foren les 
regions que més contribuïren a l’increment de la càrrega mundial en salut de 
la baixa DMO. Les tasses de DALYs mundials per 100.000 habitants 
augmentaren significativament des del 1990 al 2010, però l’augment fou més 
discret amb l’estandardització per edat, la qual cosa reflecteix el creixement i 
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envelliment de la població. Les tasses estandarditzades per edat foren més 
altes, en general, en regions en vies de desenvolupament o 
subdesenvolupades. La mortalitat prematura (YLLs) contribuí a la càrrega 
mundial en salut lleugerament més que la discapacitat (YLDs), representant 
el 51% i el 53% de tots els DALYs atribuïbles a la baixa DMO pel 1990 i pel 
2010, respectivament. Els homes obtingueren més DALYs que les dones tant 
pel 1990 com pel 2010, amb un 56% i un 60% de tots els DALYs pel 1990 i el 
2010, respectivament. 
 
6. La càrrega relativa en salut mundial de la DMO en comparació amb altres 
factors de risc en l’estudi GBD 2010 fou més aviat baixa. La classificació de la 
baixa DMO es trobà en la posició 20 entre 21 categories de factors de risc 
analitzats en les estimacions mundials pel 1990, i en la posició 23 entre 25 
categories pel 2010. En general, la baixa DMO ocupà posicions més 
elevades en regions més desenvolupades. Una millora en la classificació 
mundial dels factors de risc s’observà en seleccionar els subgrups d’edat 
avançada, amb la posició màxima observada pel subgrup de població a partir 
de 70 anys d’edat, essent la baixa DMO l’11è factor de risc (d’entre 17 
categories) amb el màxim nombre de DALYs al món pel 1990, i el 13è (entre 
21 categories) pel 2010 (Figure 4.11) en aquest subgrup de població. Els 
resultats en les classificacions foren similar per homes i dones. 
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7  Projeccions de Futur 
El projecte GBD és una iniciativa dinàmica. L’autora d’aquesta tesi forma part del 
grup de treball de l’estudi GBD 2013, el qual pretén actualitzar les dades obtingudes 
en la darrera versió del 2010. En aquest darrers projecte s’han tingut en compte 
moltes de les lliçons apreses exposades en aquesta tesi. Les millores en l’estimació 
de l’impacte en salut de la DMO inclouen:   
 
1) Incorporació de noves dades epidemiològiques actualitzant la revisió 
sistemàtica; aquest cop també incloent individus entre els 20 i els 50 anys 
d’edat.  
2) Actualització dels valors de referència pel llindar de DMO ideal en l’anàlisi de 
risc comparatiu (TMRED) amb fonts més recent de l’estudi NHANES.  
3) Inclusió de tot tipus de lesions que tinguin com a conseqüència una fractura 
independentment de la causa (incloent, per tant, fractures resultant 
d’accidents de trànsit, assalts, etc).   
4) La cerca de dades epidemiològiques fiables sobre la relació de risc entre 
DMO i fractura en poblacions joves.  De moment, però, a data de presentació 
d’aquesta tesi, encara no s’han identificat estudis prospectius en població 
jove que abastin grans rangs d’edat, ja que les disponibles inclouen com a 
molt, dones premenopàusiques dels 40 als 50 anys d’edat.  
5) La consideració d’incloure fractures diferents a les de maluc i vèrtebra en els 
càlculs de mortalitat deguts a baixa DMO. Aquest aspecte també es troba en 
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discussió actualment, ja que la informació en mortalitat continua estant 
basada en registres vitals i dades hospitalàries, i per tant, amb poca capacitat 
de detectar causes subjacents molt allunyades temporalment de 
l’esdeveniment de la fractura.  
 
Per ajudar en tasques futures, és important que els sistemes d’informació en salut, 
així com els professionals que els utilitzen, estiguin preparats per detectar la 
mortalitat i la discapacitat a curt i llarg termini relacionades amb les fractures 
osteoporòtiques o amb totes aquelles fractures on l’osteoporosi hi juga un paper 
rellevant. En aquest sentit, augmentar la utilització dels codis relacionats amb 
l’osteoporosi, i la doble codificació (causa i naturalesa) de les lesions en els 
sistemes ICD és fonamental. La informació obtinguda pot ser utilitzada per les 
autoritats per una millor planificació en els programes de prevenció i maneig de 
l’osteoporosi.  
 
L’equip d’investigadors principals en el MSK EG per l’estudi GBD 2010 es troba 
actualment colˑlaborant amb l’OMS (WHO) per tal que les malalties 
musculoesquelètiques, entre elles l’osteoporosi i les fractures per fragilitat, es trobin 
entre les prioritats marcades per l’OMS per les malalties no comunicables, i es 
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Introduction: Osteoporosis and osteoporotic fractures represent an enormous 
health burden and economic cost for most societies in the world, and future 
projections forecast their steady increase over the next few decades. Strategies to 
detect and treat those individuals with high risk of fracture have proved to be cost-
effective, but still an important lack of awareness exists among health professionals, 
public health institutions and general population. Low bone mineral density (BMD) is 
one of the factors better correlated with fracture risk, and its predictive value for hip 
and non-hip fractures has been well established. Standard and easy methods to 
measure BMD are available, which allow to compare values among different 
population groups. The Global Burden of Disease Study 2010 estimated the 
worldwide health burden of 291 diseases and injuries and 67 risk factors. The main 
metrics for the burden measurements were the Disability-Adjusted Life Years 
(DALYs), the Years lived with disability (YLDs), the Years of Life Lost due to 
premature mortality (YLLs) and Deaths. For the first time, BMD was analysed as a 
risk factor for fractures, which formed part of the health burden due to falls. Risk 
analysis followed the Comparative Risk Assessment (CRA) methodology to 
determine which proportion of the falls burden was attributable to low BMD.  
 
Objectives: To calculate the global distribution of BMD, its population attributable 
fraction (PAF) for falls, and the number of DALYs, YLDs, YLLs and deaths due to 
low BMD, with estimates for each region, age group, sex and time period (1990 and 
2010).  
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Methods: Systematic review was performed seeking population-based studies with 
BMD measured by Dual-X-Ray-Absorptiometry at femoral neck in people 50 years 
and over. Age- and sex- specific levels of mean BMD+/-SD (g/cm2) were extracted 
from eligible studies. For the CRA methodology to calculate PAFs of BMD for 
fractures, the theoretical minimum risk factor exposure distribution was estimated as 
the age and sex-specific 90th percentile from NHANES III. Relative risks for fractures 
were obtained from a previous meta-analysis. Hospital data with double coding 
(cause and nature of injury) was used to calculate the fraction of the health burden of 
falls due to fractures.  
 
Results: Global deaths and DALYs attributable to low BMD increased from 103,000 
and 3,125,000 in 1990 to 188,000 and 5,216,000 in 2010 respectively. The 
contribution to the total DALYs was slightly superior for YLLs compared to YLDs. 
The percentage of low BMD in the total global burden almost doubled from 1990 
(0.12%) to 2010 (0.21%). In population 70 years old and over these percentages 
increased from 0.64% in 1990 to 0.79% in 2010. Around one third of all falls-related 
deaths were attributable to low BMD. Males showed more contribution to the global 
deaths and DALYs, with a higher increase over time, compared to females. Low 
BMD was not among the top risk factors causing health burden in the world, 
although its relative weight was more important in older ages.   
 
Conclusion: This is the first study of its kind in assessing the role of low BMD in the 
global health burden as a continuous variable. Results showed an increase of the 
burden worldwide, greatly influenced by the ageing of the population. A significant 
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fraction of all falls-related deaths and health burden in the world was attributable to 
low BMD and, therefore, preventable. Data systems should improve in the detection 
of injuries potentially related to low BMD and osteoporosis in general. This 
information can be used by health institutions and authorities to identify priorities and 
allocate resources.  
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Justification of This Thesis. Professional and General Motivations 
Since I was a medical student, I had always felt very attracted to travel abroad, and 
explore other ways to study and practice Medicine. My first overseas medical 
experience arrived as a medical student, when I enjoyed a scholarship of my local 
university in Reus, Tarragona, to attend the Queen’s Medical Hospital in Nottingham, 
United Kingdom, as a visiting student during my last bachelor course. Later on, in the 
last year of my Rheumatology training in Hospital Universitari de Bellvitge, I was 
lucky enough to have a department’s chief who was enthusiastic about student 
exchange and external rotations. I will never forget that Friday afternoon, when I 
appeared with the greatest disappointment in Joan Miquel Nolla’s office, after 
receiving the letter from a San Francisco’s institution (the name of which I would 
prefer to keep private) declining to accept any visiting fellows by free. Joan Miquel 
showed himself very supportive and sympathetic. We started to discuss other 
options, and suddenly he thought about Philip Sambrook and his Institute of Bone 
and Joint Research (IBJR) in Sydney University. The department of Rheumatology in 
Bellvitge had a long experience in Osteoporosis research, and professor Sambrook 
was one of the international figures in the field most admired by professor Nolla and 
the other team members. To be honest, I had never heard about that name before, 
and my clinical interest for bone metabolism diseases was rather low compared to 
inflammatory arthropathies. Then, Joan Miquel googled professor Sambrook and we 
went through his brief biography, his citations in Pubmed, and finally visited the IBJR 
and the University of Sydney websites, while we were both getting progressively 
more and more excited about the idea. In case I had any doubt regarding the 
suitability of the institution and the research team, Joan Miquel searched for some 
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nice photos of Sydney, including its glamorous beaches and its multinational cultural 
background. “The city of Nemo, you will love it and they will love you”, he said. I 
didn’t’ know who Nemo was, to what Joan Miquel answered “that is because you 
don’t have children”. I must say that I watched the movie “Finding Nemo” some years 
later, and my skin got goose bumps when I saw in the screen the cartoon skyline of 
Sydney. Once I was convinced that an external rotation in the IBJR could be a nice 
academic and life experience, we sent an email to Philip Sambrook, and to another 
professor of the same institution who seemed to be very active in the research of 
musculoskeletal diseases, Lyn March.  
 
And this is how my research career begun. Lyn March answered our email on behalf 
of herself and the IBJR accepting my attendance as a visiting research fellow. So I 
spent a three-month period in this institution led by Philip Sambrook in 2007. During 
my stay, I took part in the FREEDOM STUDY: A randomized controlled trial of 
sunlight and calcium supplementation to reduce vitamin D deficiency in older people 
in residential care. Duties included data collection from the study subjects with the 
research team, preparation of blood samples in the laboratory, attendance to the 
study research meetings and manuscript writing. Besides, I attended some of the 
daily clinical and academic activities in the hospital as well as the meetings of the 
regional society of Rheumatology. Those three months completely changed the 
course of my career and my life in general. On one side, I had the privilege of 
working in an internationally recognized research institution, beside professionals of 
the greatest academic and human quality, who were generous enough to invest their 
time and energy in introducing me in the world of the formal medical research. 
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Working in the IBJR and participating in the FREEDOM study opened my eyes to the 
research in musculoskeletal diseases. I discovered how challenging was to 
investigate common conditions such as vitamin D deficiency, osteoporosis, 
osteoarthritis, and frailty in the elderly. Suddenly I realized what an enormous impact 
can have the study of such conditions in the overall population, and I decided I 
wanted to become part of the global network that works to improve the knowledge 
and management of common musculoskeletal conditions. It was not anymore about 
the study of rheumatic conditions; it was about public health and improving the 
health of the people at a population level…to make a difference!  On the other side, I 
spent one of the most beautiful times in my life. Lyn March turned out to be the most 
extraordinary person I have ever met, admirable for her professional and personal 
achievements. Apart from her duties as Rheumatology consultant, professor of 
Public Health in the Medical School at the University of Sydney, and president of the 
Australian Society of Rheumatology at that time, she managed to have a lovely 
family and an endless list of good friends. She is one of those persons that radiates 
positivity around her. Lyn opened the doors of her knowledge and her house to me. 
So I fell in love with the IBJR, with medical research, with the March-Williams family, 
with the city of Sydney, with the Australian culture…and most importantly, I fell in 
love with Nicholas, a clinical researcher who is nowadays my best professional 
colleague, my husband and the father of the baby to come.  
 
My stay in the IBJR in Australia in 2007 was awarded by The Catalan Society of 
Rheumatology (Societat Catalana de Reumatologia) and the Spanish Society of 
Rheumatology (Sociedad Española de Reumatología) with seldom prizes for short 
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overseas research stays. Overall, the experience could not have been better. At my 
return to Barcelona to finish the last year of my Rheumatology training, it was 
already clear I would be back to Sydney.  
 
I worked in the Rheumatology department in Hospital Universitari de Bellvitge and 
Hospital Sant Camil for the following year, combining the clinics with research in 
premenopausal osteoporosis, led by Joan Miquel Nolla. Work was satisfying and life 
was nice; however, my internal will to go back to Australia was unstoppable. So 
when Lyn March contacted me in 2008 to go back to the IJBR and Sydney University 
as a visiting research fellow, I had no doubt about it. The purpose was to become the 
main project officer for Osteoporosis in an international epidemiological initiative 
called the Global Burden of Diseases (GBD) Study 2005 (changed to 2010 later on). 
The project was the greatest effort in Epidemiology ever done to update and improve 
estimations of the health burden for the main diseases, injuries and risk factors in the 
world. Lyn had been designated the leader of the Musculoskeletal Expert Group, 
which would be based in the University of Sydney. It was a great opportunity for a 
PhD project, with the only inconvenient that it was an honorary position and it could 
not be done fully funded through the University of Sydney. Joan Miquel, again, was 
very supportive and encouraging; we planned to undertake the project with the 
academic support from Investigació Biomèdica de Bellvitge (IDIBELL) and the 
Universitat de Barcelona. Lyn found the way to get funds for me through my 
participation in another research project, an international initiative led by the 
Outcomes Measures in Rheumatology (OMERACT) and the Osteoarthritis Research 
Society International (OARSI) about pain and functional disability in patients with 
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knee and hip osteoarthritis. This project represented around 30% of my research 
activity during my first two years in the GBD project, and in actual fact, turned out to 
be a great learning experience in terms of research logistics and international 
networking. Furthermore, it became my master’s research project for Universitat de 
Barcelona when I undertook the Màster en Investigació en Ciències Clíniques as the 
first step for my PhD curriculum. Later on, with Joan Miquel and Lyn’s support (as 
well as Loreto Carmona’s), I successfully applied for the national grant from 
Sociedad Española de Reumatología for long overseas research stays in 2009 and 
2010, which was only granted for two fellows per year and represented a great 
financial support at the time of a significant personal achievement. 
 
My work in the GBD 2010 study was a challenging task. Since the end of 2008, I 
have dedicated an enormous amount of time to this project, with the main core 
papers published not before end 2012 and the musculoskeletal series just in 2014.  
Actually, “all” the musculoskeletal expert team has undertaken an amazing task, 
starting by their leaders Lyn March and Anthony Woolf.  We used to joke with Lyn 
and talked about the “never-end study”. However, the scientific and technical 
knowledge I have acquired is priceless, not to mention the great value of improving 
my English to the level of doing my things-to-do list in English. I can say that I finally 
achieved my goal of being part of the international network of professionals that work 
for a world where musculoskeletal conditions, particularly osteoporosis, are 
recognized in their burden for the people and the societies. I am still actively 
collaborating with the Institute for Health Metrics and Evaluations (University of 
Washington) and the World Health Organization in such goals. Recently, I have 
 75 
started my work as an academic fellow in the University of Zurich, as part of an 
international leading research team in vitamin D deficiency, fractures and frailty in 
the elderly, led by Professor Heike Bischoff-Ferrari. When I look at all the things I 
have learned with this experience and all the extraordinary people coming to take 
part of my life, I can’t regret any step I took.  
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1.1 Osteoporosis and Osteoporotic Fractures: Definition 
Osteoporosis is defined as a systemic skeletal disease characterized by a low bone 
mass and a microarchitectural deterioration of bone tissue, with a subsequent 
increase in bone fragility and susceptibility to fracture (NIH Consensus Development 
Panel on Osteoporosis Prevention 2001). It behaves as a silent disease. A high 
percentage of affected people are not aware that they have the condition. 
Consequently, osteoporosis burden is better assessed by measuring the burden of 
its clinical outcome, i.e. osteoporotic fractures (also known as “”fragility fractures”), 
which usually occur after a low energy trauma, such as a casual fall. The most 
common and better characterized fractures are, by order of their disability burden, 
hip, vertebra, and wrist fractures. There are other peripheral fractures considered to 
be related to osteoporosis, such as proximal humerus, pelvis, rib, proximal tibia, 
clavicle, hand and foot fractures (Seeley, Browner et al. 1991). 
 
For the last two decades, the operational definition for osteoporosis has been based 
on BMD values: osteoporosis may be diagnosed in postmenopausal women and in 
men age 50 and older if the BMD measured by dual-x-ray absorptiometry (DXA) at 
lumbar spine, total hip, or femoral neck (in certain circumstances the 33% distal 
radius may be utilized) is -2.5 standard deviations (SD) or less from the mean BMD 
value in young females (T score -2.5 or less) (WHO 1994; Kanis 2008) (Figure 1.1). 
The young reference values should be obtained by population-based studies and T 
scores should be calculated within the reference population, as BMD shows great 
geographical variation at population level (Sanchez-Riera, Wilson et al. 2010). 
Osteoporosis is less common in premenopausal women and younger men and 
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screening of secondary causes of osteoporosis (i.e. underlying health problems 
predisposing to the condition) needs to be thorough, as they account for a significant 
proportion of all the cases of osteoporosis in this subpopulation (Khosla, Lufkin et al. 
1994). Based on BMD values from DXA, premenopausal women and men below 50 
may be considered to be “below the expected range for age” when the BMD is -2.0 
SD or less compared to the mean BMD of the age- and sex-matched peers (referred 
as the Z score) from the reference population. Diagnosis of osteoporosis in these 
population may be defined by the presence of a fragility fracture or a Z score -2.0 or 
lower in the presence of risk factors for osteoporosis (Binkley, Bilezikian et al. 2006; 




Figure 1.1 Classification Criteria by the World Health Organization 
(WHO) 
T score represents the number of SD below the mean value of bone mineral 
density of the young female reference, which follows a normal distribution. Z 
scores are based in the same concept, although the Gaussian curve is within a 
specific sex and age group. BMD: bone mineral density. Adapted from World 
Health Organization (WHO 1994).   
 
For clinical applications, T scores at the spine and Z scores are preferred to be 
country-specific, while an international reference has been purposed by world expert 
leaders (Kanis, McCloskey et al. 2008), and supported by the International 
Osteoporosis Foundation (IOF) (Kanis and Gluer 2000) and the International Society 
for Clinical Densitometry (ISCD) (Binkley, Bilezikian et al. 2006; Watts, Leslie et al. 
2013) to define T scores based on femoral neck (FN) measurements. This approach 
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uses the mean BMD values at femoral neck (FNBMD) from the white young females 
at the National Health and Nutritional Examination Survey III (NHANES III) (Looker, 
Wahner et al. 1998), considered to be a truly population-based sample. It has the 
advantages of giving a single location for osteoporosis definition (i.e. FN), for both 
men and women, as well as enabling the application of a fracture prediction tool (i.e. 
FRAX®®) based on the most solid epidemiological data available to the moment in 
regards to the gradient of risk for fracture due to BMD (Johnell, Kanis et al. 2005). 
Moreover, it has the capacity to enable comparisons among different countries, 
therefore appearing suitable for epidemiological research.  
 
The above definitions for osteoporosis are pragmatic for diagnostic and therapeutic 
decisions.  However, based on such definitions, there is no burden associated with 
osteoporosis per se and it becomes difficult to have a real prevalence of the 
condition in a given population. Furthermore, the sensitivity of the BMD measures to 
predict an osteoporotic fracture is good but limited, as we will discuss later in this 
introduction (see bone mineral density as a risk factor for osteoporotic fractures). 
Despite its importance, BMD is not the only factor contributing to fracture 
susceptibility, and the latter is better predicted when other factors are taken into 
account. For this reason, the epidemiology of osteoporosis is better reflected by 
studying the epidemiology of osteoporotic fractures. Life-time risks and 10-year 
probability for fractures are more suitable to measure the burden of osteoporosis, 
and both the World Health Organization (WHO) and the IOF, a WHO-collaborating 
centre for metabolic bone diseases, have recommended the 10-year time frame to 
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base public health analysis and intervention thresholds (Genant, Cooper et al. 1999; 
Kanis and Gluer 2000). 
 
1.2 Health Burden Related to Osteoporotic Fractures 
Population-based studies in different world regions have found an independent 
relationship between low BMD at different skeletal sites and mortality (Trivedi and 
Khaw 2001; Pinheiro, Castro et al. 2006; Nguyen, Center et al. 2007; Bliuc, Nguyen 
et al. 2009; Suzuki and Yoshida 2009; Johansson, McCloskey et al. 2010). However, 
as mentioned previously, the health burden related to osteoporosis is better 
measured by accounting for the burden related to osteoporotic fractures, the 
consequences of which can range from chronic pain, loss of mobility and 
independence to institutionalization and death (Johnell and Kanis 2004; Johnell and 
Kanis 2006; Bliuc, Nguyen et al. 2009; Bertram, Norman et al. 2011).  
 
Hip is the location of fracture where the health outcomes are potentially worst, partly 
because the peak incidence of such fractures occur in population 70-79 years old 
(Johnell and Kanis 2004), and therefore incidence is considerably higher in 
developed countries (Johnell and Kanis 2004). At 1 year after the hip fracture event, 
cumulative mortality reaches up to 37% in men and 25% in women and it is 
remarkably higher than in general population (Kanis, Oden et al. 2003; Kannegaard, 
van der Mark et al. 2010). Mortality is higher in men, even after adjusting by age and 
comorbidities (Kannegaard, van der Mark et al. 2010). About half of the patients lose 
their prior level of physical function and many lose their independence and require 
long-term care (Magaziner, Simonsick et al. 1990; Sernbo and Johnell 1993; Melton 
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2003). Only half of the survivors will walk again and often not at the same level as 
prior to the fracture (Magaziner, Simonsick et al. 1990; Sernbo and Johnell 1993; 
Melton 2003), and a high percentage report chronic pain after one year post-fracture 
(Bertram, Norman et al. 2011).  
  
Vertebral fractures cause pain and limitation of the spinal movement, affecting 
considerably the overall quality of life (Naves Diaz, Diaz Lopez et al. 2001). Both 
prevalent and incident fractures increase steadily with age from 50 to 80 years of 
age (O'Neill, Felsenberg et al. 1996; Jansson, Blomqvist et al. 2010).  One fifth 
requires hospitalisation and some will require subsequent long-term care (Silverman 
1992; Ross 1997). Pain and disability become worse with each new fracture, as 
does the risk of mortality. Fractures occur more often in the thoracolumbar transition; 
spinal mobility is impaired even in the absence of significant pain. Despite only one 
third of the vertebral fractures being symptomatic (Cooper, Atkinson et al. 1992), 
undiagnosed vertebral fractures are also associated with disability (Silverman 1992; 
Ross 1997). Co-morbidity is common, such as kyphosis, restrictive lung disease and 
spinal stenosis, in particular at advanced ages, and contributes to the burden on 
quality of life and increased mortality (Kado, Browner et al. 1999). In a large 
prospective study in United States, women with one or more vertebral fractures 
showed 23% greater age-adjusted mortality rate, and this rate doubled in women 
with 5 or more vertebral fractures (Kado, Browner et al. 1999). Similar results were 
drawn from a longitudinal study in Sweden, where 28% of all deaths associated with 
vertebral fracture requiring hospital admission could be attributable to the fracture 
itself (Kanis, Oden et al. 2004). 
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Forearm fractures tend to occur in earlier ages than hip and vertebral locations with 
a peak incidence in women between 40 and 65 years old. Around one fifth of Colles’ 
fractures (fractures of the distal radius with dorsal radius displacement, with or 
without ulna fracture) in developed countries result in hospitalisation (O'Neill, Cooper 
et al. 2001), which is often very prolonged in elderly patients (Lubbeke, Stern et al. 
2005). Only 50% report a good functional outcome at 6 months (Kaukonen, 
Karaharju et al. 1988).  
 
Premature death in the first year after a fracture, particularly at the hip site, is closely 
related to the short-term outcomes of the fracture (Cooper, Atkinson et al. 1993; 
Leibson, Tosteson et al. 2002; Ioannidis, Papaioannou et al. 2009), including the 
risks associated with prolonged hospitalisation and those related to the surgical 
repair or joint replacement that most of individuals require (except for vertebral 
fractures that more often don’t require surgical intervention). Nevertheless, the 
excess risk for premature mortality after an osteoporotic fracture remains high for 
many years. Recent population-based studies with long follow up periods have 
estimated that mortality rates remain significantly higher than in the general 
population up to 5-15 years after the fracture event, and that includes not only hip 
fractures, but also most of the other sites for osteoporotic fractures (vertebral, pelvis, 
distal femur, proximal tibia, proximal humerus, multiple ribs) (Bliuc, Nguyen et al. 
2009; Melton, Achenbach et al. 2013). For all ages, mortality following a fracture is 
higher in men than in women, particularly within the first year after the fracture, albeit 
the difference between mortality rates in both sexes tends to disappear over time 
(Melton, Achenbach et al. 2013). 
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1.3 Epidemiology of Osteoporosis and Osteoporotic Fractures 
Osteoporosis has been estimated to affect 200 million women worldwide (Kanis 
2007). For a person over 50 years living in a developed country, the lifetime risk of 
sustaining any fracture has been estimated in approximately 50% for women and 
20% for men, most of these related to osteoporosis (Sanders, Nicholson et al. 1999; 
van Staa, Dennison et al. 2001). Considering the ageing of the global population, the 
worldwide incidence of hip fracture is projected to increase by three-fold by 2050 
compared to 1990 (Gullberg, Johnell et al. 1997).  
 
Epidemiology of osteoporosis was recently gathered from 58 countries around the 
world from an important systematic review on hip fracture incidence (Oden, 
McCloskey et al. 2013). Prevalence of osteoporosis defined by T score of -2.5 or 
less using international reference standard (white 20-29 females from NHANES III), 
was around 3% and 10 % in men and women 50-59 years of age, respectively. This 
percentage increased to 6% and 19% respectively in population aged 60-69, 
followed by 9% and 35% respectively in those aged 70-79, and finally, 19% and 51% 
respectively in people aged 80 or over. The countries included in such study 
accounted for around four fifths of the world population aged 50 years or more. 
Extrapolating the data to the world, the authors estimated that approximately 2.7 
million hip fractures took place in 2010, of which approximately half were attributable 




Previous works from the global burden of diseases (GBD) initiative estimated 9.0 
million osteoporotic fractures in the world in the year 2000, of which 1.6 million were 
at the hip (70% women), 1.7 million were at the forearm (80% women) and 1.4 
million were clinical vertebral fractures (58% women) (Johnell and Kanis 2006). 
Although hip fractures only accounted for 18.2% of all fractures, they represented 
40% of all the global health burden due to fractures, reflecting the higher mortality 
and disability of hip fractures compared to other sites.   
            
The greatest number of fractures was in Europe, followed by the Western Pacific 
region, Southeast Asia and the Americas. Collectively, these regions accounted for 
the 97% of the overall numbers of fractures worldwide, highlighting the influence of 
the aging populations on the incidence of osteoporotic fractures, in particular on hip 
fracture rate, with a peak number between 75 and 79 years for both men and women 
(Johnell and Kanis 2006). When combining mortality and disability in the same 
standard measure, known as disability-adjusted life years (DALYs), osteoporotic 
fractures accounted for more DALYs lost than rheumatoid arthritis and all sites of 
cancer, with the exception of lung cancer (Johnell and Kanis 2006). 
 
Life expectancy in North Africa and Middle East has improved significantly in the last 
two decades, with the consequent increased number of population at risk for fracture 
in such regions, becoming in some countries one of the top health priorities 
(International Osteoporosis Foundation 2011). In Sub-Saharan Africa, given the 
population structure with reduced life expectancy and high levels of mortality related 
to communicable diseases and nutritional deficiencies, osteoporosis and fragility 
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fractures are currently not a lead priority in the public health interventions in this 
region. Life expectancy is still considerably lower compared to developed countries, 
with an average of 56 years and only small percentage of the population being over 
60 years of age. However, studies in this region show the same paradigm of 
increased fracture risk with age (Zebaze and Seeman 2003). 
 
1.3.1 Geographic variation 
One important fact is that fracture incidence is country-specific (Kanis, Johnell et al. 
2002); variations between countries can be as high as a 15-fold range in the 10-year 
probability of hip fracture between Norway and Chile or Korea (Kanis, Johnell et al. 
2002) (Table 1.1). This observation outlines the limited weight of the life expectancy 
and the BMD to explain the important differences between countries, given the 
variations in life expectancy and BMD are much less than variations in risk of hip 
fracture (Kanis, Johnell et al. 2002). A clear example of this is the lower risk of 
fracture in Southern countries in Western Europe compared to Northern countries, 
despite BMD levels being higher in the latter (Kanis, Johnell et al. 2002) (Table 1.1). 
One major longitudinal study showed that differences in falls incidence across 
countries could play a major role in such geographical variation (Roy, Pye et al. 
2002). This probably reflects the role of other underlying factors such as diet, 
comorbidities, sunlight exposure, physical activity, and other cultural and 
environmental conditions. 
 
A study done on Southern Chinese women in Hong Kong showed that the 10-year 
risk of osteoporotic fracture in 50–79 year of age was comparable to white women in 
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Spain, the United Kingdom, and Sweden, but was higher than that for a similar 
population in mainland China (Kung, Lee et al. 2007). Although women in mainland 
China have in average lower body mass index (BMI) and lower BMD than white 
Caucasian, the former show a lower risk of hip fracture, suggesting an important role 
of their shorter femoral neck and a more active lifestyle, which results in a lower risk 
of falling and a subsequent lower risk of hip fracture (Cummings, Cauley et al. 1994; 
Cummings, Xu et al. 1994). The effect of racial variations of the hip geometry has 
been claimed as well to explain the lower risk in hip fracture of Japanese American 
compared to white American, despite Japanese women show a lower mean BMD in 
FN (Nakamura, Turner et al. 1994).  
 
Table 1.1 Ten-year probability of hip fracture averaged for age and 
gender and adjusted to the probabilities of Sweden (risk ratio of 10-year 
hip fracture for Sweden =1.00) 
Europe Non-Europe 
Country Relative Probability  Country Relative Probability 
Norway 1.24 USA 0.78 
Iceland 1.02 China (TW) 0.72 
Denmark 0.85 Canada 0.65 
Germany 0.72 Singapore 0.62 
Switzerland 0.71 Kuwait 0.59 
Finland 0.68 Australia 0.57 
Greece 0.66 China (HK) 0.49 
Netherlands 0.64 Japan 0.39 
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Hungary 0.63 Argentina 0.36 
Italy 0.61 China 0.29 
UK 0.60 Turkey 0.18 
Portugal 0.57 Korea 0.18 
France 0.41 Venezuela 0.17 
Spain 0.39 Chile 0.08 
 
Note that relative probabilities are expressed here without the 95% confidence 
intervals from the original source. TW: Taiwan, HK: Hong Kong. 
Adapted from Kanis JA et al 2002 (Kanis, Johnell et al. 2002).  
 
Marked geographical variation is also observed in population levels of BMD 
(Sanchez-Riera, Wilson et al. 2010). Ethnicity background, anthropometric variables 
and nutritional habits might account for a significant part of the observed worldwide 
differences, as shown in some studies where geographical differences in the BMD 
were related to such factors (Lunt, Felsenberg et al. 1997; Deleze, Cons-Molina et 
al. 2000).  
 
In general, Asian ethnicity is related to lower BMD values compared to other 
ethnicities, even when adjusted by BMI (Goh, Low et al. 2004). Very low BMD values 
have been observed in Sub-Sahara region (Aspray, Prentice et al. 1996), where 
BMD was found to be lower in African black than in British white, although minimal 
trauma fractures are rare in the former. Black Americans and Brazilians by contrast, 
show higher BMD than white Americans, even after adjustment for socioeconomic 
level (Looker, Wahner et al. 1998; Siqueira, Facchini et al. 2005). Such variations 
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among black skin subjects from different world regions are probably partly explained 
by differences in nutrition and other environmental factors.     
 
1.4 Economic Cost of Osteoporotic Fractures 
The economic burden of osteoporosis results both from acute outcomes, such as 
hospital admission and surgery after an incident fracture, as well as long-term 
consequences related to chronic disability and costs of pharmacological and non-
pharmacological interventions. Simultaneously, the costs are classified in direct (e.g. 
treatment of incident fractures, pharmacological prevention, institutionalization, etc), 
indirect, which basically correspond to the productivity losses, and intangible, 
referring to the monetary value of quality-adjusted life years (QALYs) lost. The term 
QALY refers to the number of years lived in “perfect health”, and a year of life lived in 
a state of less than this perfect health is worth less than one. QALYs are often 
combined with costs to assess cost-effectivity of medical interventions (Hodgson and 
Meiners 1982).   
 
In a recent review elaborated in collaboration with the IOF and the European 
Federation of Pharmaceutical Industry Associations, several aspects of the 
osteoporosis epidemiology in Europe were thoroughly reviewed (Hernlund, Svedbom 
et al. 2013; Strom, Borgstrom et al. 2013). The cost of osteoporosis, including 
pharmacological intervention in the EU in 2010 was estimated at €37 billion. Costs of 
treating incident fractures represented 66 % of this cost, pharmacological prevention 
5 % and long-term fracture care 29 %. Excluding cost of pharmacological prevention, 
hip fractures represented 54 % of the costs, “other fractures” represented 39 %, and 
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vertebral and forearm fractures represented 5 % and 1 %, respectively (Hernlund, 
Svedbom et al. 2013). Costs derived from fragility fractures were estimated to be 
superior to some disorders with high disabling potential such as strokes, Parkinson 
and rheumatoid arthritis (Strom, Borgstrom et al. 2013).  
 
Due to changes in population demography in Europe, there is an expected increment 
in the number of people affected with osteoporosis (using WHO diagnostic criteria) 
and in the annual number of fractures in the following years (estimated in 23 % and 
28%, respectively, from 2010 to 2025). Because of this, the number of QALYs lost 
annually due to fractures have been predicted to increase from 1.2 million in 2010 to 
1.4 million in 2025, corresponding to an increase of 20%. The total cost including 
values of QALYs lost (valued at 2 × Gross Domestic Product (GDP) per capita) in the 
EU would, then, rise from €98 billion in 2010 to €121 billion in 2025, corresponding to 
an increase of 22% (Hernlund, Svedbom et al. 2013). 
 
The increasing incidence of fragility fractures over time has been likewise predicted 
for North America, Latin America, Australasia, Middle East-North Africa and Asia 
(Cooper, Campion et al. 1992; Gullberg, Johnell et al. 1997). The role of the fast 
demographics changes in high-populated word regions such as Latin America and 
Asia, with a substantial increasing trend in population levels of life expectancy, is 
shifting the global burden of osteoporosis towards such regions. By 2050, more than 
half of all hip fractures in the world are expected to occur in Asia (Cooper, Campion 
et al. 1992). As a paradigm of this, in China, the cost of hip fracture has been 
increasing at a rate of 6% per year. In 2006, the country spent around 1.5 billion 
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USD treating hip fracture and it is been estimated that this will rise to 12.5 billion 
USD in 2020 and by 2050 to more than 264.7 billion USD (Wang, Tao et al. 2009).  
 
To understand the magnitude of the problem in Western societies is helpful to 
compare with other common diseases. In Sweden, for example, the annual cost 
resulting from major osteoporotic fractures (hip, vertebral and wrist) was estimated to 
be very close to that resulting from diabetes and to account for about 3% of the total 
health care cost in Sweden (Borgström, Sobocki et al. 2007). The greatest annual 
costs resulted from the acute care (58%) and community care (38%), with hip 
fractures being responsible of over three fourths (78%) of the total costs, followed by 
vertebral fractures (17%) and wrist fractures (5%). The economic impact of 
osteoporosis compared with other common conditions was also reflected by Swiss 
administrative data on women hospitalization. For the year 2000, incidence of 
hospitalization for osteoporosis or its complications was double than for breast 
cancer, myocardial infarction or stroke, three-times as high as that for chronic 
obstructive pulmonary disease, and six-times higher than that for diabetes (Lippuner, 
Golder et al. 2005) (Figure 1.2). The mean length of stay for osteoporosis was 
comparable to that of all the other diseases included in the analysis, except for 
stroke (twice as long) (Figure 1.3).  
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Figure 1.2. Incidences of hospitalization for osteoporosis and other 
frequent diseases in Swiss women in year 2000. 
Adapted from Lippuner et al 2005(Lippuner, Golder et al. 2005). 
 
Figure 1.3 Mean length of stay for osteoporosis and other frequent 
diseases in Swiss women in year 2000. 
Adapted from Lippuner et al 2005 (Lippuner, Golder et al. 2005). 
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1.5 Risk Factors for Osteoporosis and Fractures. Role of Bone 
Mineral Density and Importance of Clinical Risk Factors 
1.5.1 Bone mineral density as a risk factor for fractures 
Bone strength primarily reflects the integration of BMD and bone quality. The latest 
may be cumbersome to assess on the individuals and more so at a population level. 
In contrast, BMD is a well-defined predictor of fracture risk (Marshall, Johnell et al. 
1996; Johnell, Kanis et al. 2005), and can be easily measured with standard 
techniques that are objective, reproducible, non-invasive, fast and relatively 
inexpensive. Besides, BMD is potentially modifiable through a great variety of non-
pharmacological (calcium intake, sunlight exposure, physical activity, smoking 
cessation, etc) and pharmacological interventions (please, refer to next chapter 1.6 
Diagnosis and Management of Osteoporosis). Therefore, it provides an excellent 
scenario for the management and follow-up of the individuals at high risk of fracture.  
 
Dual-x-ray-absorptiometry (DXA) at central sites (i.e. spine and hip) still stays as the 
most broadly used and validated technique to measure BMD, and is the 
recommended technique for both clinical management and research purposes 
(WHO 1994; The International Society for Clinical Densitometry 2007). Other 
techniques, like peripheral quantitative ultrasound (QUS), peripheral DXA (pDXA), 
spine and hip quantitative computed tomography (QCT) and peripheral QCT (pQCT) 
have shown a valid correlation with the fracture risk (Genant, Block et al. 1987; 
Marshall, Johnell et al. 1996; Johnell, Kanis et al. 2005; Moayyeri, Adams et al. 
2012; Dennison, Jameson et al. 2014). The first two offer some advantages over the 
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classical central DXA due to their fast performance, low cost, and easy portability. 
Yet, due to the lack of enough normative data, the use of such techniques is 
generally limited to screening strategies in conjunction with clinical risk factors, 
particularly in situations with low access to classical central DXA (Internaional 
Society of Clinical Densitometry 2013) (Internaional Society of Clinical Densitometry 
2013). High resolution peripheral QCT (HR-pQCT) offers good imaging on bone 
microarchitecture and quality, but high levels of radiation, limited accessibility and 
affordability are major concerns for its applicability at a population level. The above-
mentioned WHO threshold of -2.5 SD of T score for osteoporosis definition using 
spine and hip BMD measured by classical densitometers (Kanis 2008) cannot be 
applied to any of the other forms of BMD measurement (except for DXA at distal 
radius, which can be particularly useful in some occasions when hip and spine sites 
are subjected to important artefacts, such as metallic surgical materials). More 
recently, trabecular bone score (TBS) from DXA image of the lumbar spine has been 
advocated as a potential tool to improve fracture prediction. While TBS is not a direct 
physical measurement of trabecular microarchitecture, it has been shown to be 
associated with trabecular microarchitecture and bone strength by HRpQCT. 
Moreover, cross-sectional and prospective studies, involving a large number of 
subjects, have both shown that TBS is associated with vertebral, femoral neck, and 
other types of osteoporotic fractures (Silva and Bilezikian 2014). 
 
Nevertheless, the risk of fracture due to reduced BMD is gradual over a continuum, 
and in actual fact, most of osteoporotic fractures occur in patients with osteopenia 
(i.e. between 1 and 2.5 SD below mean BMD of young population) (Siris, Chen et al. 
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2004). Likewise, although less frequently, fractures can occur in subjects with normal 
BMD (T score above -1.0). Thus, the threshold to define osteoporosis by 
absorptiometry, somewhat arbitrary, has low sensitivity to detect individuals at high 
risk of fracture. As well pointed out previously (Oden, McCloskey et al. 2013), 
though, it is not more arbitrary than the threshold set for other important biological 
variables such as blood pressure for hypertension or BMI for obesity. Actually, the 
ability of hypertension and hypercholesterolemia to predict stroke and myocardial 
infarction, respectively, are not better than the predictive value of BMD for fractures 
(Marshall, Johnell et al. 1996). 
 
The gradient of risk (GR) for fracture due to BMD has been defined as the relative 
risk (RR) for fracture for each unit (either SD in T score or absolute value of BMD 
measured in g/cm2) of BMD decrease. An important meta-analysis on the 
relationship between BMD and fractures published in 1996 (Marshall, Johnell et al. 
1996) found that measurements at any site (hip, spine and wrist) predicted any 
osteoporotic fracture with a GR of approximately 1.5 per SD decrease in BMD. Risk 
assessment was improved by site-specific measurements, so to predict hip fractures 
and vertebral fractures, accuracy was better when measurement was done in the hip 
or in the lumbar spine, respectively (Table 1.2). The highest gradient of risk was 
found at the hip to predict hip fracture where the gradient of risk was 2.6. This means 
that a subject with a T-score of −3 SD at the hip would have a 2.63 or about 17-fold 
higher risk than the same subject with a T-score of 0 SD. Almost 10 years later, a 
new meta-analysis based on 12 population-based studies from Western Europe, 
USA, Canada, Japan and Australia found similar values (Johnell, Kanis et al. 2005). 
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In this latest study, FNBMD was found to be a good predictor for hip fracture, for 
osteoporotic fracture and for any fracture; the GR increased slightly with age from 50 
years to 85 years for any osteoporotic fracture, while the effect was the opposite 
when hip fractures were analysed alone. These finding may be a reflection of the 
higher frequency of additional clinical risk factors in the elderly population (poor bone 
quality, higher risk to falls), while in young population low BMD might be a stronger 
predictor of the overall fracture risk. Although fracture events occurred more often in 
women, the GR per FNBMD unit was equivalent for men and women, which means 
that the “excess” of fracture risk due solely to BMD is comparable between both 
sexes.  
 
Table 1.2 Age-adjusted relative increase in risk of fracture (with 95% 
confidence interval) in women for every 1 SD decrease in bone mineral 









Femoral Neck 1.6 (1.4-1.8) 1.4 (1.4-1.6) 2.6 (2.0-3.5) 1.8 (1.1-2.7) 
Distal Radius 1.4 (1.3-1.6) 1.7 (1.4-2.0) 1.8 (1.4-2.2) 1.7 (1.4-2.1) 
Lumbar Spine 1.5 (1.4-1.7) 1.5 (1.3-1.8) 1.6 (1.2-2.2) 2.3 (1.9-2.8) 
 
Adapted from Marshall et al 1996 (Marshall, Johnell et al. 1996). 
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1.5.2 Importance of clinical risk factors for fractures 
The predictive value of BMD to assess fracture risk can be improved with the input of 
other independent clinical risk factors (Kanis, Oden et al. 2007). Risk assessment 
tools exist in order to estimate the fracture risk of an individual even in the absence 
of a BMD testing. A systematic review published in 2013 found 48 fracture risk 
predicting tools, of which 20 had been externally validated (Rubin, Friis-Holmberg et 
al. 2013). Of those, authors found that only 6 had been tested more than once in a 
population-based setting with acceptable methodological quality as assessed with 
the Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS) checklist 
(Hollingworth, Medina et al. 2006): Osteoporosis Self-assessment Tool (OST), 
Osteoporosis Risk Assessment Instrument (ORAI), Garvan Fracture Risk Calculator 
(Garvan), Simple Calculated Risk Estimation Score (SCORE), WHO Fracture Risk 
Assessment Tool (FRAX®), and Qfracture. Probably, the most widely used of such 
predictive tools is the FRAX®. The FRAX® model is a WHO initiative currently 
available for different countries on-line (http://www.shef.ac.uk/FRAX), and it is been 
developed through the analysis of twelve longitudinal population-based cohorts from 
North America, Europe, Asia and Australia (Johnell, Kanis et al. 2005). This index 
takes into consideration 12 risk factors apart from femoral neck BMD: age, sex, 
weight, height, previous history of fracture, smoking habit, glucocorticoid therapy, 
rheumatoid arthritis, secondary osteoporosis and alcohol intake (Table 1.3). The tool 
allows the calculation of 10-year probability of hip and any osteoporotic fracture at a 
country-specific level, even in the absence of BMD information. Interestingly, authors 
from the abovementioned review (Rubin, Friis-Holmberg et al. 2013) found that 
simple tools such as OST and Garvan often performed as well as the more complex 
 104 
ones such as FRAX® and SCORE. Even more, a previous study done with an 
international cohort of almost 20,000 postmenopausal women found that FRAX® 
and Garvan tools were not superior in predicting fracture in the absence of BMD than 
a simple model using only age and history of prior fracture (Sambrook, Flahive et al. 
2011).  
 
Table 1.3 Risk factors for fracture included in the FRAX® tool  
Different Risk Factors 
Age 
 Sex 
Low body Mass 
Previous fragility fracture, particularly of the hip, wrist and spine including 
morphometric vertebral fracture 
Parental history of hip fracture 
History of fragility fracture 
Glucocorticoid treatment (≥5mg oral prednisolone daily for 3 months or more) 
Current smoking 
Alcohol intake 3 or more units daily 
Rheumatoid arthritis 
Other secondary causes of osteoporosis 
- Untreated hypergonadism in men and women, e.g., premature menopause, 
bilateral oopherectomy, anorexia nervosa, chemotherapy for breast cancer, 
hypopituitarism 
- Inflammatory bowel disease, e.g., Crohn's disease and ulcerative colitis. 
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Different Risk Factors 
- Prolonged immobility, e.g., spinal cord injury, Parkinson's disease, stroke, 
muscular dystrophy, ankylosing spondylitis 
- Organ transplantation 
- Type I diabetes 
- Thyroid disorders, e.g. untreated hyperthyroidism, over-treated 
hypothyroidism 
- Chronic obstructive pulmonary disease 
Adapted from Kanis et al 2008 (Kanis 2008). 
 
The most relevant clinical risk factor related to suffering a fracture is age (Kanis, 
Johnell et al. 2001). It is been shown that the risk of fracture increases with age at 
any given T score and it does dramatically from 50 to 80 years of age at the same 
threshold of -2.5 SD (Kanis, Johnell et al. 2001). The effect of age on fracture risk 
independently of BMD is one of the most powerful reasons to suggest intervention 
thresholds not based on fixed T-scores, but according to absolute probabilities of 
fracture (Kanis, Johnell et al. 2001). From an epidemiological point of view, age is a 
key question as well when assessing the burden of osteoporosis, as we can predict 
that the burden will be higher in those world regions with a more aged population.  
 
Gender is the second clinical risk factor that appears important in fracture risk: both 
osteoporosis and fractures are more common in women (Johnell and Kanis 2006; 
Oden, McCloskey et al. 2013). In 2000, of all the 9.0 million osteoporotic fractures 
estimated worldwide, 61% occurred in women; the percentage was 70% for hip 
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fractures, 80% for forearm fractures and 58% for vertebral fractures (Johnell and 
Kanis 2006). Reasons behind the female/male ratio predominance are diverse. First, 
physiological: women reach lower levels of peak bone mass at young ages, and 
higher bone loss rates as older adults compared to men due to estrogen deprivation 
after menopause (Berger, Goltzman et al. 2010). The lack of estrogens also involves 
a faster speed of deterioration of bone structure in females compared to males 
(Zhang, Tan et al. 2010), therefore compromising bone strength. Second, 
epidemiological: women have a higher life expectancy in most of the world regions 
(Wang, Dwyer-Lindgren et al. 2012). Finally, females exhibit an increased risk of 
falling compared to men (Winner, Morgan et al. 1989; Roy, Pye et al. 2002; Kayan, 
Johansson et al. 2009), yet in age-standardized falls rates (Roy, Pye et al. 2002), 
and it is well proven the role of falls as an independent predictor of fracture risk (Roy, 
Pye et al. 2002; Kayan, Johansson et al. 2009).  
 
The history of a previous fracture event is one of the other major risk factors for 
fractures. One meta-analysis estimated that the risk of any fracture, any osteoporotic 
fracture and hip fracture doubled in population 50 years and over when a previous 
fracture history was present (Kanis, Johnell et al. 2004). Interestingly, the RR for 
fracture decreased little when adjusted by BMD. There was no significant difference 
in the RR between men and women. One of the population-based studies included in 
the aforementioned meta-analysis, reported that 30% of women and 22% of men 
with a prior history of a fracture experience a new fracture during the next 5 years 
(Bliuc, Nguyen et al. 2009). A 5-fold probability of new vertebral fracture has been 
observed during the first year after a vertebral fracture compared to non-fractured 
 107 
patients (Lindsay, Silverman et al. 2001). A prior wrist fracture has shown to increase 
the risk of a future wrist fracture about 3-fold and doubled the risk of any osteoporotic 
fracture (Barrett-Connor, Sajjan et al. 2008). 
 
The role of weight and BMI on BMD and fractures has been in like manner well 
established in different male and female populations around the world (Cauley, 
Fullman et al. 2005; De Laet, Kanis et al. 2005; Kaptoge, Reid et al. 2007; Beck, 
Petit et al. 2009; Kim, Oh et al. 2009; Orito, Kuroda et al. 2009; Genaro, Pereira et 
al. 2010; Langsetmo, Poliquin et al. 2010; Sheng, Xu et al. 2010). One meta-analysis 
showed that a BMI below 20 doubled the risk of hip fracture compared to a BMI of 25 
and increased, though to a lesser extent, the risk for any other fracture (De Laet, 
Kanis et al. 2005). The effect of BMI on fracture risk is in great part dependant on its 
effect on BMD (the lower BMI, the lower BMD) (De Laet, Kanis et al. 2005). 
However, the relationship between BMI and fracture risk is not linear, as evidenced 
by obesity (BMI 30 and over) being a poor protector against fractures (De Laet, 
Kanis et al. 2005; Beck, Petit et al. 2009). In actual fact, recent investigations have 
demonstrated the positive effect of lean mass (in comparison to fat mass) on bone 
mass and strength, although these parameters don’t appear suitable for fracture 
prediction models at the moment (Leslie, Orwoll et al. 2014).    
 
Physical activity (PA) is a good predictor of BMD (Bonaiuti, Shea et al. 2002; 
Broussard and Magnus 2004; Devine, Dhaliwal et al. 2004; Morseth, Emaus et al. 
2010) and fracture risk (Ensrud, Ewing et al. 2007; Cauley, Harrison et al. 2013; 
Cawthon, Blackwell et al. 2014; Feskanich, Flint et al. 2014), explained by different 
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mechanisms. On one side, exercise increases quantity and quality of trabecular and 
cortical bone, therefore increases bone strength and resistance (Cousins, Petit et al. 
2010; Janz, Letuchy et al. 2014). On the other side, exercise also improves muscle 
strength, balance and gait, important components of the falls risk in the elderly. In 
fact, different physical function parameters (such as grip strength, balance and 
walking speed) have been related to a reduced fall risk both in community-dwelling 
(Nevitt, Cummings et al. 1991; Ensrud, Ewing et al. 2007; Cauley, Harrison et al. 
2013) and institutionalized individuals (Wilson, Hilmer et al. 2011). The predictive 
value of PA for falls varies with age and the presence of other comorbidities. Albeit 
PA and participation in social activities could lead to an increased likelihood of fall, 
evidence shows that those elderly with poor physical performance are more 
prompted to suffer injurious falls than those showing better physical parameters 
(Nevitt, Cummings et al. 1991; Ensrud, Ewing et al. 2007; Cauley, Harrison et al. 
2013).  
 
Falls constitute one of the major risk factors for fractures in elderly population (Roy, 
Pye et al. 2002; Ensrud, Ewing et al. 2007; Deprey 2009), but their predictive value 
for fractures is very low: while the majority of osteoporotic fractures occur after a fall 
event, most of the falls in the community don’t have a fracture as an outcome (Nevitt, 
Cummings et al. 1991; Roy, Pye et al. 2002). Despite clinicians need to take into 
account the PA levels and falls frequency when considering absolute fracture 
probability in a subject, such parameters have not been incorporated in the FRAX® 
algorithm yet, possibly due to the heterogeneity of the studies and the consequent 
difficulty in conducting a proper meta-analysis. Fracture prediction tools incorporating 
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falls frequency, such as Garvan, did not prove to be superior to more parsimonious 
models in postmenopausal women (Sambrook, Flahive et al. 2011). Fast and 
objective measurements of physical function, such as sit-to-stand test or grip 
strength might more adequate to use in the clinical practice when assessing fracture 
risk and prevention.   
 
Other factors, such as smoking, alcohol intake, and several clinical conditions have 
been identified as independent risk factors for low bone mineral density and fractures 
(Table 1.3). Among pharmacological causes of secondary osteoporosis, 
glucocorticoid therapy has the highest prevalence and fracture burden, and often 
represents the leading cause of secondary osteoporosis in developed countries 
(Allport 2008; Civitelli and Ziambaras 2008). Other therapies that increase the 
incidence and/or prevalence of medication-induced osteoporosis and fracture include 
androgen-deprivation therapy, aromatase inhibitors, protease inhibitors, selective 
serotonin reuptake inhibitors and prolactin-raising antiepileptic agents (Allport 2008). 
In the past few years, efforts have been made to summarize and quantify the effect 
of such conditions on fracture risk (Kanis, Borgstrom et al. 2005; Kanis 2008; Kanis, 








Table 1.4. Risk Ratios for Osteoporotic Fracture Associated with Risk 
Factors for Age, with and without Adjustment for Bone Mineral Density. 
Risk indicator Without BMD With BMD 
Alcohol intake ≥3 units daily 1.38 (1.16-1.65) 1.36 (1.13-1.63) 
BMI (20 v 25kg/m2) 1.27 (1.16-1.38) 1.02 (0.92-1.13) 
BMI (30 v 25kg/m2) 0.89 (0.81-0.98) 0.96 (0.86-1.08) 
Current smoking 1.29 (1.17-1.43) 1.13 (1.00-1.25) 
Ever use of systemic corticosteroids 1.65 (1.42-1.90) 1.66 (1.42-1.92) 
Parental history of hip fracture 1.54 (1.25-1.88) 1.54 (1.25-1.88) 
Prior fracture after 50 years 1.86 (1.72-2.01) 1.76 (1.60-1.93) 
Rheumatoid arthritis 1.65 (1.20-2.02) 1.47 (1.12-1.92) 
Values are risk ratios followed by 95% confidence intervals in brackets. BMD: bone 
mineral density; BMI: body mass index. Adapted from Kanis et al 2009 (Kanis, 
Johansson et al. 2009).  
  
In general, each risk factor on its own scores poor specificity and sensitivity in 
predicting fracture probability, and the influence on fracture risk (Table 1.4), as seen 
to occur with BMD, varies with age. Still the predictive value can be improved by 






Table 1.5. Ten-year probability (%) of a major osteoporotic fracture 
(clinical spine, hip, forearm and humerus fracture) according to bone 
mineral density and the number of clinical risk factors for women aged 
60 years in the UK. 
Number 
of CRFs 
BMD T-Score at the Femoral Neck 
1.0 0.0 -1.0 -2.0 -3.0 -4.0 
0 4.1 4.6 5.5 7.7 12 23 
1 6.0 (3.9-8.4) 6.8 (4.5-9.5) 8.0 (5.5-11) 11 (8.2-14) 18 (15-21) 32 (29-37) 
2 8.6 (4.6-14) 9.8 (5.4-16) 12 (6.7-18) 16 (10-24) 25 (19-34) 44 (38-54) 
3 12 (5.9-22) 14 (6.9-25) 16 (8.7-28) 23 (14-36) 35 (25-49) 58 (48-68) 
4 17 (9.4-28) 19 (11-31) 22 (14-35) 31 (22-44) 46 (35-59) 71 (59-78) 
The range is not a confidence interval but, because the weight of different risk 
factors varies, is a true range. BMD: bone mineral density; CRF: clinical risk factor. 
Adapted from Kanis et al 2009 (Kanis, Johansson et al. 2009).  
 
1.5.3 Role of vitamin D and calcium 
Vitamin D deficiency leads to secondary hyperparathyroidism and has been found to 
be related to osteoporosis (Holick 2007), hip fractures (LeBoff, Kohlmeier et al. 1999; 
Bischoff-Ferrari, Can et al. 2008; Cauley, Parimi et al. 2009) and non-hip fractures 
(Nakamura, Saito et al. 2010). Osteomalacic changes, characterized by the 
accumulation of unmineralized matrix in the bone, can occur in the presence of 
persistent severe vitamin d deficiency, and have been found in a significant 
percentage of individuals sustaining a hip fracture (Harma, Parviainen et al. 1987; 
Arnala, Kyrola et al. 1997). A recent meta-analysis showed that doses of vitamin D 
over 800 IU daily were associated with a risk reduction of 30 % for hip fracture and 
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14% for any non-vertebral fracture (Bischoff-Ferrari, Willett et al. 2012). It is thought 
that the mechanisms behind such risk reduction are not only related to the positive 
effect on the bone mineralization, but also to the role of vitamin D on muscle strength 
(Bischoff-Ferrari, Stahelin et al. 2000). In actual fact, high dose- vitamin D 
supplementation has been shown to significantly reduce the risk of falling in older 
individuals (Bischoff-Ferrari, Dawson-Hughes et al. 2009). 
 
Calcium is the major component of the inorganic bone matrix. Achieving a good peak 
bone mass as a young adult contributes to a lesser impact of the physiological 
ageing process of the bone. Human requirements of calcium intake are higher in 
certain live stages, such as childhood, teen ageing, menopause and pregnancy; in 
elderly individuals calcium requirements also increase because of the decreased 
body capacity in absorbing the dietary calcium. Calcium supplements have been 
classically among general recommendations in osteoporosis management for 
decades, but more recently, scientific evidence has shown their minimal impact on 
BMD and fracture risk (Shea, Wells et al. 2004). Additionally, the observation that 
calcium supplements could be related with a higher rate of cardiovascular events 
and kidney stones have raised concerns about the risks and benefits of such 
intervention in osteoporotic patients (Bolland, Avenell et al. 2010; Reid 2014). With 
this, though, a more recent meta-analysis did not find any relationship between 
calcium supplements and rates of coronary heart disease-associated hospitalizations 
or deaths (Lewis, Radavelli-Bagatini et al. 2014). Still, guidelines recommend to 
educate individuals in an adequate calcium intake, from dietary source when 
possible. The IOF provides with a free-access calculator to estimate the personal 
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requirements and daily calcium intake based on regular diet 
(http://www.iofbonehealth.org/calcium-calculator).      
 
1.5.4 Role of ethnicity and genetics in low bone mineral density and fracture 
risk 
The variations in mean BMI have been advocated as one of the primary explanations 
behind the significant differences of mean BMD among different races (Nam, Shin et 
al. 2010; Yang, Lu et al. 2013). Other authors have found that some ethnicities reach 
their peak bone mass later than others and that could allow a better preservation of 
their BMD later in life (Berenson, Rahman et al. 2009; Yang, Lu et al. 2013).  
However, it’s important to highlight that the extensive disparity of fracture rates 
among world regions cannot be explained only by such factors, and by contrast, 
fracture incidence among Asians, with relatively low average BMI and BMD, is 
generally lower than in Caucasian populations, despite the higher BMD in the latter 
(Sanchez-Riera, Wilson et al. 2010). In NHANES III, an important multi-ethnic 
population-based study in the United States, being non-Hispanic white was 
independently associated with a lower BMD and an increased risk for fracture (in 
comparison to be Mexican American or Black Americans), while the excess of risk 
due to FNBMD was comparable among the three ethnicities; that is, the fracture risk 
approximately doubled for each SD decrease in FNBMD regardless the ethnic group 
(Broussard and Magnus 2004; Looker, Melton et al. 2009). 
 
Hip geometric parameters (longer hip axis length, increasing femoral neck/shaft 
angle and shaft cortical area) have been found to be independent predictors for hip 
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fracture among postmenopausal women (Faulkner, Cummings et al. 1993; 
Pulkkinen, Partanen et al. 2004; Gnudi, Sitta et al. 2007) and elderly men (Marshall, 
Zmuda et al. 2008), and have also been suggested to explain some of the important 
ethnic variations of fracture risk, (e.g. lower fracture risk among black and Asian men 
compared to white men) (Marshall, Zmuda et al. 2008). 
 
Finally, there is also a significant hereditary component in the ability to retain bone 
mass and the risk to suffer a fracture. The genetic role has been demonstrated in 
twin studies (Slemenda, Christian et al. 1991; Arden and Spector 1997; Harris, 
Nguyen et al. 1998), as well as in the observation that family history of fragility 
fracture is a strong predictor of fracture risk; the RR of fracture is the highest when 
paternal/maternal history of hip fracture is present, which doubles the risk (Kanis, 
Johansson et al. 2004).   
 
1.6 Diagnosis and Management of Osteoporosis 
1.6.1 Diagnosis of osteoporosis and assessment of fracture risk  
Osteoporosis is a skeletal disease where bone mass and bone architecture are 
compromised. Both elements play a key role in the bone strength and its 
susceptibility to fracture. Yet, from a practical point of view, diagnosis of osteoporosis 
is based in BMD, and WHO categories (i.e. normal, osteopenia and osteoporosis) 




Table 1.6. World Health Organisation’s diagnostic thresholds for bone 
mineral density at spine, hip or distal forearm.   
Diagnosis BMD T-Score (SD units) 
Normal ≥ -1 
Low Bone Mass (Osteopenia) < -1 but > -2.5 
Osteoporosis ≤ -2.5 
Severe Osteoporosis ≤ -2.5 plus one or more fragility fracture 
 
However, it is important to differentiate such operational definitions from the 
assessment of the fracture risk and the intervention thresholds. In the clinical 
practice, doctors may decide to start pharmacological treatment in individuals with 
major risk factors for fracture, even in the absence of BMD measurement.  
 
At present, there is no universally accepted policy for population screening to identify 
those individuals at high risk of fracture. Instead, patients are identified 
opportunistically using a case finding strategy when a previous fragility fracture or 
the presence of significant risk factors are present (Table 1.3). A general approach to 
risk assessment is shown in Figure 1.4 where subjects are screened for fracture 
probability based on their clinical risk factors. When probability of fracture is high, 
treatment is recommended independently of the results of the BMD test. In contrast, 
BMD information becomes more relevant in those cases where fracture probability is 
intermediate and BMD will lead to re-classify the case as having high or low risk of 
fracture. Finally, subjects falling into the low risk group, probably don’t need neither 
screening with BMD testing nor pharmacological intervention. The assessment of 
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BMD is more commonly done with central DXA, but this basic decision making 
strategy is valid using other BMD testing methods, such as QUS or pDXA.  
 
 
Figure 1.4. Fracture probability and decision making.  
Adapted from Kanis JA et al 2009 (Kanis, Johansson et al. 2009) 
 
Country-specific guidelines exist in regards to screening of individuals at high risk of 
osteoporosis, as well as management in primary and secondary prevention of 
fractures. Applicability of screening tools and interventional thresholds based on 
multifactorial risk assessments such as FRAX®, are variable depending on the 
geographical area. Reasons for this are multiple, such as the availability of DXA 
machines, the cost and availability of the main pharmacological interventions and the 
existence of cost-effectiveness studies in the target population (keeping in mind that 
fracture risk is country-specific). In countries with high access to densitometry, 
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referral for DXA is expected in any individual with any clinical risk factors for 
osteoporosis, and intervention is recommended when the algorithm of fracture 
probability integrating BMD indicates that the risk is above the interventional 
threshold (Figure 1.5). 
 
Figure 1.5 Assessment of fracture risk in countries with high access 
to Dual-X-Ray-Absorptiometry (DXA)  
 
DXA is undertaken in women presenting with a clinical risk factor, while DXA 
assessment and/or treatment is not recommended where the FRAX® probability is 
lower than the lower assessment threshold (grey area). DXA measurement is 
recommended in the rest of the women and treatment recommended when the 
fracture probability exceeds the upper threshold intervention line. Adapted from 
Kanis JA et al 2013 (Kanis, McCloskey et al. 2013).  
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In contrast, countries with limited access to DXA, only individuals with an 
intermediate fracture probability are recommended to be sent for BMD testing 
(Figure 1.6) (Kanis, McCloskey et al. 2013). 
  
Figure 1.6. Assessment of fracture risk in countries with low access 
to Dual-X-Ray-Absorptiometry (DXA) 
 
When fracture probability is first assessed without BMD information, DXA test is only 
recommended when the probability is intermediate (dark grey region). DXA 
assessment and/or treatment are not recommended where the FRAX® probability is 
lower than the lower assessment threshold (light grey area). Adapted from Kanis JA 
et al 2013 (Kanis, McCloskey et al. 2013). 
 
 119 
Ultimately, assessment of fracture risk and the risk/benefit of intervention has to be 
individualized in each case taking into account other factors, such as comorbidities, 
insurance coverage, and compliance.  
 
Apart from fracture risk evaluation, an initial diagnostic work-up is recommended in 
order to screen for secondary causes of osteoporosis (e.g: thyroid disease, 
hyperparathyroidism, malabsorption syndromes, etc) and allow differential diagnosis 
with other diseases that also present with low BMD and increased risk of fracture, 
such as osteomalacia and multiple myeloma (Table 1.7).  
 
Table 1.7 Recommended procedures in the diagnostic work-up in 
patients with osteoporosis. 
Routine 
- Complete clinical history including screening of FRAX® clinical risk factors 
- Physical Examination including height and weight 
- Complete blood count, creatinine, serum calcium, alkaline phosphatase, 
serum phosphate, PTH, TSH, calcidiol (25-OH-VitD), albumin, liver 
transaminases, ESR   
- Lateral radiograph of thoracic and lumbar spine  
- Bone mineral density test (DXA) in hip and spine  
- Lateral imaging DXA for vertebral fracture assessment (VFA) 
In selected cases 
- Markers of bone turnover 
- Serum or urine protein electrophoresis, fasting and 24-h urinary calcium, 
urinary free cortisol, IgA anti-tissue transglutaminase antibody or IgA 
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endomysial antibody 
- FSH, LH, prolactin, free testosterone 
- Trans-iliac bone biopsy 
- DXA in distal radius 
- Other BMD measurement methods (QUS, pDXA, QCT) 
Markers of bone turnover when available and mainly for research purposes. DXA in 
distal radius if DXA in central sites (hip and spine) is not applicable (e.g. hip 
replacements). Other BMD measurement methods when DXA is not available. 
FRAX®: fracture risk assessment tool; PTH: parathyroid hormone; TSH: thyroid 
stimulating hormone; ESR: erythrocyte sedimentation rate; DXA: dual-X-ray-
absorptiometry; QUS: quantitative ultrasound; pDXA: peripheral DXA; QCT: 
quantitative computerized tomography. 
 
1.6.2 General management: non-pharmacological interventions 
1.6.2.1 Physical activity and prevention of falls 
Immobilization constitutes an important cause of bone loss, and should always be 
avoided when possible (e.g. prolonged hospitalisations, elderly living in age care 
facilities, etc). In contrast, physical activity has a positive impact in bone mass, 
muscle strength and balance, as exposed in the previous chapter. Risk factors for 
falls (Table 1.8) should be identified and corrected or minimised if feasible (e.g. by 
prescribing walkers in those with impaired gait, correcting visual loss, reducing 
medication that alters balance, etc), together with improvement of the home 
environment (shower chairs, handrails, ground obstacles, etc). 
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Table 1.8 Common risk factors associated with falling 




History of falls 
Impaired gait and balance 




Neuromuscular or musculoskeletal disorders 
Adapted from Kanis et al (Kanis, McCloskey et al. 2013) 
 
Hip protectors have been used in several randomized controlled trials in order to 
reduce hip fracture after falls. While it seems that they might collaborate in reducing 
hip fracture incidence in nursing care facilities, data suggests that they may mildly 
increase the rate in pelvic fractures (Santesso, Carrasco-Labra et al. 2014). 
Additionally, they show low acceptance and adherence among the older population, 








Adequate intake of calcium, vitamin D and proteins are required to achieve a good 
musculoskeletal health during all human life. In older individuals is important to 
maintain a good level of such nutrients to avoid sarcopenia and osteoporosis. The 
capacity of the skin to synthesize vitamin D from the sunlight exposure diminishes 
with age, and hours of outdoor life tend to decrease in the older population. 
Therefore, most of the individuals diagnosed with osteoporosis require supplements 
of vitamin D. Additionally, there is a high prevalence of insufficient calcium and 
protein intake in the elderly.  
 
The ESCEO recommends optimal dietary protein intake of 1.0-1.2g/kg of bodyweight 
per day with at least 20-25g of high-quality protein at each main meal, with adequate 
vitamin D intake at 800IU/d to maintain serum 25-hydroxyvitamin D levels >50nmol/L 
as well as calcium intake of 1000mg/d, alongside regular physical activity/exercise 3-
5 times/week combined with protein intake in close proximity to exercise, in 
postmenopausal women for prevention of age-related deterioration of 
musculoskeletal health (Rizzoli, Stevenson et al. 2014). Dietary sources of calcium 
are the preferred option, and calcium supplementation should only be targeted to 
those who do not get sufficient calcium from their diet and who are at high risk for 
osteoporosis or they have already been diagnosed. 
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1.6.3 Major pharmacological interventions  
Several agents are approved for the treatment of osteoporosis. They have all shown 
to increase BMD and reduce the risk of vertebral fracture in randomized clinical 
trials. Some have also shown to reduce the risk of non-vertebral fractures, and in 
some cases, the risk of hip fracture (Table 1.9). Risk reductions of between 30-70 % 
have been demonstrated for vertebral fractures, around 15-20 % for non-vertebral 
fractures and up to 40% for hip fracture (Kanis, McCloskey et al. 2013). Mortality 
reduction has been estimated in around 11% globally in one meta-analysis including 
four different agents (risedronate, zoledronic acid, strontium ranelate and 

















































































































































































































































































































































































































































































































































































































































































































































The mechanism of action of such drugs is diverse, but most of the agents produce 
their effect through the inhibition of bone resorption, except recombinant parathyroid 
hormone (1-34 PTH and 1-84 PTH), which given at small doses intermittently, 
stimulate osteoblastic line and lead to bone formation. Strontium ranelate, despite 
being mainly an inhibitor of bone resorption, has also shown some simultaneous 
stimulation on osteoblast activity.  
 
Benefits from concomitant use of such agents have not been fully demonstrated yet. 
Instead, sequential treatment, particularly the administration of an inhibitor of bone 
resorption following PTH analogs, may potentiate the benefits obtained during the 
anabolic treatment (Black, Bilezikian et al. 2005; Eastell, Nickelsen et al. 2009).     
 
In general, safety profile of all major pharmacological intervention is quite favorable 
(Kanis, McCloskey et al. 2013). One exception is the use of hormonal replacement 
therapy (HRT), which is not recommended as first line for the treatment of 
osteoporosis anymore given the increased risk in cardiovascular events and breast 
cancer (Kanis, McCloskey et al. 2013). Most of guidelines only recommend HRT for 
climacteric symptoms and with a total accumulative dose as small as possible. Other 
treatments, such as calcitonin and vitamin D derivates (i.e. alfacalcidiol), have been 
abandoned due to their low cost-effectivity and the presence of risks (e.g. cancer in 
long-term use of calcitonin; hypercalcemia and nephrocalcinosis in alfacalcidiol) that 
possibly outweigh the potential benefits. More recently, the European Medicines 
Agency (EMA) has put a black box warning for strontium ranelate in patients with 
known cardiovascular disease.    
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Screening strategies followed by pharmacological interventions have shown to be 
cost-effective in osteoporosis (Schousboe, Ensrud et al. 2005; Mobley, Hoerger et al. 
2006; Hiligsmann, Gathon et al. 2010; Nayak, Roberts et al. 2011). In addition, cost-
effectivity in the prevention and treatment of osteoporotic fractures has been 
established for all major pharmacological interventions individually (Strom, 
Borgstrom et al. 2007; Borgstrom, Strom et al. 2010; Hiligsmann, Vanoverberghe et 
al. 2010; Jonsson, Strom et al. 2011; Pham, Datta et al. 2011; Nayak, Roberts et al. 
2012; Hiligsmann, Ben Sedrine et al. 2013; Hiligsmann, Boonen et al. 2013; 
Majumdar, Lier et al. 2013; Kim, Svedbom et al. 2014; Parthan, Kruse et al. 2014). 
Taking into account the lack of head-to-head randomized controlled trials and the 
absence proof of one treatment being clearly superior to another in terms of efficacy, 
first line and second line interventions are often based on the product’s price. For 
this reason, generic alendronate tends to become first line option in lots of public 
health systems, while PTH analogues are reserved only for severe cases non 
responding adequately to antiresorptive therapy (Strom, Borgstrom et al. 2013). 
However, aspects related to tolerability and adherence to medications can highly 
impact the cost-effectivity of osteoporosis screening and treatment (Hiligsmann, 
Gathon et al. 2010), and they need to be considered both in population economic 
analysis as well as in individual decisions during clinical practice.  
 
1.6.4 Invasive interventions: vertebroplasty and kyphoplasty 
In patients with acute vertebral fracture with persisting pain despite optimization of 
analgesia, injection of cement in the fractured vertebral body without (vertebroplasty) 
or with preceding balloon inflation (kyphoplasty) may lead to short-term reduction of 
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pain. Their use is been controversial, particularly after a randomized controlled trial 
showing no beneficial effect versus placebo (Buchbinder, Osborne et al. 2009; 
Kroon, Staples et al. 2014). Furthermore, concerns exist about a possible increased 
risk of subsequent vertebral fracture after vertebroplasty, even though this 
conception has not been confirmed (Han, Wan et al. 2014; Kroon, Staples et al. 
2014).  
 
These techniques are exclusively for pain management and cannot substitute the 
rest of interventions for secondary prevention of fractures.  
 
1.6.5 Monitoring of treatment 
Compliance with anti-osteoporosis medications affects significantly their anti-fracture 
efficacy (Curtis, Westfall et al. 2008; Patrick, Brookhart et al. 2010). Poor adherence 
to medical therapies is a widespread public health problem. In osteoporosis, maybe 
because of being a silent disease for a big proportion of treated individuals with no 
history of fractures, compliance and persistence with treatment are poor. It is been 
estimated that approximately 50% of patients do not follow their prescribed treatment 
regimen or discontinue treatment within one year (Compston and Seeman 2006) 
Thus, it is important to check tolerability and adherence to pharmacological 
interventions in subsequent visits after starting bone therapies. 
 
The goal of bone therapies is to improve bone strength and subsequently reduce the 
risk of fracture. It is likely that the long-term anti-fracture efficacy of anti-osteoporosis 
medications is only partly dependent on the extent to which they increase or 
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maintain BMD (Rabenda, Bruyere et al. 2011). Anyhow, BMD is one of the major 
predictors of bone strength, and it constitutes an objective, non-invasive and 
reproducible measurement to monitor treatment-related changes in the bone. In 
addition, evidence supports the correlation between the change in BMD and fracture 
risk reduction (Hochberg, Greenspan et al. 2002; Delmas, Li et al. 2004). Serial BMD 
testing can detect non-responding individuals by finding loss of bone density, 
suggesting the need for re-evaluation of diagnosis and treatment. As per 
recommendations of the ISCD, follow-up BMD testing should be done when the 
expected change in BMD equals or exceeds the least significant change (LSC), to 
ensure that the BMD change detected is real. The LSC is related to the 
measurement variability of the technique itself. Typically one year after initiation or 
change of therapy is appropriate, with longer intervals once therapeutic effect is 
established (The International Society for Clinical Densitometry. 2007). 
  
Several bone markers from serum and urine can be used to monitor the rate of bone 
formation and bone resorption. The most broadly used are procollagen I N-terminal 
extension peptide (P1NP) for bone formation and C-telopeptide breakdown products 
(especially serum Carboxy-terminal collagen crosslinks or CTX) for bone resorption. 
Changes in bone markers once treatment is started occur typically before detectable 
BMD changes (within the first 3-6 months). Early change in bone markers have been 
correlated with future increases in BMD, and importantly, to vertebral fracture risk 
reduction in antiresorptive therapies. (Reginster, Collette et al. 2008). However, the 
effect on bone markers does not seem to be determinant in the choice of an anti-
osteoporosis therapy, and more research is still required to establish standardized 
use of those in the clinical practice. 
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Duration of treatment will first depend on individual medical reasons. In general, 
evidence of fracture risk reduction is been shown up to 5 years for some of the 
antiresorptive drugs, and up to 10 years for strontium ranelate. On the other hand, 
use of PTH analogues is only approved for a 24-month period. In general, long-term 
safety is good for most of the drugs (Cooper, Reginster et al. 2012). Exceptions to 
this, as mentioned previously, are the long-term use of HRT and calcitonin, as well 
as the prolonged use of bisphosphonates, the latter due to occurrence of 
subtrochanteric femoral fractures, despite this being a rare secondary effect (Black, 
Kelly et al. 2010; Rizzoli, Akesson et al. 2011). Sequential treatment is advisable in 
those patients exhibiting high risk of fracture despite long-term antiresorptive 
therapy, who might benefit from anabolic treatment, followed by resuming 
antiresorptive therapy upon finalization of PTH analogues (Black, Bilezikian et al. 
2005; Eastell, Nickelsen et al. 2009; Boonen, Milisen et al. 2011). Even though 
optimized improvement of BMD is been achieved on combination treatment 
(simultaneous administration of antiresorptive and anabolic therapy) (Muschitz, 
Kocijan et al. 2013; Walker, Cusano et al. 2013; Leder, Tsai et al. 2014), the 
influence of such approach on fracture risk and the cost-effectivity of this type of 
intervention is not well established yet, and therefore, not globally recommended in 
the clinical practice.     
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1.7  Osteoporosis in the real world: underdiagnosed and 
undertreated  
It has been exposed in a previous chapter how enormous the costs from fragility 
fractures are, and the way the ageing of the global population will affect the 
increasing economical toll that societies will face soon.  
 
Recent reviews have demonstrated the cost-effectiveness of treating osteoporosis 
(Zethraeus, Borgstrom et al. 2007; Strom, Borgstrom et al. 2013). Branded 
alendronate showed to be cost-effective in nine countries of Western Europe in a 
longitudinal fracture intervention trial (Strom, Borgstrom et al. 2007), and 
complementary data indicates that the cost-effectivity of such intervention is probably 
maintained in both men and women over 50 years of age at high risk of fracture in 
most Western countries (Strom, Borgstrom et al. 2013). Cost-effectiveness improves 
with the number of risk factors (Strom, Borgstrom et al. 2013). Furthermore, other 
authors have shown that the cost-effectiveness of screening and treatment of 
osteoporosis with alendronate is cost-effective for all alendronate price ranges in the 
United States, and even cost-saving for the cheapest formulations (Nayak, Roberts 
et al. 2012).  
 
It is also been highlighted before that, the ability of hypertension and 
hypercholesterolemia to predict stroke and myocardial infarction, respectively, are 
not better than the predictive value of BMD to predict fractures (Marshall, Johnell et 
al. 1996). In addition, cost-effectiveness of therapeutical intervention for the three 
risk factors has shown to be cost-effective for each of them at a population level 
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(Zethraeus, Strom et al. 2008). What’s more, the cost-effectivity improves with age 
for osteoporosis treatment, but not always for cholesterol lowering and 
antihypertensive therapy (Zethraeus, Strom et al. 2008). 
 
These observations contrast enormously with the lack of osteoporosis screening and 
treatment among people suffering fragility fractures (Strom, Borgstrom et al. 2013). 
Systematic review of international studies have shown that most of the patients are 
not offered proper osteoporosis management after the acute care of a fragility 
fracture, including low rate of laboratory tests and BMD testing referrals (less than 
one third of the patients), as well as low rate of pharmacological interventions in 
those with osteoporosis diagnosis, with less than 20% of patients discharged in any 
bone medication (Elliot-Gibson, Bogoch et al. 2004; Giangregorio, Papaioannou et 
al. 2006). In contrast, more than 75% of elderly patients discharged after a 
myocardial infarction are prescribed beta-blockers as secondary prevention of 
ischemic heart disease (Austin, Tu et al. 2008), which clearly shows the gap of 
disease awareness among osteoporosis and cardiovascular diseases.  
 
Despite some efforts towards the implementation of systematic screening of 
osteoporosis in population at high risk of fracture, there is still a generalized lack of 
awareness of the magnitude of the problem both by professionals and patients. Still, 
osteoporosis doesn’t count among top research and public health priorities (Daar, 
Singer et al. 2007). A paradigm of this, it’s the no appearance of any musculoskeletal 
condition among the health priorities of WHO for non-communicable diseases, with 




1.8  Context of the Thesis Project: The Global Burden of Diseases 
2010 Study (The GBD 2010 study) 
The Global Burden of Diseases (GBD) taskforce started in 1990 as a World Bank 
initiative to estimate the health burden of the main diseases and injuries in the world 
in a comparable, systematic, and rigorous epidemiological manner (Murray, Lopez et 
al. 1994). The initiative involved the collaboration among epidemiologists and public 
health experts from different universities and institutions throughout the world. The 
health burden resulting from 109 health conditions was assessed through data 
review on the incidence, prevalence and mortality from all countries. The first GBD 
Study 1990 generated widely published findings and comparable information on the 
burden of disease for all the world. From 2000 to 2004, albeit only for some 
diseases, the WHO updated these data (Lopez, Mathers et al. 2006), and multiple 
regional- and country-specific reports as well as disease-focused burden analysis, 
have been generated since then. These burden estimates have been used by 
governments and non-governmental agencies to establish priorities for research, 
health policies and funding. The Global Burden of Diseases, Injuries, and Risk 
Factors Study 2010 (GBD 2010) was implemented from 2007 to 2012 as a 
collaboration of seven institutions: the Institute for Health Metrics and Evaluation 
(IHME) as the coordinating center providing academic leadership; the University of 
Queensland School of Population Health; the WHO; the Johns Hopkins Bloomberg 
School of Public Health; the Harvard School of Public Health; Imperial College 
London; and the University of Tokyo (Murray, Lopez et al. 2007) (Figure 1.7. The 
Global Burden of Diseases 2010 study timeframe.). The GBD 2010 study was 
undertaken to update and revise previous GBD studies, addressing key limitations of 
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previous studies by using updated and more advanced methods. The improvements 
in the methodology included a more standardized approach to evidence synthesis, 
inclusion of assessments of comorbidity and uncertainty around estimates, and more 
specific breakdowns of the data. For example, the GBD 1990 used a modification of 
World Bank regions to divide the world into 8 groups. These were modified in the 
GBD 2000 to start with the six political regions of WHO and then subdivided into 14 
regions based on estimates of adult and child mortality available at that time. For the 
GBD 2010, 21 world regions were created on the basis of two criteria: 
epidemiological homogeneity and geographic contiguity. For some types of analysis 
in the GBD, seven super-regions, which cluster together related groups of regions on 
the basis of cause of death, were created. Age groups were amplified from 8 (in the 
GBD 2000) to 20 groups in the GBD 2010 study.  The list of health causes also 
expanded, from 134 of the original GBD 1990 to 291 diseases and injuries of the 
GBD 2010, and so did the risk factors, from 27 in the GBD 2000 to 67 in the GBD 





Figure 1.7. The Global Burden of Diseases 2010 study timeframe. 
Steps taken from formation of expert groups in 2007 to publication of main estimates 
end 2012 in Lancet. Adapted from Hoy D et al 2014 (Hoy, Smith et al. 2014). 
 
Prevalence data were gathered through systematic reviews, with variability between 
studies regarding case definition, age groupings and prevalence period used. In 
addition, data were often missing for specific age groups, regions and years of 
interest. A Bayesian meta-regression tool, DisMod-MR (DISease MODelling Meta-
Regression), was developed by the Core Team (CT) specifically for the GBD 2010 
study to deal with these challenges (Vos, Flaxman et al. 2012). In brief, DisMod-MR 
is a tool that helps to pool heterogeneous data presented in different age groups; to 
adjust data for methodological differences; to check data on incidence, prevalence, 
duration, remission and mortality risk for internal consistency; and to predict values 
for countries and regions with little or no data using disease-relevant country 
characteristics (such as average BMI in knee osteoarthritis) and random effects for 





The two primary outcome measures for the GBD work include Deaths and DALYs, 
which combine the years lived with disability (YLDs) and the years of life lost due to 
premature mortality (YLLs). One DALY can be thought as the loss of one year of 
‘healthy’ life. DALYs used in burden measurement are the gap between current 
health status and an ideal situation where everyone lives into old age free of disease 
and disability. This measure allows comparisons of the burden caused by different 
conditions on the overall health status, as well as comparisons between countries, 
regions, age groups and genders. 
 
The number of ‘incident YLDs’ are calculated by the number of incident cases x the 
average duration (expressed in years) x the Disability Weight (DW). Prevalent YLD is 
the other form of YLD’s and can be calculated as prevalence x DW. The DW goes 
from zero (a health state equivalent to ideal health) to one (a health state equivalent 
to death).   
 
Then,  
DALY= YLL + YLD 
where: 
YLL=years of life lost due to premature mortality; YLD=years lived with disability  
and   
YLL = N x L  
where N = number of deaths; L = standard life expectancy at age of death in years  
YLD = I x DW x L  
where I = number of incident cases; DW = disability weight; L = average duration of 
the case until remission or death in years 
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The initiative attributes DWs to different health states in order to calculate DALYs. In 
GBD methodology, the term “sequela" includes severity and disabling consequences 
of a disease. Partitioning a condition into a series of sequelae enables disability 
variations within a condition to be taken into account through the application of 
different DWs to the different sequelae (recognizing, for example, the diverse 
disabling consequences of mild OA and severe OA). Disease definitions, range of 
disease severity and functional health sequelae resulted from literature review or, in 
absence of published evidence, through expert group consensus with initial concept 
mapping followed by a series of modified Delphi exercises. The aim was to describe 
the “average” or “typical” common general manifestations within each condition. 
Health states were mapped to standardised health check-lists to describe functional 
impairment (Salomon 2008; Salomon, Vos et al. 2012). In that way, for the latest 
revision of the GBD (GBD 2010), YLDs have been computed for 1160 sequelae 
resulting from 289 disease and injury causes, by multiplying the number of people 
living with each sequela by an associated disability weight (Figure 1.8). The 1160 
sequelae were mapped into a set of 220 distinct health states that capture the most 
salient differences in symptoms and functioning. 
 
To produce DWs, surveys were conducted through personal interviews in 
Bangladesh, Indonesia, Peru, and Tanzania; telephone interviews in the United 
States; and an open-access web-based survey. In household surveys, households 
were randomly selected with a multistage, stratified sampling design, with 
probabilities of being selected proportional to population size. All samples were 
designed to be representative in a specific geographical area or, in the case of the 
USA, to be nationally representative. The surveys used paired-comparison 
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questions, in which respondents considered two hypothetical individuals with 
different functional limitations (corresponding to a randomly selected pair of health 
states), and indicated which person they regarded as healthier. The web survey 
added ‘population health equivalence’ questions, which compared the overall health 
benefits of different life saving or disease prevention programs. Paired comparison 
responses were analysed using probit regression analysis, and results were 
anchored on a scale from 0 (implying no loss of health) to 1 (implying a health loss 
equivalent to death) using results from the population equivalence responses to 




Figure 1.8 Steps for the production of health burden 
The Dismod-MR program adjusts for heterogeneity, derives missing values, ensure 
internal consistency, and produces estimates cause-sex-age-region-specific. 
DisMod-MR: Disease modelling meta-regression tool; YLLs: years of life lost due to 
premature mortality; YLDs: years lived with disability; DALY: disability-adjusted life 
years. 
 
Out the 291 causes of health burden in the GBD 2010 study, 235 were causes of 
mortality (Lozano, Naghavi et al. 2012). For the YLLs calculations, database 
development was based in vital registration with medical certification of deaths, 
verbal autopsy data, police and crime reports, maternal mortality surveillance, 
population-based cancer registries, burial and mortuary data, and hospital-based 
deaths. The last three sources of data were only chosen for deaths due to injuries. 
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The model used a common framework for all causes of mortality to allow all cause-
specific deaths to equal the total number of deaths from all causes in each country, 
region, gender and age group (Lozano, Naghavi et al. 2012).  
 
One of the main limitations of the GBD initiative is that burden estimates are limited 
to the impact of the different causes on individual health. It does not count for the 
burden that conditions may cause into family structures, workforce and economic 
burden for the societies. Despite the GBD study represents the most important effort 
to summarize the health burden of the main causes in a comprehensive and 
comparative manner, social and economic outcomes of health conditions are equally 
relevant to properly plan public health strategies. This is particularly important at a 
regional level, because of the different access and cost to screening tools and 
treatments across the different countries in the world.     
 
The core papers with the main results from the GBD 2010 study were published in 
Lancet in December 2012 (Lim, Vos et al. 2012; Lozano, Naghavi et al. 2012; 
Murray, Vos et al. 2012; Salomon, Vos et al. 2012; Vos, Flaxman et al. 2012). Since 
then, disease-focused and regional reports have been published in order to 
disseminate results more widely. Detailed data on methods and burden estimates 
can be found open access in the IHME website (http://www.healthdata.org/gbd).  
 
This project is part of the Musculoskeletal (MSK) Expert Group (EG) series within the 
GBD 2010 study, based in the Institute of Bone and Joint Research in the University 
of Sydney and led by Professor Lyn March. The MSK EG was part of cluster C led 
by one of the CT members in the University of Queensland (Figure 1.9), Theo Vos. 
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Extended reports on the overall methods for MSK conditions (Hoy, Smith et al. 
2014),  global burden of osteoarthritis(Cross, Smith et al. 2014), rheumatoid arthritis 
(Cross, Smith et al. 2014), gout (Smith, Hoy et al. 2014), low back pain (Hoy, March 
et al. 2014), neck pain (Hoy, March et al. 2014), occupationally-related low back pain 
(Driscoll, Jacklyn et al. 2014), other musculoskeletal conditions (Smith, Hoy et al. 
2014), and final conclusions (Hoy, Smith et al. 2014) were published in the first half 
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Figure 1.9 The Musculoskeletal Expert Group as part of cluster C that 
included also the Injuries and Mental Health Expert Groups. 
Cluster C was led by one of the core team members in University of Queensland. 
Modified from the GBD Operations Manual. 
 
Details on the results from the GBD 2010 study are out of the scope of this present 
work and all data can be found free of charge in the Lancet core papers (Lim, Vos et 
al. 2012; Lozano, Naghavi et al. 2012; Murray, Vos et al. 2012; Salomon, Vos et al. 
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2012; Vos, Flaxman et al. 2012) and in the IHME website 
(http://www.healthdata.org/gbd). Briefly, DALYs remained stable from 1990 (2.503 
billion) to 2010 (2.490 billion). However, the crude rate of DALYs per 1000 people 
decreased in 23% during the same time period, showing the improvement trend in 
the global health burden over the last two decades. The changes in the global health 
were marked by two important facts, which were the increase of life expectancy and 
the global shift from communicable to non-communicable causes. The first was 
highly influenced by the reduction of mortality due to maternal, newborn and 
nutritional causes, and communicable diseases in general. As per non-
communicable causes, such as ischemic heart disease and diabetes, they increased 
around 30% from 1990 to 2010, contributing enormously to the worldwide increase in 
YLD. Of the global DALYs for 2010, loss of life due to premature mortality (YLLs) 
and loss of life due to disability (YLDs) represented 68.8% and 31.2%, respectively, 
of the total DALYs. Cardiovascular diseases were the leading causes of YLLs 
worldwide, while mental and behavioural disorders ranked first among causes of 
YLDs, followed by musculoskeletal disorders, representing 22.7% and 21.3%, 
respectively, of all YLDs worldwide. Low back pain ranked first in the top causes of 
YLD’s both in 1990 and 2010. Neck pain and other MSK disorders (including 
diseases such as systemic lupus erythematosus) ranked within the top 10 causes of 
disability both for 1990 and 2010, and osteoarthritis significantly increased its rank 
from 15th to 11th between 1990 and 2010. Falls also ranked relatively high in 
disability burden (number 10 in the rank list of YLD causes for 2010), with only a 




Figure 1.10. Top Twenty Causes of Years Lost Due to Disability (YLDs) 
Continuos lines indicate no change or increase of rank from 1990 to 2010, while 
dotted lines denotes a decrease in the rank. Adapted from IHME website 
(http://www.healthdata.org/gbd). 
 
In previous editions of the GBD initiative, the health burden of osteoporosis was 
reflected through the burden of osteoporotic fractures. For the year 2000, 9.0 million 
osteoporotic fractures were estimated to occur worldwide, of which 1.6 million were 
at the hip, 1.7 million at the forearm and 1.4 million were clinical vertebral fractures. 
The greatest number of fractures occurred in Europe (34.8%). Almost 6 million 
DALYs were lost in the world due to osteoporotic fractures, half in Europe and in the 
Americas. In Europe, osteoporotic fractures accounted for more DALYs lost than all 
causes of  cancer except lung cancer, and among MSK causes,  DALYs lost in 
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Europe due to osteoporosis (2.0 million) were less than for osteoarthritis (3.1 million) 
but greater than for rheumatoid arthritis (1.0 million) (Johnell and Kanis 2006). 
 
Osteoporosis per se was not considered as a disease in the GBD 2010 study, and 
for the first time, low BMD was included in the global burden estimates, as a risk 
factor for fractures, which represented a proportion of the global burden from falls 
(Figure 1.11). The present project describes the methods used to calculate the 
contribution of low BMD to the global health burden due to falls and presents results 
on the estimates of the burden of low BMD by age, sex, and world region, both for 
1990 and 2010. Comparative risk assessment (CRA) methodology was used to 
calculate the burden estimates, following the risk factor analysis within the GBD 




Figure 1.11. Burden Due to Low Bone Mineral Density in the GBD 2010 
Study. 
The burden attributable to low BMD is calculated as part of the burden due to 
fractures, which is part of the burden associated with falls in the GBD 2010 study. 




















2.1 Hypotheses:  
 
1) An important percentage of the global health burden due to falls could be 
potentially avoided in the hypothetical scenario that the aged global 
population presented an ideal bone mineral density (BMD).  
2) The global burden due to low BMD is expected to have increased in the last 
20 years with the growth of ageing populations in all world regions. The 
burden can vary depending on the world region, the age group and the sex.  
 
2.2 Objectives:  
 
1) To estimate the global levels of BMD measured by dual-x-ray-absorptiometry 
at femoral neck in populations 50 years and over as the exposure variable for 
1990 and 2010. 
2) To estimate the global burden of low bone mineral density as a fraction of the 
global burden due to falls for 1990 and for 2010.  
3) To estimate the percentage of the global health burden attributable to low 
BMD for 1990 and 2010. 
4) To estimate the global number of deaths due to low BMD for 1990 and 2010. 
5) To estimate the global number of Disability-adjusted life years (DALYs) due to 
low BMD for 1990 and for 2010.  
6) To compare the health burden of low BMD to that derived from other risk 















3.1  Introduction to Comparative Risk Assessment Methodology 
In Comparative Risk Assessment (CRA) methodology (Ezzati, Hoorn et al. 2011; 
Lim, Vos et al. 2012), the health burden due to a risk factor is compared to the 
hypothetical burden that would occur if the risk factor distribution was at the optimal 
level. Estimates are based on a counterfactual exposure distribution that would result 
in the lowest population risk exposure, referred to as the theoretical-minimum-risk 
exposure distribution (TMRED) (Figure 3.1). This has to be theoretically possible 
based on current scientific evidence, irrespective of whether currently attainable in 
practice. As a result, the CRA methodology maps alternative population health 
scenarios that arise from changes in the distribution of exposure to risk factors.  
 
Using the exposure distributions to the risk factor and the risk relationship between 
the risk factor and a health outcome, population attributable fractions (PAFs) are 




where PAF is the population attributable fraction, RR(x) is the relative risk at the 
exposure level x, P(x) is the population distribution of exposure, P’(x) is the 





Figure 3.1 Counterfactual analysis in the Comparative Risk Assessment 
(CRA) methodology 
In the CRA methodology, the incidence of fractures (outcome) for the observed 
distribution of the exposure variable (BMD) is compared to an ideal scenario 
where the population has an optimal level of BMD, conferring the minimum 
possible relative risk for fracture. BMD: bone mineral density. Adapted from 
Lennert Veerman, through personal communication.  
 
The PAF represents the proportion of health burden that could be saved in the 
hypothetical scenario that the exposure to the risk factor was ideal (i.e minimal). In 
the present study, this leads to our main research question: 
 
What proportion of the falls burden in the world could be avoided if all population had 






In order to answer this, the following steps were taken: 
 
1) Definition of exposure variable: low bone mineral density (BMD) 
2) Definition of the risk relationship between BMD and fractures by systematic 
review (SR) 
3) Estimation of the global and regional levels of exposure by SR 
4) Estimation of falls-related burden due to fractures 
5) Estimation of PAFs of falls due to low BMD  
6) Estimation of the global and regional health burden due to low BMD 
 
Following the GBD framework, estimates of the health burden were done by country, 
world region, age group, gender and year (1990 and 2010). Estimates were limited 
to population 50 years and over due to the lack of valid longitudinal epidemiological 
data in premenopausal women and young male on the risk relationship between 
BMD and fractures, even after personal communication with the IOF in order to seek 
for valid non-published data. Other reasons to exclude younger population was the 
lower frequency of osteoporosis in premenopausal women (Odabasi, Turan et al. 
2009) and young men and the high frequency of secondary causes of osteoporosis 
in this subgroup of population (e.g. glucocorticosteroid treatment, rheumatoid 
arthritis, Cushing disease, etc ) (Peris, Guanabens et al. 2002; Odabasi, Turan et al. 
2009), leading to altered bone quality, sarcopenia and increased risk of falls, factors 




3.2 Constitution of the Osteoporosis Working Group 
The project took into consideration networking efforts to analyse the results in the 
most suitable way, with the guidance from experts in osteoporosis epidemiology. An 
“Osteoporosis Work Group” (OWG) was created to develop a peer-reviewed 
assessment of the tools and the results of the SR, and ensure its consistency. The 
OWG was divided in “The Review Team” (RT) and the “Expert Leaders Group” 
(ELG), who were invited by formal letter. The ELG was constituted by public health 
experts enrolled in the GBD 2010 study, as well as world expert leaders in 
epidemiology of osteoporosis. All steps taken in the SR as well as provisional results 
were supervised by the MSK EG coordinators, the MSK EG leaders and members of 
the core team (CT) in the IHME (University of Washington), in order to provide 
feedback on unresolved issues and ensure the homogeneity within the GBD study 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The RT was formed by 9 reviewers, guided by the main project officer (MPO) of the 
OWG, a rheumatologist with experience in osteoporosis research who was part of 
the GBD 2010 study working group. The MPO performed the screening of eligible 
studies from the SR, led the data extraction process, provided scientific evidence to 
ELG for team discussion when necessary, coordinated meetings and communication 
with member of the ELG, and led oral communications and manuscript writing 
related to the results of the study (Figure 3.2).  
 
A series of workshops were undertaken within the RT and conducted by the MPO, in 
order to standardise and ensure the accuracy of the data extraction process and the 
correct application of the risk of bias tool (RoB). Any doubt or inconsistency 
appearing during raw data extraction, was consulted with the MPO directly to 
achieve consensus, who contacted the EGL or manuscripts’ authors when required. 
 

















































































































































































































































































































































































































































































































































































Duties of the ELG included Delphi exercises for consensus in search strategies and 
development of the RoB, agreement in the definition of the exposure variable, 
feedback on data extraction sheet format, networking to obtain non-published data, 
advice on the choice of the TMRED for the CRA analysis, feedback on RR for 
fractures obtained from previous meta-analysis and new data, critical approach of 
provisional results from the SR, and providing ideas on how to deal with missing 
data. This was undertaken by personal communication through email, phone, 
teleconferences and in group meetings during international conferences.   
 
Finally, data on fracture incidence and prevalence obtained through the SR was 
coded separately and shared with the Injury Expert Group (IEG) in the GBD 2010 
study (the search strategy for RR BMD-fractures captured a great amount of 
manuscripts with such information: the MPO classified the potential eligible articles 
by fracture type, data extraction was performed by the RT and all the information 
was shared with the IEG). The role of the MPO from the OPG in the literature review 
for fractures in the GBD 2010 study was reflected in the website of the IEG 
(https://sites.google.com/site/gbdinjuryexpertgroup/Home/literature-review#TOC-
Literature-Review-Package). Worth to mention that data obtained from the OPG on 
fracture prevalence/incidence was not aiming to substitute the SR conducted by the 
IEG, but instead providing support on some tasks that were inevitably overlapping 
between both expert groups. Furthermore, the search strategy of low BMD as a risk 
factor for fractures was not originally designed to specifically capture articles on 
incidence and prevalence of fractures. Final management of fracture data provided 
by the OPG was entirely under the responsibility of the IEG and is beyond the scope 
of the present thesis.   
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3.3 Definition of the Exposure Variable: Low Bone Mineral 
Density 
Low bone mineral density measured at femoral neck (FNBMD) by DXA in g/cm2 was 
chosen as a continuous variable for the levels of risk of exposure. Reasons for 
selection of the technique and location are as follow: 
 
1) Central DXA is the most validated and reliable technique to measure BMD, 
recommended as first choice for clinical and research purposes (WHO 1994; 
The International Society for Clinical Densitometry 2007).  
2) More available epidemiological data is expected to be found with DXA than 
with other alternative and more recent techniques to measure BMD (QUS, 
pDXA, QCT, etc) 
3) Measures with DXA are highly reliable and reproducible. Standard calibration 
methods are well established to ensure quality control of the DXA machines. 
The precision error (PE) is usually expressed as the coefficient of variation 
(CV), which is the ratio of the SD to the mean of the measurements. The 
ISCD has defined the acceptable ranges of PE in official positions (The 
International Society for Clinical Densitometry 2007).  
4) Morbidity and mortality related to hip fracture (the osteoporotic outcome with 
the highest health burden) is better predicted when BMD is measured at FN 
rather than spine or forearm (Marshall, Johnell et al. 1996; Johnell, Kanis et 
al. 2005). Furthermore, measurement at the FN has been found to correlate 
well with vertebral and other osteoporotic fractures, and with any fracture 
(Johnell, Kanis et al. 2005). 
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5) Measurement of BMD at FN are more reliable than those performed at lumbar 
spine because of less interference of potential artefacts such as osteoarthritic 
changes and aortic calcification. Besides, BMD measurements at total hip 
have not proved to increase the predictive value of FN for fractures (Kanis, 
McCloskey et al. 2008).    
6) The most solid epidemiological data available at the moment in regards to the 
RR of fracture related to BMD uses FNBMD (Johnell and Kanis 2006).  
 
3.4 Description of the Systematic Review and Data Extraction 
Process 
We performed a SR of Medline, Embase, CAB Abstracts, CINHAL, WHOLIS, and 
SIGLE databases using search strategies for risk factor levels of exposure (low 
BMD) and for risk relationship BMD-fracture. Inclusion criteria for both strategies 
were: population-based studies, publication from 1980 to 2009, BMD values in g/cm2 
measured by DXA at FN.  
 
Search strategy 1. Risk factor levels of exposure (March 9th 2009)  
mp. [mp=title, original title, abstract, name of substance word, subject heading 
word]  
limit to (humans and yr="1980 - 2009") 





(prevalen* OR inciden* OR cross-sectional OR cross sectional OR epidemiol* 
OR survey OR population-based OR population based OR population study 
OR population sample OR cohort OR follow-up OR follow up OR longitudinal 
OR regist* OR data collection) 
AND 
(GBD Countries MeSH MEDLINE) (Appendix 1) 
 
Search strategy 2. Risk relationship BMD-fracture (March 9th 2009) 
mp. [mp=title, original title, abstract, name of substance word, subject heading 
word] 
limit to (humans and yr="1980 - 2009") 
(osteoporosis OR osteopenia OR osteopaenia OR bone mineral density OR 
radiolucency) 
AND 
(fracture* OR risk) 
AND 
(GBD Countries SH EMBASE) (Appendix 1) 
 
Exclusion criteria were: Exclusion criteria: A: Subsample not representative of the 
population (i.e: athletes); B: Non- population based studies (i.e: clinical based); C: 
No prevalence/incidence data (only applied for fracture data); D: Only concrete 
subtypes of osteoporosis assessed (i.e. steroid-induced OP); E: sample number 
<150. F: Reviews. In regions with limited data we also included other types of studies 
(e.g. non-population-based) as long as the sample was considered to be 
representative of the national population. No language exclusion criteria were set.  
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Retrieving of search results through databases was performed by one of the MSK 
EG coordinators. The next steps in the SR process from search results to final list of 
eligible studies were performed by the MPO of the OWG. All titles from SR were 
screened for eligibility. Eligible titles were then screened based on abstract content.  
Finally, full-text articles from eligible abstracts were retrieved in order to finish 
selection of eligible studies. Reference list of final eligible articles was screened as 
well as updates on search results from March 2009 to August 2010. When 
necessary, authors were contacted to voluntarily provide with raw data not available 
in the manuscripts.  
 
3.4.1 Data extraction process 
A database was developed and implemented in MS Excel and information was 
extracted from included studies into the following pre-determined fields for the 
exposure variable: region, country (for a complete list of countries in each GBD 
region, please refer to Appendix 1), year of publication, study type (cross-sectional, 
longitudinal, retrospective), sample size, population description, coverage, urbanicity 
(rural, urban or both), start year of data collection, last year of data collection, age 
group start, age group end, sex, ethnicity, DXA manufacturer, FN-specific CV, mean 
+/- SD of FNBMD value in g/cm2. For risk relationship BMD-fractures, some 
additional fields were collected: follow-up duration (months), case definition for the 
outcome (i.e. fracture), outcome assessment method, parameter type for the effect 
size (i.e. relative risk, hazard ratio, odds ratio, etc), exposure unit for effect size (i.e. 
SD of BMD, absolute unit of BMD, osteoporosis WHO categories, etc) denominator, 
numerator (fracture cases), effect size value, lower and upper confidence interval 
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(CI), percentage of the CI, p value, outcome rate in the exposed group, outcome rate 
in the non-exposed group (applicable if the exposure unit was categorical such as 
number of SD, quartiles, etc), mean exposure value in non-fracture cases (i.e. mean 
BMD, mean T score, etc), mean exposure value in fracture cases, reference 
population (relevant if T or Z scores were used), presence and identification of 
adjustments (age, ethnicity, BMI, etc).  
 
All mean FNBMD and SD values with different DXA manufacturers (mainly Hologic®, 
Norland® and Lunar®) were standardized by an international conversion formulas to 
standardized mean FNBMD (sFNBMD) and SD (sSD) (Lu, Fuerst et al. 2001; 
Binkley, Kiebzak et al. 2005) (Table 3.2). Personal communication with the authors 
of such standardization equations (Lu, Fuerst et al. 2001) was established to ensure 












Table 3.2. International Conversion Formula to Standardize BMD Tests 





sBMD = a + (b * X) 
 




sBMD = +0.019 + (1.087 x Hologic BMD) 
 




sBMD = -0.023  + (0.939 x Lunar BMD) 
 




sBMD = +0.006 + (0.985 x Norland BMD) 
 sSD = 0.985 x Norland SD 
Conversion formulas for FNBMD (Lu, Fuerst et al. 2001; Binkley, Kiebzak et al. 
2005). sBMD: standardized Bone Mineral Density; sSD: Standardized Standard 
Deviation. 
 
3.4.2 Data quality control 
All included studies were assessed for bias using a modified version of a validated 
RoB tool (Appendix 2) (Hoy, Brooks et al. 2012) developed for prevalence studies, 
and adapted for low BMD (Sanchez Riera, Wilson et al. 2010). First step in the 
creation of this BMD-specific RoB tool was the development of the first draft by the 
MPO after performing literature review on the topics included when required. Next, a 
series of Delphi exercises took place within MSK EG and the EGL in the OWG until 
achievement of the provisional final version. An initial exercise with around 20% of 
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eligible studies chosen randomly was undertaken within the RT to test the 
applicability of the tool during data extraction process, and feedback was provided in 
order to improve the tool. Group workshops were carried out in the RT to discuss 
controversies and guarantee homogeneity of criteria among reviewers. Assessment 
items in the RoB tool for low BMD included: 1) definition of the anatomical location of 
the BMD measurement, 2) definition of measured outcome (fracture), 3) reliability of 
the BMD measurement, 4) reliability of the outcome measurement, 5) 
representativeness of the national population, 6) quality of the sample frame, 7) 
randomization, 8) non-response bias, 9) adjustment for confounding factors, 10) 
length of the follow-up period, 11) adequacy of follow-up cohort, 12) selection bias, 
and 13) overall risk of bias. Items 2, 4, 9-11 were only applicable to papers with 
fracture risk data related to low BMD. Risks of bias for each item were Low, 
Moderate (only some items), High and Unclear taking into account established and 
peer-reviewed criteria attached with the RoB tool for all the reviewers.  
 
Regular quality checks were done by the MPO with the aim to ensure accuracy of 
the data. Besides, a random sample of one third of the studies was doubled 
reviewed by the MPO to check precision in data extraction and right application of 
the RoB tool.  
 
Generalized linear models were used to assess whether there were significant 
differences in mean sBMD between overall bias groups. Analytical weights were 
used when dealing with the data containing averages. Potential correlations within a 
specific study were taken into account by specifying the estimator’s “cluster clustvar” 
option in StataTM version 11.1. 
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Finally, a systematic data cleaning process was performed to identify duplicated data 
and inconsistencies in the values. When necessary, full-text review or contact with 
the authors was carried out. Final set of raw clean data was provided to the CT in the 
University of Washington. As data were available for only selected country-time 
periods, the mean sBMD and sSD was estimated separately for all country-time 
periods using DisMod-MR, a Bayesian meta-regression tool developed specifically 
for GBD 2010 (Vos, Flaxman et al. 2012). The model included fixed effects for study-
specific covariates, and random effects by GBD super-region, region, and country. 
Estimates for males and females in 5-year groups for population 50 years and over 
for 1990, 2005, and 2010 were produced. 
 
3.4.3 Missing data 
A screening of the dataset results from the SR helped to identify those regions and 
countries where there was insufficient data or data obtained was uncompleted for the 
purposes of this project, as shown in Figure 4.2 of Results. In such cases, authors 
were contacted through email and asked to voluntarily provide the data in the right 
format or to facilitate non-published data.  
 
Using DisMod-MR, study-specific covariates accounted for inconsistencies in the raw 
data; for example, data that were subnational (rather than nationally representative), 
or data that were collected in a non-gold-standard way (e.g. non-population based). 
National-level covariates could be used in the model to inform the global and 
country-level trends, and were not study-specific; lag-distributed income per capita, 
mean body mass index (BMI), and availability of milk based on the Food and 
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Agriculture Organization of the United Nations disappearance data (imports plus 
local production minus exports) were tested. Even though there are other well-known 
predictors of low BMD, the analysis was limited to variables with good national data 
within the GBD 2010 project. For example, available estimates for physical activity 
only included solid data from 2005 period with very few surveys pre-2000. Raw data 
introduced in Dismod-MR did not allow production of estimates by ethnicity or race 
breakdown either, although regional effects were considered to account for part of 
that. Other risk factors such as alcohol or smoking gave ambiguous results, and after 
consensus with ELG, their inclusion in the model was ruled out given that their 
impact in the BMD distribution at a population level was thought to be rather small. 
 
3.5 Relative Risk Assessment: Low Bone Mineral Density as a 
Risk Factor for Fractures 
3.5.1 Risk Factor Effect Size 
Defining the right relationship between low BMD and fracture risk was a key step in 
our methodology. 
 
Few studies in search strategy 2 met inclusion criteria (i.e. population-based studies 
using FNBMD measured by DXA). Given the major relevance of one existing meta-
analysis (MA) published in 2005 (Johnell, Kanis et al. 2005), a consensus was 
reached with the ELG to screen for high quality data after the abovementioned MA. 
Hence, only longitudinal studies with long-follow up periods to enable fracture risk 
assessment published after 2005 were considered. As it will be shown later on (refer 
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to 4.1 Results from Systematic Review), a very little number of studies met such 
criteria. Moreover, the RRs of fracture related to FNBMD was comparable to those 
found in the MA, with a total sample size which was clearly inferior to that from the 
MA, and with important heterogeneity among studies in terms of study design, 
location of BMD measurement and fracture outcome (e.g. some studies measured 
morphometric vertebral fractures while other only considered clinical vertebral 
fractures). For all this, no need to update fracture risk data from the MA was 
considered to be required or relevant for the results.  
 
Thus, our estimates on the RR of FNBMD for fractures were based on this crucial 
meta-analysis (Johnell, Kanis et al. 2005), which has become the cornerstone of the 
most widely accepted fracture prediction tool around the world (i.e. FRAX®) (Cauley, 
El-Hajj Fuleihan et al. 2011). Such MA studied 9891 men and 29,082 from 12 
population-based cohorts from Western Europe, USA, Canada, Japan and Australia. 
The mean follow-up period was 16.3 years, with a total of 168,366 person-years. 
Authors reported age- and gender-adjusted RRs for hip and non-hip fractures 
attributable to BMD for population 50 years and older.  
 
The estimates of the gradient of risk (RR/SD) for FNBMD Z-scores, based on the 
combined data for men and women, were obtained from the authors of the MA 
(Johnell, Kanis et al. 2005) by personal communication. In the MA, Z-scores were 
established within each study population separately, which made the RRs dependent 
on the spread within the study population. For our purposes this was undesirable, 
and therefore the ‘relative’ RR/SD values were converted to ‘absolute’ RR/0.1g/cm2 
values (Table 3.3 Relative Risk (RR) for hip and non-hip fractures for each 0.1g/cm2 
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decrease in bone mineral density) using a weighted average of the spread in 
FNBMD values for the populations that were represented in the MA, as they were 
estimated in the DisMod-MR output, and so derived risk estimates for men and 
women separately by 5-year age group.  
 
Table 3.3 Relative Risk (RR) for hip and non-hip fractures for each 
0.1g/cm2 decrease in bone mineral density 
  Age Non-hip fractures Hip fractures 
Males 
 
Mean LCI HCI Mean LCI HCI 
  50-54 1.152 1.058 1.254 2.603 2.042 3.319 
  55-59 1.183 1.104 1.268 2.421 1.978 2.961 
  60-64 1.215 1.147 1.286 2.282 1.938 2.689 
  65-69 1.249 1.189 1.311 2.177 1.914 2.478 
  70-74 1.297 1.238 1.357 2.100 1.897 2.324 
  75-79 1.338 1.279 1.402 1.921 1.781 2.072 
  80+ 1.371 1.302 1.444 1.730 1.627 1.840 
Females 
         50-54 1.158 1.061 1.265 2.697 2.096 3.470 
  55-59 1.201 1.114 1.296 2.629 2.109 3.278 
  60-64 1.237 1.162 1.317 2.466 2.062 2.951 
  65-69 1.286 1.216 1.358 2.412 2.084 2.792 
  70-74 1.342 1.274 1.413 2.315 2.064 2.596 
  75-79 1.398 1.327 1.475 2.118 1.942 2.311 
  80+ 1.438 1.355 1.526 1.878 1.750 2.016 
  
169 
(Table on previous page) Values are relative risk for fracture (RR) per each 0.1 unit 
of bone mineral density (BMD) decrease at femoral neck (FNBMD). Units of BMD 
are g/cm2. LCI: lower 95% confidence interval; HCI: high 95% confidence interval. 
Using original data from Johnell et al 2005 (Johnell, Kanis et al. 2005) through 
personal communication.  
 
3.5.2 Definition of the Theoretical Minimum Risk Exposure Distribution  
Defining the theoretical minimum risk exposure distribution (TMRED) for our PAFs 
estimations was one of the most difficult decisions taken in this project. We 
compared three possible scenarios: 
1) Initially, we adopted the young white female reference from NHANES III 
(Looker, Wahner et al. 1998) as the current recommended international 
reference standard for definition of osteoporosis using FNBMD measured by 
DXA (Kanis, McCloskey et al. 2008; The International Society for Clinical 
Densitometry. 2007). Controversies appeared in regards to this approach. 
The reason behind is that in the GBD framework, risk factor analysis focuses 
on modifiable risk factors. The TMRED should be theoretically possible at the 
population level and supported by convincing epidemiological evidence of a 
continuous risk reduction to that exposure distribution (Ezzati, Hoorn et al. 
2011). Hence, to support such approach, scientific evidence proving that 
women could exhibit similar FNBMD than men in the presence of an ideal 
health should have been obtained. This could have been relevant from an 
individual scope, but rather unrealistic at a population level, given than BMD 
in any age group, similarly to other biological parameters such as height or 
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body muscle mass, follows a normal distribution in both sexes, but exhibits, 
physiologically, higher values in men than in women.  Besides, females show 
faster rates of bone loss after menopause compared to males (Jones, Nguyen 
et al. 1994; Burger, de Laet et al. 1998; Yoshimura, Kinoshita et al. 2002). 
Furthermore, preliminary calculations of PAFs of BMD for fractures gave 
negative values in males from few world regions both for hip (Figure 3.3) and 
non-hip fractures (Figure 3.4). Such results were not plausible within the CRA 
analysis, as it would have meant that the risk factor exposure (i.e. low BMD) 
in this subgroup was protective against the analysed outcome (i.e. fractures).    
2) The next tested scenario was drawn from the TMRED set at the sex-specific 
young white reference from NHANES III (Looker, Wahner et al. 1998). This 
approach solved the issue of finding negative PAFs for males. However, it 
could still capture non-modifiable declines of FNBMD due to age.  
Independent literature review on this topic was carried out by the MPO, and 
reviewed by the CT and the ELG. Few longitudinal studies (Burger, de Laet et 
al. 1998; Cauley, Lui et al. 2009) were found demonstrating that a small 
percentage of elderly could maintain their bone mass over the time in the 
absence of risk factors for osteoporosis. However, the extents to which the 
differences in BMD observed by age were modifiable were not certain, and we 
didn’t find definitive evidence showing that individuals could maintain their 
young peak bone mass as they age. In contrast, longitudinal cohorts have 
shown a clear bone loss associated with ageing at a population level in 
different genders, ethnicities and world regions (Steiger, Cummings et al. 
1992; Jones, Nguyen et al. 1994; Burger, de Laet et al. 1998; Yoshimura, 
Kinoshita et al. 2002; Kaptoge, Reid et al. 2007).  
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3) Finally, we compared the two previous scenarios with a third approach using 
an age- and sex-specific TMRED from NHANES III (Looker, Wahner et al. 
1998) in order to remove the non-modifiable effect of age and sex from the 
theoretical achievable optimal level of BMD.  For the choice of the concrete 
percentile within each gender and age group (e.g. 75th percentile, 95th 
percentile, etc) the following considerations were made: First, there is an 
evidence of a continuous risk relationship between BMD and fracture risk up 
to very high levels (i.e. gradient of risk keeps decreasing up to Z scores as 
high as +4 in the MA used for our RR BMD-fractures) (Johnell, Kanis et al. 
2005), supporting the choice of a high sex- and age-specific percentile from 
NHANES III for the TMRED. Second, a significant correlation of BMD with 
genetic factors has been found in twin studies, which remains independent 
after adjusting for other biometric parameters and environmental factors, 
despite it tends to attenuate with age (Pocock, Eisman et al. 1987; Slemenda, 
Christian et al. 1991; Harris, Nguyen et al. 1998). Based in such 
consideration, a TMRED set at the 99th or 95th percentile could not be 
achievable for most of the population even in the absence of risk factors for 
low BMD. However, a feasible way to map such findings into the NHANES III 
BMD distribution in order to help with the percentile choice for the TMRED 
was not found. Several group discussions were held with public health experts 
from the ELG and epidemiology and statistics experts from the CT to solve 
this issue. The final decision was to take the 90th percentile as the threshold 
for an achievable optimal level of BMD. Albeit arbitrary, this threshold seemed 
realistic without being too conservative. 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To assist with the choice of the TMRED among the three possible approaches, 
comparative exercises were performed by public health experts from the 
University of Queensland, shown in Figure 3.3 and Figure 3.4. Finally, the sex 
and age-specific 90th percentile of FNBMD (after standardization) (Lu, Fuerst et 
al. 2001) from whites in NHANES III (Looker, Wahner et al. 1998) was used as 
the TMRED (Table 3.4) for PAFs calculations. The SD of the TMRED was 
estimated based on the relationship between means and SDs from a regression 
of all studies in the final dataset that measured means and SDs of FNBMD.  
 
Table 3.4 Theoretical-minimum-risk exposure distribution 
 (TMRED) for males and females 50 years and over. 
  Age Mean sBMD SD 
Females 50-59 1.00 0.14 
  60-69 0.92 0.14 
  70-79 0.84 0.13 
  80+ 0.78 0.13 
Males 50-59 1.09 0.16 
  60-69 1.06 0.16 
  70-79 1.02 0.16 
  80+ 0.98 0.16 
Values are expressed in g/cm2 and correspond to the age- and sex-specific 90th 
percentile of the mean FNBMD from whites in NHANES III (Looker, Wahner et al. 
1998) after internationally recognized standardization (Lu, Fuerst et al. 2001). sBMD: 
standardized bone mineral density; SD: standard deviation 
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3.6 Health Burden of Falls Attributable To Low Bone Mineral 
Density 
3.6.1 Mortality related to low bone mineral density 
Mortality associated with low BMD was estimated through the calculation of deaths 
due to osteoporotic fractures in population 50 years old and over. As explained 
previously, mortality data in the GBD 2010 study was obtained from different 
sources; most importantly from  national vital registries and in-hospital data (Lozano, 
Naghavi et al. 2012) (refer to section 1.8: Context of the Thesis Project: The Global 
Burden of Diseases 2010 Study (The GBD 2010 study). For attributing deaths to low 
BMD the difficulty was that deaths were categorised according to cause of injury (i.e. 
falls), not nature of injury (i.e. fracture), and low BMD or osteoporosis was not 
generally coded as a cause. Fractures can be found as a consequence of many 
injuries such as road injury, assault or natural disasters. For the purposes of this 
analysis, estimates were restricted to fractures due to accidental falls, where we 
expected most osteoporotic fractures to be coded. We used official nationwide 
hospital data with double coding (i.e cause and nature of injury) from Brazil (Ministry 
of Health (Brazil). 2006-2009), Canada (Canadian Institute for Health 
Information.1994-2009), Mexico (Ministry of Health (Mexico). 2000-2009) and the 
United States (Healthcare Cost and Utilization Project. 2003-2008) to estimate the 
fraction of in-hospital deaths from falls that involved hip and vertebra fractures.  
 
Those with a mention of concurrent head or internal injury were excluded, as they 
would potentially interfere in the mortality outcome directly attributed to the fracture. 
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Other fracture types were excluded as these were considered less likely to lead to 
death, as supported by an analysis of the Australian mortality database 
(http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3303.0Main+Features12003?
OpenDocument). Among those inpatient deaths where the primary cause for 
admission was a fall, a large fraction, especially at older ages, had a hip fracture. 
Only a small proportion of deaths associated with vertebral fracture were not also 
associated with a hip fracture (non-hip vertebra fractures) (Table 3.5). As this was 
the only data source used to determine the fraction of deaths from falls due to hip 
fracture or vertebra fracture, it was necessary to apply these age and sex-specific 
proportions to falls to every country.  
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Table 3.5. Hip fractures and non-hip vertebra fractures as a fraction of 
all in-hospital deaths attributable to falls. 
Sex Age Hip Fracture (%) Non-hip Vertebra Fracture(%) 
Females 50-59 61.6 2.6 
 60-69 73.2 1 
 70-79 79.4 0.6 
 80+ 82.5 0.5 
Males 50-59 46 8 
 60-69 67.5 4.6 
 70-79 79.8 0.9 
  80+ 84.2 0.4 
Percentages express the fraction of in-hospital deaths from falls that involve hip 
fractures and non-hip vertebra fractures (deaths from vertebral fractures that occur 
without hip fracture). Calculated with in-patient hospital data from Brazil (Ministry of 
Health (Brazil). 2006-2009), Canada (Canadian Institute for Health Information. 
1994-2009), Mexico (Ministry of Health (Mexico). 2000-2009) and the United States 
(Healthcare Cost and Utilization Project. 2003-2008; National Center for Health 
Statistics, Centers for Disease Control and Prevention, US Census Bureau. 1979-
2009) 
 
The ICD-9 and ICD-10 codes used for falls were those coding for accidental or 
unintentional falls with some important exclusions such as road accidents and can 
be found in Appendix 3. Of relevance is the fact that some of the falls codes were 
likely to include both high energy and  low energy injuries (e.g. E884 Other fall from 
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one level to another), and therefore fractures due to some of those falls would have 
not been classified as fragility fractures or osteoporotic (i.e. fractures occurring due 
to falls from standing height). Nevertheless, the differentiation between high energy 
and low energy injuries in such cases was virtually not possible, and the inclusion of 
all falls types in Appendix 3 was considered necessary in order not to lose any 
potential burden due to low BMD. Application of the RRs from Table 3.3 (derived for 
osteoporotic fractures) were still considered to be acceptable for all falls codes for 
the following reasons: First and most important, the risk relationship between BMD 
and fractures for any fracture was only mildly different to that for osteoporotic 
fracture in the MA used to derive the RRs from Table 3.3. In particular, RR/SD in 
BMD decrease (FNBMD of young white females from NHANES III) for males and 
females combined was 1.46 (95% CI: 1.40-1.52) versus 1.56 (95% CI: 1.49-1.64) for 
any fracture and osteoporotic fracture, respectively. Second, creating a new subset 
of RR BMD-fractures for high energy falls would have been too tedious, due to the 
possible different weight of BMD in the fracture occurrence for each type of fall and 
the lack of enough high quality epidemiological data to run such analysis. And finally, 
the use of the RRs in Table 3.3 allowed to separate the estimations for hip and non-
hip fractures, which was considered relevant due to the major health burden due to 
hip fractures compared with other fracture types and the higher relative weight of low 
BMD in the fracture event in comparison to other locations.  
 
3.6.2 Disability related to low bone mineral density 
Disability from unintentional falls (Appendix 3) was estimated by the nature of 
associated injury and therefore the short and long-term disability was estimated for 
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fractures by site. Estimations of the disability related to falls were the responsibility of 
the IEG in the GBD 2010 study, and data was shared with the OPW and the CT in 
order to calculate the proportion of that disability attributable to low BMD. In brief, 
injury causes (including falls) in the GBD 2010 study were analysed using five steps 
(Vos, Flaxman et al. 2012). First, household surveys and hospital discharge data 
(hospital in-patient and emergency department data) were analysed using DisMod-
MR for each external cause to generate estimates of incidence by age, sex, country, 
and year. Second, hospital data from 28 countries that had dual coding of discharges 
by external cause and nature of injury was analysed. Third, for each nature of injury 
probability of individuals developing long-term functional impairment was estimated 
through follow-up data from selected studies. Fourth, DisMod-MR was used to 
estimate the prevalence of individuals in the population who were likely to have 
functional limitation because of a previous injury. And finally, fifth, YLDs due to 
prevalent cases of long-term injury were attributed back to external causes in 
proportion with the contributions of these causes (e.g. falls) to every type of injury 
(e.g. fractures). 
 
Table 3.6 shows final lay descriptions and disability weights (DWs) for each fracture 
type. Summary of the methods used to calculate DWs can be found in section 1.8 
Context of the Thesis Project: The Global Burden of Diseases 2010 Study (The GBD 
2010 study), and detailed methodology to generate DWs and lay descriptions have 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































To understand the relative weight of the fractures burden for the YLDs calculation, a 
comparison with other GBD causes (sequelae) is a helpful exercise (Appendix 4). 
The short-term DW resulting from hip fracture (i.e. 0.308) can be compared, for 
example, to the DWs from severe heart failure (0.186), short-term disability from 
severe traumatic brain injury (0.235), or a severe major depression episode (0.655). 
Similarly, the long-term disability resulting from hip fracture after treatment (0.072) 
can be weighed against those from amputation of one leg after treatment (0.021), 
severe Parkinson disease (0.549) or moderate dementia (0.346). In general, DWs 
associated to causes with currently no or little healing treatment (e.g. dementia, 
multiple sclerosis, Parkinson disease, etc) and mental and drug abuse disorders 
scored the highest in the DWs list. 
    
To calculate the YLDs due to low BMD, the RR of BMD for hip fracture (Table 3.1) 
was applied to the YLD estimates for fracture of hip due to falls sub-cause (Table 
3.6). The RR of low BMD for non-hip fracture (Table 3.1) was applied to YLD 
estimates for all other fracture sites (Table 3.6).  
 
3.6.3 Attributable Burden Estimation Method 
 
The attributable health burden due to low BMD was calculated by comparing the 
observed distribution of sFNBMD to the counterfactual distribution for each age, sex, 






where RR(x) is the relative risk at exposure level x, P(x) is the population distribution 
of exposure, P’(x) is the counterfactual distribution of exposure, and m the maximum 
exposure level.  
 
Resulting PAFs of BMD for fractures were, then, applied to the YLDs of fractures for 
falls.  For mortality estimations of the burden, PAF’s were applied to the fractions of 
falls-related deaths due to hip and non-hip vertebra fracture exposed in Table 3.5. 
 
3.7 Ethical Aspects 
 
Ethical requirements in the GBD 2010 study were under the scope of the core team 
(CT) from the University of Washington. 
 
As per the present work, details on the type of research were provided to the 
Northern Sydney Local Health District Human Research Ethics Committee, which 















4.1 Results from Systematic Review 
The flowchart for the systematic review is shown in Figure 4.1. There were 130 
eligible articles (Appendix 5), with a total of 860 data points from 49 countries and 17 
world regions (Figure 4.2). Number of data points was very diverse among world 
regions, with 4 out of the 21 world regions with no data at all. Data on population 
levels of BMD was presumably more robust for the 2010 time point, as number 
publications clearly increased with the years from 1990 to 2010 (Figure 4.3). 
 
The RoB did not prove predictive value for sFNBMD for the overall risk of bias at any 
age group in men or women (Table 4.1). Selection bias was clearly heterogeneous 
among studies, considered Low (34% of studies) when most recruited subjects were 
included, Moderate (38%) when those under diseases or therapies with potential 
effect on bone metabolism were excluded, and High (28%) when subjects with prior 
fractures were excluded. The distribution was not remarkably different when 
percentages were analysed by sex group (Figure 4.4). Subgroup analysis based on 
selection bias was undertaken under the hypothesis of being one of the key sources 
of potential bias. However, no significant differences in sFNBMD values were found 
between High risk of bias and Low risk of bias for both males and females; sFNBMD 
was significantly higher for Moderate risk when compared to Low risk, in males only 
(p=0.042) (Figure 4.5). At the view of these results, no differential weight was given 
to data depending on the RoB category, and all sFNBMD values were included in the 
final analysis with the same relative weight of 1.0 (that is, all studies were attributed 
the same importance based on the results of the RoB tool).  
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None of the covariates tested in DisMod-MR (income per capita, mean BMI, and 
availability of milk) demonstrated a significant improvement in the predictive ability of 
the model and were therefore not included. 
 
As per the results of the second search strategy (risk factor-disease relationship) 
(Figure 4.1), very few articles were found to have a potential impact on the RRs 
derived from the MA (Johnell, Kanis et al. 2005) used in the PAF calculations. After 
focusing in those ones published after such MA, taking out those from previous 
cohorts used in the latter, and selecting only longitudinal population-based studies, 
only a very short list of articles was considered (Table 4.2). The data was shared 
with the ELG, which in view of the relative small sample size of the studies all 
together and the comparable risk relationship BMD-fractures of the individual studies 
to those ones observed previously, recommended no further updates of the RRs 






5800 eligible titles 
1801 eligible abstracts
 
324   abstracts – exclusion A  
680   abstracts–  exclusion B 
2859 abstracts – exclusion C 
825   abstracts – exclusion D 
225   abstracts – exclusion E 





18161 non-duplicated articles from 
MEDLINE, EMBASE, CINAHL, CAB, 
WHOLIS, SIGLE, reference lists 
606 papers with BMD prevalence data, 











Search strategy for “Risk factor-
disease relationship”
2
 11524 results 
 
 
40 papers from 
References check 
and updates 
 202 included for BMD prevalence data and 
fracture risk data 
 
Elimination of 
duplicated data from 
different papers 
 175 papers subjected to Risk of Bias Tool and 
data extraction
 
153 papers with useful data extracted 
(130 papers for “risk factor levels of exposure”) 
 22 papers with no useful data 
format and not able to retrieve 
from authors (authors only 
contacted for GBD regions with 
little or no data) 
 
1. Search strategy for “Risk 
factor levels of exposure” 
(osteoporosis OR osteopenia OR 
osteopaenia OR bone mineral 
density OR radiolucency) 
AND 
(prevalen* OR inciden* OR cross-
sectional OR cross sectional OR 
epidemiol* OR survey OR 
population-based OR population 
based OR population study OR 
population sample OR cohort OR 
follow-up OR follow up OR 




(GBD Countries SH)* 
 
2. Search strategy for “Risk 
factor-disease relationship” 
(osteoporosis OR osteopenia OR 
osteopaenia OR bone mineral 
density OR radiolucency) 
AND 
(fracture* OR risk) 
AND 
 
(GBD Countries SH)* 
 
Figure 4.1. Flowchart for the Systematic Review Process  
 
LEFT: Flowchart for the systematic review process. RoB: Risk of Bias. RIGHT: Search strategies for BMD as 
the exposure variable and BMD as a risk factor for fractures.Review process included all published studies 
until February 2008 with updates up to August 2010* The whole list of the world countries (Appendix 1) was 
used as Subject Headings in Medline, Embase, Cinhal, and CAB abstracts. Exclusion criteria: A: Subsample 
not representative of the population (i.e: athletes); B: Non- population based studies (i.e: clinical based); C: 
No prevalence/incidence data; D: Only subtypes of osteoporosis assessed (i.e. steroid-induced OP); E: 

































































































































































































































































































Table 4.1. Statistical differences between overall risk of bias groups. 
 
Risk of Bias P  95% Confidence Interval 
For males and females (adjusted for 124 clusters) 
 
Moderate 0.237 -.006 - 0.022 
 
High 0.360 -.035 - 0.013 
For males (adjusted for 48 clusters) 
 
 
Moderate 0.827 -0.028 - 0.035 
 
High 0.124 -0.053 - 0.006 
For females (adjusted for 106 clusters) 
 
 
Moderate    0.532 -0.011 - 0.021 
 
High 0.477 -0.037 - 0.017 
P values are for comparing to studies with low risk of bias after adjustment by age. No 
significant difference was found for low risk of bias compared to moderate or high risk of bias 
























































Figure 4.5. Selection bias-group distribution in females (upper) and males 
(lower)
High vs Low: p value=0.160 
Moderate vs Low: p value=0.948 
High vs Low: p value 0.575 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2 Results for Risk Factor Levels of Exposure: Worldwide 
Distribution of Bone Mineral Density 
Worldwide distributions of mean BMD for people aged 50 years and over for 1990 
and 2010 are shown in Figure 4.6. Asia and Africa were the world regions with the 
lowest values of FNBMD, while High-Income North America, Caribbean and Eastern 
Europe showed the highest FNBMD values both for men and women. Although age-
adjusted data showed an improving trend of the FNBMD values over time in 
preliminary analysis (Sanchez-Riera, Wilson et al. 2010), especially in Asia and 
Western Europe, FNBMD at a population level decreased in some regions due to the 
ageing of the population. 
 
4.3 Low Bone Mineral Density Burden as a Fraction of Falls Burden 
Population attributable fractions (PAFs) of FNBMD for falls were generally higher for 
females compared to males both for 1990 and 2010. In general, world regions with low 
GDP showed the highest PAFs (Asia East and South-East, Sub-Saharan Africa East 
and West), with the exception of Eastern Europe. However, big disparities in PAFs 
were observed among high income countries, even within the same world region; e.g., 
Scandinavian countries compared to UK (Figure 4.7).  
 
In 1990 global DALYs and deaths attributable to low BMD constituted 12.1% and 
29.6% of all falls-related DALYs and deaths, respectively. These percentages 
increased slightly to 14.8% and 34.7% for 2010 estimates (Table 4.3). 
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4.4 Health Burden due to Low Bone Mineral Density: DALYs, YLDs, 
YLLs and Deaths 
Global deaths and DALYs attributable to low BMD increased from 103,000 and 
3,125,000 in 1990 to 188,000 and 5,216,000 in 2010 respectively (Table 4.4). The 
percentage of low BMD in the total global burden almost doubled from 1990 (0.12%) to 
2010 (0.21%), with both YLLs and YLDs increasing significantly in both sexes (Table 
4.4). In population aged 50-69 years, such percentages increased to 0.41% for 1990 
and 0.5% for 2010, and were even higher in population aged 70 years and above 
(0.64% and 0.79%, respectively) (http://www.healthdata.org/gbd). The fraction of the 
total regional burden increased in all regions except the Caribbean and Oceania. Asia 
East and South were the major contributing regions to the increase of the global 
burden of low BMD. Rates of global DALYs per 100,000 population increased 
remarkably from 1990 to 2010, but the increase was modest with age-standardization 
(Table 4.5), which reflects population growth and ageing. Rates were higher in 
Western Europe, Central Europe and High-Income Asia Pacific, while the highest age-
standardized rates were more frequently found in developing regions like Sub-Saharan 
Africa East and West, Oceania, Asia East and South (Table 4.5 and Figure 4.8). For 
all time periods, YLLs contributed to the global burden of low BMD slightly more than 
YLDs, representing 51%, 54% and 53% of all DALYs for 1990, 2005 and 2010, 
respectively (Table 4.4).  
 
When looking at sex groups, males obtained more DALYs than females for all 
analysed time periods, with a gap between both sexes that tended to progressively 
increase from 1990 to 2010, with 56%, 59% and 60% of all DALYs corresponding to 
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males for 1990, 2005 and 2010, respectively (Table 4.4). Differences between sexes 
were more remarkable for YLLs than for YLDs for all years. Rates of DALYs per 
100,000 population for all ages increased from 1990 to 2010 in both sexes separately 
(66.06 vs 89.37 in males and 51.73 vs 61.82 in females). Rates increased dramatically 
within the age group 50-69 years compared with all ages estimates, again more 
remarkably in men (315.85 and 329.78 for 1990 and 2010 respectively) than in women 
(192.34 and 177.84 for 1990 and 2010 respectively). Rates of DALYs became around 
three-fold in ages from 70 years onwards from those in the 50-69 age group, also 
showing considerably greater values in males than females for both 1990 (861.81 vs 
568.97) and 2010 (924.21 vs 569.43). Deaths (mean followed by uncertainty interval 
95%) attributable to low BMD almost doubled in males from 1990 to 2010, from 52,816 
(43,882-69,605) to 103,440 (67,743-124,596), while in females they increased around 
60% between both time periods, with 50,455 (40,408-62,110) and 84,146 (57,863-
102,441) deaths in 1990 and 2010, respectively (http://www.healthdata.org/gbd).  
 
For all diseases, injuries and risk factors, data on DALYs, YLDs, YLLs and deaths can 








4.5 Health Burden due to Low Bone Mineral Density Compared to 
Other Risk Factors in the GBD 2010 study 
Low BMD ranked low in terms of attributable DALYs compared to most risk factors, 
such as dietary factors, high blood pressure, smoking, alcohol use, high fasting 
plasma glucose, high body mass index, high cholesterol and low physical activity 
(Figure 4.9) (Lim, Vos et al. 2012).  
 
When dietary risk factors and occupational risk factors were clustered into one 
category each, low BMD ranked 23rd among 25 risk factor categories globally for 2010 
for all ages together (20th among 21 clusters for 1990) (Figure 4.9). By region, the 
highest ranks for low BMD were observed in Western Europe and High Income Asia 
Pacific, ranked 12th and 13th respectively, followed by Central Europe, Australasia, and 
High Income North America at 15th, and Asia East at 16th (Figure 4.9). Improvement of 
the ranking for all regions and both sexes was observed in older ages in comparison to 
the general population (Figure 4.10 and Figure 4.11) When ranking was looked for 
population 70 years and over only, low BMD moved to 13th position globally over 21 
clusters of risk factors for the same time period.  (11th out of 17 clusters for 1990) 
(Figure 4.11). Great shifts in the rankings of YLDs and YLLs separately were similarly 
observed with the selection of elderly population, as shown in Figure 4.12 to Figure 
4.17, with low BMD becoming part of the 10 top risk factors for YLDs in the age group 
≥ 70 years (Figure 4.14). Results were similar for females and males, with changes of 
one position maximum in the rank within the sex group 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Osteoporosis is a systemic skeletal disease in which bone strength is deteriorated 
with a subsequent increased risk of fracture. The consequences of osteoporotic 
fractures range from pain and disability to chronic institutionalization and death, with 
tremendous social and economic costs, which often exceed those resulting from 
other common conditions. The improvements in life expectancy and the massive 
growth of the ageing population in the world have predicted an enormous rise in the 
number of fractures worldwide, becoming one of the major epidemics in the following 
decades. Health initiatives are urgently required in order to promote early diagnosis 
and treatment, which has proven to be cost-effective. However, awareness of the 
disease is still very insufficient among individuals, health professionals and scientific 
institutions.  
 
In the scope of the GBD 2010 study, low BMD was taken into account, for the first 
time, in the global health burden estimates. Given the complexity of measuring 
osteoporosis per se, low BMD was selected as a risk factor given its well established 
relationship with osteoporotic fractures and its relatively ease of measurement with 
standard techniques. Simultaneously, bone fractures were not analysed as a disease 
or condition and instead, included in the burden of falls within the injury group 
estimates. Hence, comparative risk assessment (CRA) methodology was used to 
estimate the population attributable fraction of falls burden due to low levels of BMD. 
Bone mineral density measured at FN by DXA was chosen as the exposure variable 
for the risk assessment with fractures because of data reliability and availability of 
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epidemiological data. Finally, systematic review, survey-derived DWs and hospital 
data were used to define relationship between falls and fracture-related morbidity 
and mortality. 
 
Our results showed that, although age-adjusted data demonstrated an improving 
trend of the global BMD values over time, the absolute burden of low BMD increased 
from 1990 to 2010, probably related to the global growth of the aged population. 
Higher age-standardized rates of DALYs and PAFs in developing regions probably 
reflected the importance of the potentially modifiable determinants of low BMD (such 
as nutritional factors and access to health care). Premature mortality (YLLs) had 
slightly more contribution in the global DALYs than YLDs. This finding is partially 
explained by the major contribution of deaths in the overall burden, given that low 
BMD was responsible for at least one-third of all the deaths attributable to falls, 
which were the second (following road injuries) and the first cause in the list of 
injuries with the major global health burden in population 50-69 years and 70 years 
and above, respectively (http://www.healthdata.org/gbd) (Murray, Vos et al. 2012).  
 
For all burden estimates, males showed higher values than females despite of the 
finding of higher PAFs of low BMD for falls for females than for males. One of the 
reasons for this was the higher fracture incidence in males than in females. Another 
reason was the higher mortality following a fracture in males compared to females, 
particularly at younger age groups, which is compatible with previous observations in 
longitudinal studies (Center, Nguyen et al. 1999; Kannegaard, van der Mark et al. 
2010; Melton, Achenbach et al. 2013). The higher PAFs for falls in females 
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compared to males might have seem contradictory at the view of preliminary 
analysis of PAFs of low BMD for fractures (higher in males) (Figure 3.3 and Figure 
3.4). However, falls burden represented a greater percentage of the overall health 
burden in females compared to that in males for both 1990 (13.93% vs 11.19%) and 
for 2010 (16.71% vs 13.51%), and therefore PAFs for falls (in contrast to PAFs for 
fractures) were higher in females that in males when sexes were analysed 
separately. The selection of all sites of fractures, including those not clearly related 
to osteoporosis (e.g. face, skull and finger), and the broad spectrum of the falls sub-
causes for our estimations (including high energy injuries) is the most likely 
explanation behind the higher health burden of low BMD in males compared to 
females, together with the relatively high impact of low BMD in males compared to 
females using the age- and sex-specific TMRED for the CRA analysis.  
 
Low BMD ranked relatively low compared with other risk factors in the GBD 2010 
study, albeit the ranking improved for estimates focused in population 50 years and 
over. However, the contribution of low BMD to the global health burden compared 
with other risk factors was little, and it is likely that the burden of osteoporosis was 
underestimated for several reasons.   
 
First, the choice of an age and sex-specific TMRED masked the important role of 
age and sex in the fracture risk (Kanis, Johnell et al. 2001), and it may explain in part 
the relatively lower health burden of BMD compared with other risk factors. Given 
that the gradient of risk of fracture for each unit of BMD decrease is the same in both 
men and women (Johnell, Kanis et al. 2005), the use of the young female reference 
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seems reasonable in clinical settings to decide whether intervention is recommended 
in individual subjects. Yet, the GBD study has the ultimate goal of providing useful 
information to establish health priorities; public health preventive campaigns are 
suitable for modifiable, in contrast to non-modifiable, risk factors. In consequence, 
sex and age should be taken out of the analysis if they are found to be independently 
related to the risk factor, and such is the case for low BMD. Moreover, in the CRA 
methodology, the TMRED should be theoretically possible at the population level by 
clear epidemiological evidence (Ezzati, Hoorn et al. 2011). Longitudinal studies 
(Burger, de Laet et al. 1998; Cauley, Lui et al. 2009) have demonstrated that a small 
percentage of older people can maintain their bone mass over the time in the 
absence of risk factors for osteoporosis. Cauley et al studied a cohort of 8224 
women 65 years of age and older recruited at four clinical centres in the U.S. 
followed for 15 years (Cauley, Lui et al. 2009); a small percentage (9%) of the 
women maintained their BMD at the hip during the follow up period. Authors found 
that factors known to influence BMD, such as smoking, weight loss, physical activity 
and calcium intake, were more favourable in the maintainers group than in those 
women who experienced expected or accelerated bone loss. However, the extent to 
which the differences in BMD observed by age are modifiable at a population level is 
not certain. Furthermore, population-based studies in different parts of the world 
have demonstrated the opposite, showing different degrees of bone loss in older 
adults for all age groups, and faster rates of bone loss after menopause in females 
compared to age-matched males (Jones, Nguyen et al. 1994; Burger, de Laet et al. 
1998; Yoshimura, Kinoshita et al. 2002). The finding of a BMD-maintainer group by 
Cauley et al supported our approach to use the sex- and age-specific 90th percentile 
  
224 
from the reference population (whites from NHANESIII) (Looker, Wahner et al. 
1998), but extending the maintenance rule from the young reference was not 
supported by any valid scientific evidence, and seemed rather unrealistic. In spite of 
all these observations, we tested a PAFs model using young female reference for 
few regions with numerous data points (Western Europe, North America and Asia 
East). This approach led to negative PAFs for men up to the seventh decade, which 
is essentially contradictory in the CRA analysis; that is a risk factor cannot be 
protective even at the lowest population exposure possible and therefore, values are 
not meant to be below zero. Given the observation that a significant genetic 
component is as well related to the ability to retain bone mass (Arden and Spector 
1997; Harris, Nguyen et al. 1998), the 90th percentile (instead of 95th or 99th 
percentiles) was considered, albeit arbitrary, feasible.   
 
The use of regional versions for the TMRED were considered, however an 
international reference was chosen in order to enable worldwide comparisons, and to 
follow the current recommendation for T scores calculations by the International 
Osteoporosis Foundation, the World Health Organization and the International 
Society for Clinical Densitometry (Kanis 2008; Kanis, McCloskey et al. 2008; 
Internaional Society of Clinical Densitometry 2013). The choice of a white American 
reference (Looker, Wahner et al. 1998) could lead to the assumption that the burden 
of low BMD might have been overestimated or underestimated depending on the 
world region. In reality, in NHANES, different cohorts have shown significant 
variations in their age-and sex-adjusted levels of BMD depending on their ethnicity 
(Looker, Wahner et al. 1998; Looker, Melton et al. 2009). Nonetheless, in the Study 
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of Women's Health Across the Nation (SWAN study), a multi-centre multi-ethnic 
longitudinal study in the U.S., has recently shown how little ethnicity differences in 
BMD explain the variations in fracture risk across African–American, Caucasian, 
Chinese, and Japanese (Ishii, Cauley et al. 2012). Instead, these authors found that 
composite indices measuring hip geometry and other parameters rather than low 
BMD alone, were responsible for a large inter-ethnicity variation in the fracture risks, 
which were consistent with those reported previously in a large cohort of almost 
200,000 American women from 5 different ethnic groups (Barrett-Connor, Siris et al. 
2005). On the other hand, the SWAN study had previously pointed out the role of 
anthropometric and lifestyle factors (Finkelstein, Lee et al. 2002) in the observed 
BMD racial differences, and so have other large studies (Barrett-Connor, Siris et al. 
2005; Looker, Melton et al. 2009; Nam, Kweon et al. 2013; Araujo, Yang et al. 2014), 
including socio-economic status(Araujo, Yang et al. 2014). Interestingly, despite the 
existence of data supporting the role of poverty levels on BMD in different world 
regions (Shatrugna, Kulkarni et al. 2005; Amiri, Nabipour et al. 2008; Brennan, Henry 
et al. 2009; Brennan, Henry et al. 2010; Araujo, Yang et al. 2014), our study did not 
find any value of the lag-distributed income per capita to predict BMD, likewise for 
mean BMI and availability of milk.  This probably indicates the complex multi-factorial 
nature of variables affecting BMD in different world regions. In the present study, for 
example, estimates on the population levels of BMD in Caribbean region, despite 
being a low income region, were higher both in men and women compared with most 




The potential impact of the global improvement of nutritional status and body size 
over the last 20 years was not reflected by selecting two different TMRED, one for 
1990 and another one for 2010. Personal communication was established with the 
main bone investigator in NHANES initiative (Looker, AC) to obtain data from 
NHANES 2005-2008, as preliminary publications from such study had shown a 
general improvement in the population levels of BMD (Looker, Melton et al. 2012), 
thought to be at least partly related to factors such as body size, calcium intake and 
non-smoking. Unfortunately, at the time of this present study, age- and sex-specific 
90th percentiles of FNBMD from this most recent cohort were still not ready. 
Additionally, differences in FNBMD from the 1988-1994 survey (NHANES III) were 
less than 3% and thus, not appearing as crucial factor to take into account in our 
estimates. What is more, NHANES III is the reference used in the meta-analysis 
from which we derived the risk relationship between BMD and fractures (Johnell, 
Kanis et al. 2005), and therefore, it was reasonable to use the same cohort for the 
TMRED. Posterior studies after such MA published in 2005 have found comparable 
values on the relationship BMD-fractures and the RR values have not been updated 
yet in the FRAX® tool.    
 
Beside all these considerations in regards to the choice of TMRED for our CRA 
analysis, what is important to highlight is that the risk relationship between BMD 
alone and fracture risk is comparable among ethnicities. In a very eloquent exercise, 
Leslie showed how using FNBMD that was average for ethnicity or average for white 
females minimally altered the FRAX® output in any ethnicity (Leslie 2012). The 
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same BMD-fracture homogeneity across ethnic group has recently been shown in 
older men (Shin, Zmuda et al. 2014). 
 
Separating deaths due to specific fractures from the overall deaths due to falls was 
not straightforward. In the GBD 2010 study, injuries were classified in the cause list 
according to the external cause such as a road injury or self-harm, whereas the 
outcomes after the injury were determined by the nature of injury such as brain 
trauma or spinal cord transection (Vos, Flaxman et al. 2012). Hence, burden due to 
fractures was part of the total health burden due to falls. Hospital data with dual 
coding of discharges by external cause and nature of injury was the only available 
quality data to elucidate how many fracture-related deaths and disability were 
attributable to falls. Selecting population 50 years and over with hip and non-hip 
vertebra fractures non-including head or internal injuries served a double purpose. 
On one hand, acted as a proxy for osteoporotic or fragility fracture (particularly the 
exclusion of internal injury); on the other hand, facilitated the mortality analysis due 
to the fracture event itself (head injuries can easily lead to dramatic consequences 
without the event of a skull fracture, such as an intracranial cerebral haemorrhage). 
Our review did not find solid data on mortality due to falls-related fractures covering 
both sexes and all ages over 50 years old. Most of the studies reporting deaths from 
falls-related fractures had been done retrospectively from medical charts and death 
certificates, or they were restricted to old frail populations. The European 
Prospective Osteoporosis Study (EPOS) had reported incidence of falls and 
incidence of fracture-free falls for a large cohort of almost 15,000 men and women 
aged 50–79 years recruited from population-based registers in 30 European centres 
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and followed-up for a mean of 3 years (Roy, Pye et al. 2002). This study could have 
helped, albeit with some limitations such as the recall bias (i.e. fracture-free 
individuals are less likely to report a fall event), to elucidate what percentage of all 
falls in a population led to a fracture-related death. However, no mortality data on 
falls-related deaths had been published from EPOS cohort at the moment of our 
mortality estimations. A very recent extensive report from the IOF on osteoporosis in 
the European Union has published statistics on fracture-incidence and fracture-
related deaths for most of the countries in the EU (Strom, Borgstrom et al. 2013; 
Svedbom, Hernlund et al. 2013). Number of deaths within the first year after the 
fracture have been collected over the last years by the IOF European Review Group 
through literature review, official statistical bureaus and personal communications. 
While this represents a very valuable effort to summarize the health and economic 
burden of osteoporotic fractures in Europe, it still leaves the issue of identifying the 
fall-related fracture death unresolved. Continuous communication was established 
with the leaders of the IOF, including personal meetings with its president John A 
Kanis, although no final consensus was reached in regards to this point. In 
conclusion, identifying falls-related deaths attributable to fragility fractures was very 
tedious with the current available data, and we accept that this is one of the potential 
sources of burden underestimation due to low BMD.  
 
Contrary to the notion that most of the fracture burden is related to disability levels 
(most of subjects don’t die after suffering a fracture), YLLs contributed in higher 
proportion to the global DALYs attributable to low BMD than YLDs. A plausible 
explanation for this is the very low DW assigned for long-term treated hip fracture 
  
229 
(Table 3.6). It is possible that the wording of the lay description (which included the 
term “fixed”) had induced a falsely optimistic result from the population surveys from 
which DWs were derived. Another possible source of missing data for YLDs is the 
predominant use of hospital data for falls-related fracture incidence, given the 
likelihood of non hospital consultation in case of minor fractures, particularly in non-
developed regions.   
 
Assuming that only accidental falls-related fractures were associated with low BMD 
has missed part of the potential health burden attributable to this risk factor. In the 
GBD 2010 study, risk factors such as high blood pressure and smoking were 
analysed assessing their impact on different outcomes: among others, ischaemic 
heart disease, ischemic and haemorrhagic stroke, chronic kidney disease, and atrial 
fibrillation for high blood pressure, and chronic respiratory diseases, ischaemic heart 
disease, and several cancer types for smoking (Lim, Vos et al. 2012). In contrast, 
only falls-related fractures in population 50 years and over (where we thought we 
would find most of osteoporotic fractures) were taken into account for the low BMD 
analysis, which went against previous studies showing the important role of BMD in 
both low-energy and high-energy trauma (Karlsson, Hasserius et al. 1993; Sanders, 
Pasco et al. 1998; Mackey, Lui et al. 2007), even in young population. One 
prospective study in subjects 65 years and older, with 8022 women from the Study of 
Osteoporotic Fractures and 5995 men from the Osteoporotic Fractures in Men Study 
(Mackey, Lui et al. 2007) showed that total hip BMD was associated with an 
increased risk of high-trauma fracture that was comparable to the risk of low trauma 
both in men and women (around 50% higher risk both for low- and high-energy 
  
230 
traumas for each 1 SD decrease in total hip BMD). Then, if we consider, for 
example, all fractures involved in road injuries and self-harm (first and second cause 
of injuries-related health burden globally, respectively), the potential percentage of 
low BMD burden that we may have left out is immense. Not to mention that road 
injuries were in the top ten rank of global health burden for 2010 among 291 
conditions analysed in the GBD 2010 study and it showed an increasing trend from 
1990.  
 
On the other hand, only clinical fractures (those resulting from falls) accounted for 
fracture estimates for the GBD 2010 study, while it is well known that symptomatic 
vertebral fractures only represent about one third of all radiographically diagnosed 
spine fractures (Ross 1997). Vertebral compression fractures, even if occurring 
without acute symptoms, frequently involve long-term consequences such as chronic 
back pain, kyphosis and restrictive respiratory disease (Silverman 1992; Ross 1997). 
We expected the health burden of such radiographic spine fractures to be included in 
the low back pain estimates, admitting their exclusion from the falls burden, and 
therefore, decreasing the population attributable fraction of low BMD for fractures 
and consequently for falls. 
 
The exclusion of all fractures locations other than hip and vertebra from fracture-
related deaths analysis would also have contributed to the underestimation of the 
mortality burden attributable to low BMD. Hip fractures and clinical vertebral fractures 
have been shown to be the first and second most important sites for osteoporotic 
fractures-related deaths, respectively (Browner, Pressman et al. 1996; Bliuc, Nguyen 
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et al. 2009; Ioannidis, Papaioannou et al. 2009). For our mortality analysis, we used 
in-hospital data, and other fracture types were excluded as these were less likely to 
be the underlying cause of death, as shown in the Australian mortality database. 
(http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3303.0Main+Features 
12003?OpenDocument). This finding was observed as well in the Canadian 
Multicentre Osteoporosis Study (CAMOS), a population-based study with 2187 men 
and 5566 women aged 50 years and older (the same age scope of this present 
analysis), where 5-year mortality risk was only increased after hip and vertebral 
fractures (Ioannidis, Papaioannou et al. 2009). The Study of Osteoporosis Fractures 
in U.S. had found similar results 10 years earlier (Cauley, Thompson et al. 2000) 
during a 3.8-year follow-up. However, other authors have observed that other 
osteoporotic fracture sites are related to a higher risk of long-term mortality 
compared with age and gender-matched peers (Bliuc, Nguyen et al. 2009; Morin, Lix 
et al. 2011; Melton, Achenbach et al. 2013). A prospective population-based study 
conducted over a 18-year period in Australia, the Dubbo Osteoporosis Epidemiology 
Study (DOES), showed that the fall-fracture event was likely to be missed out as an 
underlying cause for some deaths that occurred long time after the fall, particularly in 
non-hip and non-vertebral fractures (Bliuc, Nguyen et al. 2009). The study shows 
that non-hip non-vertebral fractures are responsible for one fourth of all fracture-
related excess mortality for the first 5 years post-fracture (Bliuc, Nguyen et al. 2009; 
Bliuc, Nguyen et al. 2014). Mortality is higher in individuals over 75 years old 
compared to the 60-74 year group, and in major osteporotic fractures (pelvis, distal 
femur, proximal tibia, 3 or more simultaneous ribs, and proximal humerus). But half 
of the excess mortality is attributable to the risk of subsequent fractures with high 
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burden such as hip fracture. And in actual fact, long-term mortality following fractures 
is tedious to interpret within the GBD study scope, particularly when the risk of death 
is very intrinsically associated with the risk of future fractures. Moreover, previous 
studies have demonstrated that mortality is highly related to baseline frailty 
(Cawthon, Marshall et al. 2007; Ensrud, Ewing et al. 2007; Tosteson, Gottlieb et al. 
2007; Patel, Brennan et al. 2014), and it is hard to estimate which percentage of the 
long-term excess mortality is really due to the fracture event. 
 
As the exposure variable measurement, DXA is considerably more expensive and 
technically more complicated than measurement systems for other risk factors such 
as high blood pressure or body mass index. Consequently, the availability for DXA 
scans is limited (International Osteoporosis Foundation 2008), leading to a selection 
bias towards countries with better access to DXA scanning systems. Furthermore, 
the application of standardization equations among different DXA manufacturers (Lu, 
Fuerst et al. 2001) is unlikely to have removed all differences, especially between 
models in the same manufacturer (Barthe, Braillon et al. 1997; Henzell, Dhaliwal et 
al. 2003). 
 
Selecting the FN as the only location for the exposure variable measurement might 
have further underestimated the prevalence of low BMD, given the observation that 
T scores at lumbar spine tend to be lower than in FN when patients are screened for 
osteoporosis, sometimes leading to different WHO classification categories (the so-
called diagnostic discordance) (Woodson 2000; O'Gradaigh, Debiram et al. 2003; 
Looker, Melton et al. 2012). In addition, despite BMD at femoral neck being a good 
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predictor of fracture risk for both hip and non-hip fractures, the best predictive value 
for vertebral fracture is found when BMD is measured at lumbar spine and not at the 
hip (Marshall, Johnell et al. 1996). Discordance, although to a much lesser extent, 
has also been found between hips in the same individual. The reasons behind the 
differences in hip and spine BMD are thought to be diverse, some of them due to 
known physiological mechanisms. Trabecular bone, found in more proportion in the 
lumbar spine, is known to lose mineral content more rapidly in comparison with 
cortical bone, which is found in higher proportion in the neck of the femur (Watts 
2004). The density of the bone also changes depending on the site, with the spine 
reaching peak at least 5 years before the hip (Blank, Malone et al. 2006). Many 
secondary osteoporosis, such as glucocorticoid-induced, tend to affect trabecular 
bone first, leading to higher prevalence of lumbar osteoporosis (Cooper, Syddall et 
al. 2005). However, osteoarthritic changes, vascular calcifications and old vertebral 
fractures can falsely increase BMD in the spine, and need to be interpreted with 
caution in clinical settings. In contrast, the measurement of BMD at FN is rarely 
affected by these artefacts, and therefore, constitutes a more objective measurement 
of bone mass (Paggiosi, Glueer et al. 2011). Furthermore, until now, the most robust 
epidemiological data in the risk relationship between BMD and fracture uses FNBMD 
as the exposure variable (Johnell, Kanis et al. 2005).  
 
This study is focused in the potential health burden of low BMD, which despite being 
well correlated with fracture risk and being one of the strongest predictors of 
osteoporotic fracture, has low sensitivity by itself in identifying absolute fracture risk 
(Siris, Chen et al. 2004). Measuring BMD alone provides with a quantitative value 
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not accounting for other anatomical and mechanical properties of the bone known to 
influence bone strength, and consequently, leading to an underestimation of the 
burden associated with osteoporosis. It is possible that future research may include 
composite measures of bone strength that include not only BMD, but also hip 
geometry parameters, thickness of cortical and trabecular bone, etc. For now, this is 
not applicable at a population level for a global analysis. Still, for health burden 
estimates, we defend assessing BMD as a continuous variable rather than 
osteoporosis as per WHO categorical definition (which is based on BMD only), as it’s 
been done in another recent work (Oden, McCloskey et al. 2013).  
 
As per the quality of the studies finally included from the SR, selection bias in some 
of the selected studies was a potential source of bias. Most of the studies excluded 
subjects with prior history of fracture, with bone metabolism diseases, or those 
receiving treatments that might affect bone metabolism. We expected to find 
discrepancies in the BMD values among different study groups depending on the 
exclusion or inclusion of such subjects, but linear regression models failed to prove 
such assumption. Reasons for this are not fully apparent, but it might be related to 
the heterogeneity among studies and the relatively low number of studies for each 
bias group. These authors recommend including individuals with previous fractures 
or diagnosed bone disease in similar future studies. This is particularly important in 
elderly populations, as the percentage of individuals with a history of previous 
fragility fractures is high, and excluding such subjects makes the sample not truly 




Finally, it is important to remember that the GBD initiative does not take into account 
the social loss and the economic burden due to the different health causes. As 
shown in section 1.4 Economic Cost of Osteoporotic Fractures, osteoporotic 
fractures involve an enormous economic cost for most of the word regions, and it’s 
predicted to keep growing in the following decades due to the ageing of the global 
population. Screening of osteoporosis and pharmacological treatment to increase 
BMD and reduce fracture risk is relatively cheap and clearly cost-effective (refer to 
section 1.6.3 Major pharmacological interventions). Moreover, the cost-effectivity is 
well supported in advanced ages, which is not always the case for other risk factors 
such as hypertension or hypercholesterolemia, which seem to reach a plateau with 
the age (Zethraeus, Strom et al. 2008). Therefore, all these important factors should 
be considered by public health authorities when deciding on health priorities and 
allocating resources, and not simply the top rank of conditions causing the major 















This study is the first of its kind in measuring the health burden attributable to low 
BMD as a continuous variable from a global perspective, enabling estimates 
comparisons among different world regions, countries, age groups, sexes, and time 
periods. The main conclusions of the study are as follow:  
 
1.  Asia and Africa were the world regions with the lowest values of FNBMD among 
population 50 years and over, while High-Income North America, Caribbean and 
Eastern Europe showed the highest FNBMD values both for men and women. 
Although age-adjusted data showed an improving trend of the global FNBMD 
values between 1990 and 2010, especially in Asia and Western Europe, FNBMD 
at a population level decreased in some regions due to the ageing of the 
population. As expected, population levels of FNBMD were lower in females than 
in males for both time periods. 
2.  Population attributable fractions (PAFs) of low BMD for falls were generally 
higher for females compared to males both for 1990 and 2010. In general, 
world regions with low GDP showed the highest PAFs (Asia East and South-
East, Sub-Saharan Africa East and West), with the exception of Eastern 
Europe. However, big disparities in PAFs were observed among high income 
countries, even within the same world region. Global PAFs of low BMD for 
falls increased from 1990 to 2010 both for males and females. In 1990 global 
DALYs and deaths attributable to low BMD constituted 12.1% and 29.6% of 
all falls-related DALYs and deaths, respectively. These percentages 
increased to 14.8% and 34.7%, respectively, for 2010 estimates  
3.  The percentage of low BMD in the total global health burden almost doubled 
from 1990 (0.12%) to 2010 (0.21%). In population aged 50-69 years, such 
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percentages increased to 0.41% for 1990 and 0.5% for 2010, and were even 
higher in population aged 70 years and above (0.64% and 0.79%, 
respectively). The fraction of the total regional burden increased in most of 
world regions.   
4.  Global deaths attributable to low BMD increased from 103,000 in 1990 to 
188,000 in 2010. Deaths attributable to low BMD almost doubled in males 
from 1990 to 2010, from 52,816 to 103,440, while in females they increased 
around 60% between both time periods, with 50,455 and 84,146 deaths in 
1990 and 2010, respectively. Around one third of all falls-related deaths 
occurring in the world were attributable to low BMD.  
5.  Global DALYs attributable to low BMD increased from 3,125,000 in 1990 to 
5,216,000 in 2010 respectively. Asia East and South were the major 
contributing regions to the increase of the global burden of low BMD likely 
due to the growth of the ageing population and the relatively low population 
levels of BMD compared with other world regions. Rates of global DALYs per 
100,000 were higher in developed regions, while the highest age-
standardized rates were in developing regions. For all time periods, YLLs 
contributed to the global burden of low BMD slightly more than YLDs, 
representing 51% and 53% of all DALYs for 1990 and 2010, respectively. 
Males obtained more DALYs than females for the analysed time periods, with 
a gap between both sexes that increased from 1990 to 2010, with 56% and 
60% of all DALYs corresponding to males for 1990 and 2010, respectively. 
6.  Low BMD had a relatively low weight in the global burden compared to other 
risk factors in the GBD 2010 study. It ranked 20th among 21, and 23rd among 
25 risk factor categories globally for 1990 and 2010, respectively. By region, 
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the highest rankings were observed in developed regions. By age group, the 
highest ranking was found in population 70 years and over, moving to the 
11th position out of 17 risk factors categories for 1990 and to the 13th position 















The contribution of low BMD to the global health burden compared with other risk 
factors was little, and it is likely that the burden of osteoporosis was underestimated 
for several reasons, as discussed previously. To improve the estimates of the health 
burden of low BMD in fractures and falls, the osteoporosis working group for the 
ongoing GBD 2013 study, which the author of the present thesis is part of, is 
updating the burden estimates by:  
 
1) Incorporating new epidemiological data from updated systematic review on 
population levels of bone mineral density, including as well young adults from 
20 to 50 years of age.  
2) Updating reference values for the TMRED from most recent NHANES data. 
3) Including all kind of injuries with a fracture as an outcome and not only falls, 
such as road injuries, non-venomous animal contact, assaults and exposure 
to forces of nature. The inclusion of road injuries, particularly, will represent a 
great contribution to increase the estimated health burden due to low BMD, as 
preliminary data has shown. 
4) Looking for reliable epidemiological data assessing risk relationship of BMD 
and fractures in young adults.  
5) Evaluating the inclusion of non-hip non-vertebra fractures in the mortality 
burden due to low BMD. 
 
The last two points mentioned above are offering some difficult challenges to the 
research team: First, no prospective population-based studies have been found to 
solidly establish a relationship between BMD and fractures in population younger 
than 50 both for men and women, even after personal communication with worldwide 
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experts. It might be possible to extend the estimates to population aged 40 to 50 
years, particularly in women, but for the moment, it seems there is no 
epidemiological data to calculate burden of low BMD in younger adults. Second, the 
inclusion of non-hip non-vertebra fractures in mortality estimates is still under debate. 
This is because great part of the excess mortality derived from such fractures is 
consequence of the long-term risk of suffering a hip or a vertebra fracture, and 
therefore, there is still a difficulty to causally relate the mortality burden to the first 
fracture event.  
 
Future endeavours in the GBD initiative might consider to include “osteoporosis” as a 
disease, rather than (or apart from) low BMD as a risk factor. Yet, methodology 
should be able to overcome some important challenges, such as the lack of 
osteoporosis coding in most of the death certificates for fractures-related deaths.    
 
Considering that the risk of fracture due to reduced BMD is gradual over a 
continuum, and the important epidemiological weight of fractures occurring in 
patients with osteopenia, future approaches should still be based in BMD as a 
continuous variable, rather than studying osteoporosis based in the WHO definition 
of T score of -2.5 or below.   
 
Most recent technologies in bone imaging, such as high-resolution quantitative 
computed tomography (HR-QTC), micro-computed tomography and, particularly, 
trabecular bone score (TBS) from DXA, might be used in the future to thoroughly 
assess bone strength not only considering BMD, but also bone microarchitecture. 
Nevertheless, there is insufficient data for the moment to use such techniques for the 
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GBD study estimates, which require a reasonable amount of epidemiological data. In 
the future, incorporating information on bone architecture will probably improve the 
fracture prediction algorithms and may allow to assess the global health burden of 
osteoporosis as a disease rather than low BMD alone as risk factor.  
 
Health information systems and health professionals should be better prepared to 
detect fragility fractures and long-term mortality related to them. Nature of injuries 
(e.g. fracture) should be coded together with the cause of the injury (e.g. fall) for 
early detection of osteoporotic fractures. This might require a change in the ICD 
coding system. Widespread use of electronic record systems around the world could 
be useful tool to detect individuals at high risk of fracture, and should be better 
equipped in order to improve screening and management of osteoporosis. The 
information provided can also be used to better plan public health prevention and 
management programs. 
 
The MSK EG of the GBD 2010 study, in collaboration with the Bone and Joint 
Decade initiative, is currently collaborating with the WHO in order to increase 
recognition of the burden of MSK diseases, including low BMD and fragility fractures. 
In particular, background papers are currently being prepared to be part of the WHO 
health reports for ageing and frailty, as well as epidemiological data on disability is 
being collected in order to recognize the great role of MSK disorders in the overall 







8 APPLICABILITY  
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Our project provides a unique methodology that enables comparison of the health 
burden of low bone mineral density among different world regions, age groups and 
genders, and the ability to analyse time trends. 
 It provides standardized quantification of the burden (DALY’s, deaths, YLLs, 
YLDs) that can be reproducible in future studies.  
 It highlights areas where the methodology could be modified for future 
analyses.  
 It expresses the burden of low bone mineral density as a fraction of the health 
burden due to falls, which has not been calculated previously in the context of 
all other diseases and risk factors.  
 This research project is part of an important international initiative with world 
experts in global epidemiology and expert leaders in the corresponding fields. 
The four core papers of the GBD 2010 study were already published in Lancet 
in 2012, and the new updates from the GBD 2013 study will be published in 
2015. Multiple disease-focused manuscripts and regional reports have been 
published. The GBD initiative is present in the main international medical 
conferences, in newspapers, in TV programs, and in university lectures 
around the world. It represents an ongoing global network to facilitate the 
awareness of the burden of the different conditions and risk factors in the 
world, both to scientific and non-scientific audiences.   
 Our estimates can provide useful information for health authorities and policy 
makers, and can be helpful for future population campaigns for osteoporosis 
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Appendix 1. Global Burden of Disease Countries Listed by Region 
GBD Country by Region 
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Appendix 2. GBD 2010 Musculoskeletal Disorders Risk of Bias Tool to Check Study Quality: Osteoporosis Exposure 
and Fracture Risk Relationship 
Name of author(s): ________________________________________ Year of publication: _______________________  
Name of paper/study: ______________________________________________________________________ 
Quality Item Criteria for answers Additional notes Answer  
1. Was bone mineral 
density shown for a 
clearly described 
anatomical location 
(femoral neck, spine, 
distal forearm)? 
 
 LOW RISK: A clear anatomical location of 
the relevant region of the body was used in 
the study. 
 HIGH RISK: A clear anatomical location of 
the relevant region of the body was NOT 
used in the study. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low or high risk. 
 
For example:  
 A study where BMD was assessed in all individuals at femoral neck. The 
answer is: LOW RISK. 
 The article gives BMD values of the hip but doesn’t specify the region (FN, 
Wards triangle, total hip, etc.). The answer would be UNCLEAR. 
 
 Low Risk 
 




2. Was there a case 










 LOW RISK: A case definition for fractures 
was used in the study OR the outcome to 
measure is deaths. 
 HIGH RISK: A case definition for fractures 
was NOT used in the study. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low, moderate or 
high risk. 
A hip fracture is generally a fracture of the proximal femur. There are three 
types: femoral neck, intertrochanteric and subtrochanteric (just below the lesser 
trochanter).  
An osteoporotic DISTAL forearm fracture is the result of a low-impact trauma. It 
needs to involve the distal part of radius and/or ulna. There are 8 different types 
of distal forearm fractures (Frykman classification). In the ICD10 classification 
distal forearm fractures EXCLUDE fractures from the wrist and hand. 
An osteoporotic vertebral fracture is generally a fracture of the vertebra body 
due to a low-impact trauma or in the absence of specific trauma in thoracic or 
lumbar spine. The definition for a “prevalent” or “incident” fracture can vary 
among studies; thus, the values given are not directly “comparable.
1
 For 
instance, some studies have defined a new fracture as > 15 % reduction in any 
one of the three measured vertebra heights compared to a previous X-ray; to 
reduce false-positive results, other investigators propose a more stringent criteria 
of 20% or more, and others suggest to combine the latest with an absolute loss 
of 4mm to increase specificity. For prevalence, the NOF suggests that in studies 
involving community populations, prevalence vertebral fractures be defined as a 
reduction of 3 SD or more below the normal dimensions for that particular 
vertebral level 
 
For example:  
 A study assessing femur fractures not specifying if they are proximal or shaft 
femur fractures. The answer is HIGH RISK. 
 The following case definition was used: “hip fractures were considered as 
 Low Risk 
 









Quality Item Criteria for answers Additional notes Answer  
proximal femur fractures resulting from a low-impact trauma. The answer is: 
LOW RISK. 
 The following case definition was used: “hip fractures were considered as 
proximal femur fractures occurring in individuals 50 years or older. The answer 
is: LOW RISK. 
 A study assessing prevalence of vertebral fractures with lumbar X-rays 
(not including thoracic vertebrae). The answer is HIGH RISK. 
 
3. Was the study 
instrument that 
measured the exposure 
to the risk factor (BMD) 
reliable AND valid? 
   
 LOW RISK: The study instrument was 
reliable and valid. 
 MODERATE RISK: The study instrument 
was valid, but it was just moderately reliable. 
 HIGH RISK: The study instrument was not 
valid. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low, moderate or 
high risk. 
The study instrument used for measuring BMD is Dual-X-Ray-Absorptiometry 
(DXA). Other techniques to assess BMD are not eligible for this GBD study.  For 
DXA techniques, the authors should report the manufacturer and the model used 
for the BMD measures and the site-specific coefficient of variation (COV).  
For example:  
 A study using DXA not reporting the manufacturer equipment or model. The 
answer is: UNCLEAR. 
 A study using DXA reporting the manufacturer equipment, the model and a 
COV <2.5%
2:
 The answer is LOW RISK. 
 A study reporting the manufacturer and model, but no information on the COV 
is provided. The answer is: MODERATE RISK. 
 A COV between 2.5 and 3.5%. The answer is: MODERATE RISK
3
. 
 A study assessing BMD measures with a COV at FN >3.5% for an individual 
technologist. The answer is:  HIGH RISK  
 A multicentric study reporting mean values of BMD assessed with different 
instruments without cross-calibration between facilities would be HIGH RISK. 
 
 Low Risk 
 
 Moderate Risk 
 




4. Was the assessment 
of the outcome (fracture 
or mortality) reliable? 
 LOW RISK: The outcome is assessed 
through reliable data sources in all the 
subjects confirmed by radiological evidence 
(fracture) or by administrative record linkage 
(fractures or deaths). 
 MODERATE RISK: The outcome is 
assessed through reliable sources only in a 
part of the subjects, OR, the outcome is 
assessed only through chart review. 
 HIGH RISK: The outcome is not assessed 
through reliable data sources in most of the 
subjects.  
 UNCLEAR: There is insufficient information 
to permit a judgement of low, moderate or 
high risk. 
There is a lower risk of bias if clinical outcomes like fractures or deaths are 
confirmed with radiology (fractures), clinical records or administrative data. 
For example: 
 A study that collects data on fractures only through the subjects (or a proxy) 
self-report. The answer is: HIGH RISK. 
 A study that collects data on fractures or deaths through chart review. The 
answer is: MODERATE RISK. 
 A study that collects data on fractures through subjects self report and confirms 
positive cases with an X-Ray report. The answer is: LOW RISK.   
 A study that collects data on mortality through subjects relatives or chart review 
and confirm cases with death certificate or administrative record linkage. The 
answer is: LOW RISK. 
 
 Low Risk 
 
 Moderate Risk 
 




5. Was the study’s 
target population 
representative of the 
 LOW RISK: The target population was a true 
representation of the national population. 
 MODERATE RISK: The target population 
The target population of the study refers to the group of people or entities to 
which the results of the study will be generalised.  This item focuses on whether 
the target population is representative of the national population.   
 Low Risk 
 






Quality Item Criteria for answers Additional notes Answer  
national population?   was a close representation of the national 
population. 
 HIGH RISK: The target population was 
clearly not representative of the national 
population. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low, moderate, or 
high risk. 
For example: 
 The study was a national health survey of people 20 years and over and the 
sample was representative of the national population aged 20 years and over. 
The answer is: LOW RISK. 
 The study was a provincial survey and the province was considered closely 
representative of the national population.  The answer is: MODERATE RISK. 
 The study was conducted in one village only, which was clearly not 
representative of the national population.  The answer is: HIGH RISK. 
 




6. Was the sampling 
frame representative of 
the target population? 
 LOW RISK: The sampling frame was a true 
representation of the target population. 
 MODERATE RISK: The sampling frame was 
a close representation of the target 
population. 
 HIGH RISK: The sampling frame was a poor 
representation of the target population. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low, moderate, or 
high risk. 
The sampling frame is a list of the sampling units in the target population and the 
study sample population is drawn from this list.  It is rare to obtain a complete list 
of all the sampling units; however, where possible, the sampling frame should be 
representative of the target population.   
For example: 
 The sampling frame was a complete list of every individual within the target 
population.  The answer is: LOW RISK. 
 The sampling frame was an ‘almost’ complete list of every individual within the 
target population.  The answer is: MODERATE RISK. 
 The cluster sampling method was used - the sampling unit was villages. All 
villages in the target population were included.  The answer is: LOW RISK. 
 Low Risk 
 
 Moderate Risk 
 




7. Were randomised 
methods used to select 
the sample population? 
 LOW RISK: Randomised methods were 
used to select the sample (e.g. simple 
random sampling, stratified random 
sampling, cluster sampling, systematic 
sampling). 
 HIGH RISK: Randomised methods were 
NOT used to select the sample. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low or high risk. 
The sample population is selected from the sampling frame. 
For example: 
 The sample population was selected using the cluster technique.  The answer 
is: LOW RISK. 
 
 Low Risk 
 
 High Risk 
 
 Unclear 




 LOW RISK: The response rate (participation 
rate) at baseline was >/=70%
4
, OR, An 
analysis was performed that showed no 
significant difference in the variable of 
interest between responders and non-
responders (people who did not wish to 
participate), OR, An adjustment was made to 
remove any effect of non-response bias. 
 MODERATE RISK: The overall response 
rate is <70 but >/=50% Most of the subjects 
in the sample are asked to undergo BMD 
testing. 
 HIGH RISK: None of the three scenarios 
listed in the above LOW RISK criteria 
This response rate mentioned in this item relates to the study within which the 
parameter of interest was measured (e.g. BMD measures to assess 
osteoporosis prevalence). For example: 
 Although the overall response rate of the study was 48%, the researchers 
carried out an analysis and found no significant difference in the prevalence of 
osteoporosis/BMD measures between responders and non-responders. The 
answer is: LOW RISK. 
 The response overall response rate was 48% and the researchers did NOT 
carry out an analysis to compare the prevalence of low back pain between 
responders and non-responders NOR did they make any adjustment for non-
response bias. The answer is: HIGH RISK. 
 
 
 Low Risk 
 










Quality Item Criteria for answers Additional notes Answer  
existed, and the overall response rate was 
<50%. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low or high risk. 
9. Was there 
adjustments for 
confounding factors 
when analyzing the 
relationship between  
BMD and the outcome 
(fractures) 
 LOW RISK: The outcome is adjusted by 
other relevant clinical factors. 
 MODERATE RISK: The outcome is only 
adjusted by age and gender. 
 HIGH RISK: The outcome is not adjusted by 
any other clinical factor. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low, moderate or 
high risk. 
For example: 
 A study that analyzes the association between BMD and risk of fracture, 
making adjustments for age, sex, BMI and menopausal status. The answer is: 
LOW RISK. 
 A study that analyzes the association between BMD and risk of fracture or 
death only adjusting for age and gender. The answer is MODERATE RISK. 
 A study that analyzes the association between BMD and mortality with no 
adjustments for age, sex or other common risk factors (smoking, social status, 
diabetes, HTA, etc). The answer is: HIGH RISK.   
 
 Low Risk 
 
 Moderate Risk 
 
 High Risk 
 
 Unclear 
10. Was the follow-up 
period long enough for 
outcomes (fracture) to 
occur?  
 LOW RISK: The follow-up period was 
adequate for the outcome of interest. 
 HIGH RISK: The follow-up period was not 
adequate for the outcome of interest.  
 UNCLEAR: There is insufficient information 
to permit a judgement of low or high risk. 
The minimum follow-up period should be at least of 1 year. 
 
 Low Risk 
 
 High Risk 
 
 Unclear 
11. Was the follow-up 
cohort adequate to 
measure the outcome 
of interest (fracture)?  
 LOW RISK: Most of subjects completed 
longitudinal follow-up, OR the number of 
lost subjects is small (<10)% OR the 
investigators provide description of the lost 
subjects and show the unlikelihood of bias. 
 MOD RISK: The number of lost subjects is 
>10 but <30%. 
 HIGH RISK: None of the scenarios listed 
above exists. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low or high risk. 
Retrospective cohorts for the assessment of fractures will be HIGH RISK. 
 
 Low Risk 
 
 Moderate Risk 
 
 High Risk 
 
 Unclear 
12. Was there risk of 
selection bias? 
 LOW RISK: All subjects are included in the 
analysis. 
 MODERATE RISK: Subjects under bone 
supplements/treatment, diseases or 
therapies with impact on bone metabolism 
are excluded. 
 HIGH RISK: Subjects with prior fractures are 
excluded from the analysis. 
 UNCLEAR: There is insufficient information 
to permit a judgement of low or high risk. 
 
 Low Risk 
 
 High Risk 
 
 Unclear 






Quality Item Criteria for answers Additional notes Answer  
about the study’s 
overall level of bias 
to change our confidence in the estimate. 
 MODERATE RISK: Further research is likely 
to have an important impact on our 
confidence in the estimate and may change 
the estimate. 
 HIGH RISK: Further research is very likely to 
have an important impact on our confidence 
in the estimate and is likely to change the 
estimate. 
 
 Moderate Risk 
 





The minimum acceptable precision for an individual technologist is 2.5% for FN. Official positions 2007. The International Society for Clinical Densitometry: 
http://www.iscd.org/Visitors/pdfs/ISCD2007OfficialPositions-Combined-AdultandPediatric.pdf. 
3
 After the use of the universal standardization formula between Hologic and Luna, the average error for an individual patient was of 3.5%, which is considered “clinical 
acceptable”. Hui SL et al. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments (1997). JBMR; 
12:1463-70.    
4
 That is the percentage after the response rate for the sampling + response rate to undergo BMD testing. For ex. 77% X 65% =  50% In  NHANES III the response rate for BMD 
testing was about 86% (only BMD) and the overall response rate was between 62.10 (60 years old or older) and 77.19 (between 20 and 39 years old). The latest computed by 
the product of screened sample response rate, the interview sample response rate, and the examined sample response rate. Mohader,L et al. National Health and Nutrition 






Appendix 3. Cause of Fall Codes – International Classification of Diseases (ICD)-9 and -10 Codes 
ICD-9 Codes for Causes of Fall Injuries 
 
 
ACCIDENTAL FALLS (E880-E888) 
 
  
Excludes: E890.8, E891.8 burning building  
  
Excludes: E890.0-E899 into fire 
  
Excludes: E910.0-E910.9 into water (with submersion or drowning) 
  
Excludes: E919.0-E919.9 machinery (in operation) 
  
Excludes: E920.0-E920.9 on edged, pointed, or sharp object 
  
Excludes: E800.0-E845.9 transport vehicle 
  
Excludes: E846-E848 vehicle not elsewhere classifiable 
 
E880  Fall on or from stairs or steps 
 
 
E880.0  Escalator 
 
 
E880.1  Fall on or from sidewalk curb 
 
  
Excludes: E885.9 fall from moving sidewalk  
 
E880.9  Other stairs or steps 
 
 
E881  Fall on or from ladders or scaffolding 
 
 
E881.0  Fall from ladder 
 
 
E881.1  Fall from scaffolding 
 
 
E882  Fall from or out of building or other structure 
 
  
Fall from: balcony, bridge, building, flagpole, tower, turret, viaduct, wall, window 
  
Fall through roof 
 
  
Excludes: E916 collapse of a building or structure  
  
Excludes: E890.8, E891.8 fall or jump from burning building  
 
E883 Fall into hole or other opening in surface 
 
  
Includes: fall into: cavity, dock, hole, pit, quarry, shaft, swimming pool, tank, well 
  
Excludes: E910.9  fall into water NOS 
  
Excludes: E910.0-E910.9 
resulting in drowning or submersion without mention of 
injury  
 
E883.0  Accident from diving or jumping into water (swimming pool) 
  
Strike or hit: against bottom when jumping or diving into water, wall or board of swimming pool, water surface 
  
Excludes: E913.2 diving with insufficient air supply 
  






ICD-9 Codes for Causes of Fall Injuries 
 
 
E883.1  Accidental fall into well 
 
 
E883.2  Accidental fall into storm drain or manhole 
 
 
E883.9  Fall into other hole or other opening in surface 
 
 
E884  Other fall from one level to another 
 
 
E884.0  Fall from playground equipment 
 
  
Excludes: E919.8 recreational machinery  
 
E884.1  Fall from cliff 
 
 
E884.2  Fall from chair 
 
 
E884.3  Fall from wheelchair 
 
 
E884.4  Fall from bed 
 
 
E884.5  Fall from other furniture 
 
 
E884.6 Fall from commode: Toilet 
 
 
E884.9  Other fall from one level to another: Fall from: embankment, haystack, stationary vehicle, tree 
 
E885 Fall on same level from slipping, tripping, or stumbling 
 
E885.0  Fall from (nonmotorized) scooter 
 
 
E885.1  Fall from roller skates: Inline skates 
 
 
E885.2  Fall from skateboard 
 
 
E885.3  Fall from skis 
 
 
E885.4 Fall from snowboard 
 
 
E885.9  Fall from other slipping, tripping, or stumbling 
 
  
Fall on moving sidewalk 
 
 
E886  Fall on same level from collision, pushing, or shoving, by or with other person 
  
Excludes: E917.1, E917.6 crushed or pushed by a crowd or human stampede 
 
E886.0  In sports: Tackles in sports 
 
  
Excludes: E917.0, E917.5 kicked, stepped on, struck by object, in sports  
 
E886.9 Other and unspecified: Fall from collision of pedestrian (conveyance) with another pedestrian (conveyance) 
 
E888  Other and unspecified fall: Accidental fall NOS, Fall on same level NOS 
 
E888.0  Fall resulting in striking against sharp object 
 
 
E920 Use additional external cause code to identify object  
 
 
E888.1  Fall resulting in striking against other object 
 
 
E888.8  Other fall 
 
 







ICD-9 Codes for Causes of Fall Injuries 
 
 
E929.3  Late effects of accidental fall 
 ICD-10 Codes for Causes of Falls Injuries 
 
W00 Fall on same level involving ice and snow 
 
 
W01 Fall on same level from slipping, tripping, and stumbling 
 
W02 Fall involving ice skates, skis, roller skates, or skateboards 
 
W03 Other fall on same level due to collision with, or pushing by, another person 
 
W04 Fall while being carried or supported by other persons 
 
W05 Fall involving wheelchair 
 
 
W06 Fall involving bed 
 
 
W07 Fall involving chair 
 
 
W08 Fall involving other furniture 
 
 
W09 Fall involving playground equipment 
 
 
W10 Fall on and from stairs and steps 
 
 
W11 Fall on and from ladder 
 
 
W12 Fall on and from scaffolding 
 
 
W13 Fall from, out of, or through building or structure 
 
 
W14 Fall from tree 
 
 
W15 Fall from cliff 
 
 
W16 Diving or jumping into water causing injury other than drowning or submersion 
 
W17 Other fall from one level to another 
 
 
W18 Other fall on same level 
 
 







Appendix 4. Disability Weights in the Global Burden of Disease 2010 Study  
(Adapted from Salomon JA et al 2012 (Salomon, Vos et al. 2012) 
GBD 2010 health state  Weight (95% uncertainty interval) 
Schizophrenia: acute state 0.756 (0.571-0.894) 
Spinal cord lesion at neck: untreated  0.676 (0.475-0.837) 
Major depressive disorder: severe episode 0.655 (0.469-0.816) 
Heroin and other opioid dependence 0.641 (0.459-0.803) 
Schizophrenia: residual state 0.576 (0.399-0.756) 
Parkinson's disease: severe 0.549 (0.383-0.711) 
AIDS cases: not receiving ARV treatment 0.547 (0.328-0.715) 
Terminal phase: without medication (for cancers, end-stage kidney/liver disease) 0.519 (0.356-0.683) 
Terminal phase: with medication (for cancers, end-stage kidney/liver disease)   0.508 (0.348-0.670) 
Rectovaginal fistula 0.492 (0.330-0.660) 
Cancer: metastatic 0.484 (0.330-0.643) 
Bipolar disorder: manic episode 0.480 (0.323-0.642) 






GBD 2010 health state  Weight (95% uncertainty interval) 
Burns of ≥20% total surface area or ≥10% total surface area if head or neck, or hands 
or wrist involved: long term, without treatment  
0.438 (0.298-0.588) 
Headache: migraine 0.433 (0.287-0.593) 
Motor plus cognitive impairments: severe  0.425 (0.286-0.587) 
Acute myocardial infarction: days 1-2  0.422 (0.284-0.566) 
Epilepsy: untreated 0.420 (0.279-0.572) 
Major depressive disorder: moderate episode 0.406 (0.276-0.551) 
Tuberculosis: with HIV infection 0.399 (0.267-0.547) 
Fracture of pelvis: short term  0.390 (0.257-0.545) 
Alcohol use disorder: moderate 0.388 (0.262-0.529) 
Fracture of neck of femur: long term, without treatment 0.388 (0.261-0.532) 
COPD and other chronic respiratory problems: severe 0.383 (0.259-0.528) 
Cocaine dependence 0.374 (0.235-0.553) 
Amphetamine dependence 0.353 (0.215-0.525) 






GBD 2010 health state  Weight (95% uncertainty interval) 
Burns of ≥20% total surface area: short term, with or without treatment 0.333 (0.220-0.472) 
Tuberculosis: without HIV infection 0.331 (0.222-0.450) 
Cannabis dependence  0.329 (0.223-0.455) 
Abdominopelvic problem: severe  0.326 (0.219-0.176) 
Stroke: long-term consequences, moderate plus cognition problems  0.312 (0.211-0.433) 
Fracture of neck of femur: short term, with or without treatment 0.308 (0.205-0.439) 
Cancer: diagnosis and primary therapy 0.294 (0.199-0.411) 
Gout: acute  0.293 (0.198-0.404) 
Musculoskeletal problems: generalised, moderate 0.292 (0.197-0.410) 
Low back pain: acute, without leg pain  0.269 (0.184-0.373) 
Parkinson's disease: moderate  0.263 (0.179-0.360) 
Crohn's disease or ulcerative colitis  0.255 (0.152-0.314) 
Severe traumatic brain injury: short term, with or without treatment 0.235 (0.156-0.331) 
HIV cases: symptomatic, pre-AIDS 0.221 (0.146-0.310) 






GBD 2010 health state  Weight (95% uncertainty interval) 
Infectious disease: acute episode, severe  0.210 (0.139-0.298) 
Diarrhea: moderate 0.202 (0.133-0.299) 
Distance vision blindness 0.195 (0.132-0.272) 
Decompensated cirrhosis of the liver  0.194 (0.127-0.273) 
COPD and other chronic respiratory problems: moderate   0.192 (0.129-0.271) 
Disfigurement: level 2, with itch or pain 0.187 (0.125-0.264) 
Heart failure, severe 0.186 (0.128-0.261) 
Fracture of face bone: short or long term, with or without treatment 0.173 (0.111-0.257) 
Musculoskeletal problems: legs, severe 0.171 (0.117-0.240) 
Angina pectoris: severe 0.167 (0.109-0.234) 
Anaemia: severe  0.164 (0.112-0.228) 
Amputation of one leg: long term, without treatment  0.164 (0.111-0.229) 
Major depressive disorder: mild episode  0.159 (0.107-0.223) 
Fracture of sternum or fracture of one or two ribs: short term, with or without treatment 0.150 (0.098-0.215) 






GBD 2010 health state  Weight (95% uncertainty interval) 
Crush injury: short or long term, with or without treatment  0.145 (0.093-0.211) 
Musculoskeletal problems: arms, moderate  0.144 (0.077-0.159) 
Urinary incontinence 0.142 (0.094-0.204) 
Injured nerves: long term 0.136 (0.092-0.096) 
Fracture of vertebral column: short or long term, with or without treatment 0.132 (0.085-0.195) 
Amputation of one arm: long term, with or without treatment  0.130 (0.088-0.185) 
Dislocation of knee: long term, with or without treatment  0.129 (0.087-0.178) 
Burns of ≥20% total surface area or ≥10% total surface area if head or neck, or hands 
or wrist involved: long term, with treatment  
0.127 (0.086-0.183) 
Severe wasting 0.127 (0.081-0.183) 
Intellectual disability: severe 0.126 (0.085-0.176) 
Abdominopelvic problem: moderate  0.123 (0.083-0.176) 
Lymphatic filariasis: symptomatic  0.110 (0.073-0.157) 
Diabetic neuropathy 0.099 (0.066-0.145) 






GBD 2010 health state  Weight (95% uncertainty interval) 
Burns of <20% total surface area without lower airway burns: short term, with or without 
treatment 
0.096 (0.062-0.140) 
Fracture of patella, tibia or fibula, or ankle: short term, with or without treatment  0.087 (0.055-0.127) 
Stoma  0.086 (0.055-0.131) 
Dislocation of shoulder: long term, with or without treatment  0.080 (0.053-0.116) 
Musculoskeletal problems: legs, moderate  0.079 (0.053-0.110) 
Injury to eyes: short term  0.079 (0.050-0.118) 
Motor impairment: moderate 0.076 (0.050-0.109) 
Fracture of skull: short or long term, with or without treatment  0.073 (0.046-0.109) 
Severe tooth loss  0.072 (0.048-0.103) 
Epilepsy: treated, seizure free  0.072 (0.047-0.106) 
Fracture of neck of femur: long term, with treatment 0.072 (0.047-0.105) 
Disfigurement: level 2 0.072 (0.006-0.025) 
Benign prostatic hypertrophy: symptomatic cases 0.070 (0.046-0.102) 






GBD 2010 health state  Weight (95% uncertainty interval) 
Angina pectoris: moderate 0.066 (0.043-0.095) 
Fracture of radius or ulna: short term, with or without treatment  0.065 (0.040-0.101) 
Injured nerves: short term 0.065 (0.040-0.096) 
Anaemia: moderate 0.058 (0.038-0.086) 
Motor plus cognitive impairments: mild 0.054 (0.033-0.084) 
HIV/AIDS cases: receiving ARV treatment 0.053 (0.034-0.079) 
Infectious disease: acute episode, moderate 0.053 (0.033-0.081) 
Fracture of clavicle, scapula, or humerus: short or long term, with or without treatment 0.053 (0.033-0.080) 
Mastectomy  0.038 (0.022-0.059) 
Bipolar disorder: residual state  0.035 (0.021-0.055) 
Distance vision: moderate impairment 0.033 (0.020-0.052) 
Fracture of foot bones: short term, with or without treatment  0.033 (0.019-0.053) 
Hearing loss: severe  0.032 (0.018-0.051) 
Intellectual disability: mild  0.031 (0.018-0.049) 






GBD 2010 health state  Weight (95% uncertainty interval) 
Generic uncomplicated disease: worry and daily medication  0.031 (0.017-0.050) 
Amputation of finger(s), excluding thumb: long term, with treatment 0.030 (0.018-0.048) 
Anxiety disorders: mild  0.030 (0.017-0.048) 
Intestinal nematode infections: symptomatic 0.030 (0.016-0.048) 
Asthma, partially controlled  0.027 (0.015-0.045) 
End-stage renal disease: with kidney transplant 0.027 (0.015-0.043) 
Fracture of hand: short term, with or without treatment  0.025 (0.013-0.043) 
Hearing loss: moderate 0.023 (0.013-0.038) 
Diabetic foot 0.023 (0.012-0.039) 
Amputation of one leg: long term, with treatment  0.021 (0.011-0.035) 
Impotence 0.019 (0.010-0.034) 
Burns of <20% total surface area or <10% total surface area if head or neck, or hands 
or wrist involved: long term, with or without treatment 
0.018 (0.010-0.032) 
Ear pain 0.018 (0.009-0.031) 






GBD 2010 health state  Weight (95% uncertainty interval) 
COPD and other chronic respiratory problems: mild 0.015 (0.007-0.028) 
Amputation of thumb: long term  0.013 (0.006-0.025) 
Disfigurement: level 1  0.013 (0.006-0.025) 
Abdominopelvic problem: mild  0.012 (0.005-0.023) 
Dental caries: symptomatic  0.012 (0.005-0.023) 
Infertility: primary  0.011 (0.005-0.021) 
Periodontitis 0.008(0.003-0.017) 
Amputation of toe 0.008 (0.003-0.017) 
Infertility: secondary 0.006 (0.002-0.013) 
Hearing loss: mild 0.005 (0.002-0.012) 
Infectious disease: acute episode, mild 0.005 (0.002-0.011) 
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Ann Rheum Dis. 2015 Jan;74(1):4-7.  
Reflecting on the global burden of musculoskeletal conditions: lessons learnt from 
the Global Burden of Disease 2010 Study and the next steps forward. 
Hoy DG, Smith E, Cross M, Sanchez-Riera L, Blyth FM, Buchbinder R, Woolf AD, 
Driscoll T, Brooks P, March LM. 
The objective of this paper is to provide an overview of the strengths, limitations and 
lessons learned from estimating the burden from musculoskeletal (MSK) conditions 
in the Global Burden of Disease 2010 Study (GBD 2010 Study). It should be read in 
conjunction with the other GBD 2010 Study papers published in this journal. The 
strengths of the GBD 2010 Study include: the involvement of a MSK expert group; 
development of new and more valid case definitions, functional health states, and 
disability weights to better reflect the MSK conditions; the extensive series of 
systematic reviews undertaken to obtain data to derive the burden estimates; and 
the use of a new, more advanced version of the disease-modelling software 
(DisMod-MR). Limitations include: many regions of the world did not have data; the 
extent of heterogeneity between included studies; and burden does not include 
broader aspects of life, such as participation and well-being. A number of lessons 
were learned. Ongoing involvement of experts is critical to ensure the success of 
future efforts to quantify and monitor this burden. A paradigm shift is urgently needed 
among global agencies in order to alleviate the rapidly increasing global burden from 
MSK conditions. Prevention and control of MSK disability are required, along with 
health system changes. Further research is needed to improve understanding of the 
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predictors and clinical course across different settings, and the ways in which MSK 
conditions can be better managed and prevented. 
 
Rev Psiquiatr Salud Ment. 2014 Nov [Epub ahead of print] 
The Spanish Burden of Disease 2010: Neurological, mental and substance use 
disorders. 
Lara E, Garin N, Ferrari AJ, Tyrovolas S, Olaya B, Sànchez-Riera L, Whiteford HA, 
Haro JM. 
INTRODUCTION: 
We used data from the Global Burden of Disease, Injuries, and Risk Factors Study 
2010 to report on the burden of neuropsychiatric disorders in Spain. 
MATERIALS AND METHODS: 
The summary measure of burden used in the study was the disability-adjusted life-
year (DALY), which sums of the years of life lost due to premature mortality (YLLs) 
and the years lived with disability (YLDs). DALYs were adjusted for comorbidity and 
estimated with 95% uncertainty intervals. 
RESULTS: 
The burden of neuropsychiatric disorders accounted for 18.4% of total all-cause 
DALYs generated in Spain for 2010. Within this group, the top five leading causes of 
DALYs were: depressive disorders, Alzheimer's disease, migraine, substance-use 
disorders, and anxiety disorder, which accounted for 70.9% of all DALYs due to 
neuropsychiatric disorders. Neurological disorders represented 5.03% of total all 
cause YLLs, whereas mental and substance-use disorders accounted for 0.8%. 
Mental and substance-use disorders accounted for 22.4% of total YLDs, with 
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depression being the most disabling disorder. Neurological disorders represented 
8.3% of total YLDs. 
CONCLUSIONS: 
Neuropsychiatric disorders were one of the leading causes of disability in 2010. This 
finding contributes to our understanding of the burden of neuropsychiatric disorders 
in the Spanish population and highlights the importance of prioritising 
neuropsychiatric disorders in the Spanish public health system. 
 
Best Pract Res Clin Rheumatol. 2014;28(3):353-366. 
Burden of disability due to musculoskeletal (MSK) disorders. 
March L, Smith EU, Hoy DG, Cross MJ, Sanchez-Riera L, Blyth F, Buchbinder R, 
Vos T, Woolf AD. 
This chapter summarises the global and regional prevalence, disability (Years Lived 
with Disability (YLDs)) and overall burden (Disability Adjusted Life Years (DALYs)) 
and costs for the common musculoskeletal disorders including low back and neck 
pain, hip and knee osteoarthritis, rheumatoid arthritis, gout, and a remaining 
combined group of other MSK conditions. The contribution of the role of pain in 
disability burden is introduced. Trends over time and predictions of increasing MSK 
disability with demographic changes are addressed and the particular challenges 







BMC Med. 2014:12(1):236.  
The burden of disease in Spain: results from the global burden of disease study 
2010. 
Haro J, Tyrovolas S, Garin N, Diaz-Torne C, Carmona L, Sanchez Riera L, Perez-
Ruiz F, Murray C. 
BACKGROUND.  
We herein evaluate the Spanish populations trends in health burden by comparing 
results of two Global Burden of Diseases, Injuries, and Risk Factors Studies (the 
GBD studies) performed 20 years apart. 
METHODS.  
Data is part of the GBD study for 1990 and 2010. We present results for mortality, 
years of life lost (YLLs), years lived with disability, and disability-adjusted life years 
(DALYs) for the Spanish population. Uncertainty intervals for all measures have 
been estimated.  
RESULTS . 
Non-communicable diseases accounted for 3,703,400 (95% CI 3,648,270-
3,766,720) (91.3%) of 4,057,400 total deaths, in the Spanish population. 
Cardiovascular and circulatory diseases were the main cause of mortality among 
non-communicable diseases (34.7% of total deaths), followed by neoplasms (27.1% 
of total deaths). Neoplasms, cardiovascular and circulatory diseases, and chronic 
respiratory diseases were the top three leading causes for YLLs. The most important 
causes of DALYs in 2010 were neoplasms, cardiovascular and circulatory diseases, 




Mortality and disability in Spain have become even more linked to non-
communicable diseases over the last years, following the worldwide trends. 
Cardiovascular and circulatory diseases, neoplasms, mental and behavioral 
disorders, and neurological disorders are the leading causes of mortality and 
disability. Specific focus is needed from health care providers and policy makers to 
develop health promotion and health education programs directed towards non-
communicable disorders. 
 
Rheumatology (Oxford). 2014 Oct [Epub ahead of print]  
Drug utilization in patients with OA: a population-based study. 
Wilson N, Sanchez-Riera L, Morros R, Diez-Perez A, Javaid M, Cooper C, Arden N, 
Prieto-Alhambra D. 
OBJECTIVE: 
Patients with OA use different drugs in their search for relief. We aimed to study the 
prevalence of use and combinations of different medications for OA in a population-
based cohort of OA patients in Catalonia, Spain, while characterizing users of each 
of the drugs available, with a particular focus on cardiovascular risk factors. 
METHODS: 
Data were obtained from the Sistema d'Informació per al Desenvolupament de 
l'Investigació en Atenció Primària (SIDIAP) database, which includes electronic 
medical records and pharmacy invoice data for >5 million people from Catalonia. 
Study participants were those with a clinical diagnosis of OA in 2006-10. Drugs 
studied included oral and topical NSAIDs, analgesics (paracetamol, metamizole), 
opioids (tramadol, fentanyl), cyclooxygenase 2 (COX-2) inhibitors and symptomatic 
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slow-acting drugs in OA. Drug utilization was described using medication possession 
ratios (MPRs), equivalent to the proportion of days covered with the drug of interest. 
The annual incidence of new users in the first year after OA diagnosis from 2006 to 
2010 was estimated for all studied drugs among newly diagnosed OA patients using 
Poisson regression. 
RESULTS: 
We identified 238 536 study participants. The most common regimen of treatment 
consisted of at least three drugs (53.9% of patients). The drugs most frequently used 
regularly (MPR ≥50%) were chondroitin (21.2%), glucosamine (15.8%) and oral 
NSAIDs (14.4%). The incidence of the use of opioids, COX-2 inhibitors and 
chondroitin increased over the 5 year period, whereas all others decreased. 
CONCLUSION: 
Drug combinations are common in the treatment of OA patients, who are thus 
exposed to potential drug interactions, with unknown impacts on their health. The 
increasing use of opioids and COX-2 inhibitors is noteworthy because of the 
potential impact on safety and costs. 
 
Ann Rheum Dis. 2014;73(6):982-9.  
The global burden of musculoskeletal conditions for 2010: an overview of methods. 
Hoy DG, Smith E, Cross M, Sanchez-Riera L, Buchbinder R, Blyth FM, Brooks P, 
Woolf AD, Osborne RH, Fransen M, Driscoll T, Vos T, Blore JD, Murray C,Johns N, 
Naghavi M, Carnahan E, March LM. 
The objective of this paper is to provide an overview of methods used for estimating 
the burden from musculoskeletal (MSK) conditions in the Global Burden of Diseases 
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2010 study. It should be read in conjunction with the disease-specific MSK papers 
published in Annals of Rheumatic Diseases. Burden estimates (disability-adjusted 
life years (DALYs)) were made for five specific MSK conditions: hip and/or knee 
osteoarthritis (OA), low back pain (LBP), rheumatoid arthritis (RA), gout and neck 
pain, and an 'other MSK conditions' category. For each condition, the main disabling 
sequelae were identified and disability weights (DW) were derived based on short lay 
descriptions. Mortality (years of life lost (YLLs)) was estimated for RA and the rest 
category of 'other MSK', which includes a wide range of conditions such as systemic 
lupus erythematosus, other autoimmune diseases and osteomyelitis. A series of 
systematic reviews were conducted to determine the prevalence, incidence, 
remission, duration and mortality risk of each condition. A Bayesian meta-regression 
method was used to pool available data and to predict prevalence values for regions 
with no or scarce data. The DWs were applied to prevalence values for 1990, 2005 
and 2010 to derive years lived with disability. These were added to YLLs to quantify 
overall burden (DALYs) for each condition. To estimate the burden of MSK disease 
arising from risk factors, population attributable fractions were determined for bone 
mineral density as a risk factor for fractures, the occupational risk of LBP and 
elevated body mass index as a risk factor for LBP and OA. Burden of Disease 
studies provide pivotal guidance for governments when determining health priority 
areas and allocating resources. Rigorous methods were used to derive the 






Lancet. 2012 Dec 15;380(9859):2163-96.  
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 
1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. 
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, 
Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, 
Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour 
LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, Baxter A, 
Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin 
Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger 
I,Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, 
Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello 
C,Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, 
Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson 
F,Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, 
Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro 
KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, 
Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt 
L,Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, 
Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, 
Ebel B,Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan 
SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane 
MM,Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, 
Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia 
B,Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, 
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Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro 
JM,Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez 
PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, 
Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, 
Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng 
A,Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, 
Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons 
R,Ma J, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, 
Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos 
R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora 
ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, 
Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-
Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair 
MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, 
Norman P, Norman R, O'Donnell M, O'Hanlon S, Olives C, Omer SB,Ortblad K, 
Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, 
Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D,Phillips MR, 
Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, Popova S, Porrini E, 
Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D,Razavi H, Regan 
M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson 
C, De Leòn FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, 
Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez 
M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D,Singh GM, Singh JA, 
Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, 
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Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G,Tavakkoli M, Taylor HR, 
Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, 
Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C,Undurraga EA, van der Werf MJ, 
van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, 
Weatherall DJ, Weinstock MA, Weintraub R,Weisskopf MG, Weissman MM, White 
RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, 
Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK,Zheng ZJ, Zonies D, Lopez AD, 
Murray CJ, AlMazroa MA, Memish ZA. 
BACKGROUND: 
Non-fatal health outcomes from diseases and injuries are a crucial consideration in 
the promotion and monitoring of individual and population health. The Global Burden 
of Disease (GBD) studies done in 1990 and 2000 have been the only studies to 
quantify non-fatal health outcomes across an exhaustive set of disorders at the 
global and regional level. Neither effort quantified uncertainty in prevalence or years 
lived with disability (YLDs). 
METHODS: 
Of the 291 diseases and injuries in the GBD cause list, 289 cause disability. For 
1160 sequelae of the 289 diseases and injuries, we undertook a systematic analysis 
of prevalence, incidence, remission, duration, and excess mortality. Sources 
included published studies, case notification, population-based cancer registries, 
other disease registries, antenatal clinic serosurveillance, hospital discharge data, 
ambulatory care data, household surveys, other surveys, and cohort studies. For 
most sequelae, we used a Bayesian meta-regression method, DisMod-MR, designed 
to address key limitations in descriptive epidemiological data, including missing data, 
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inconsistency, and large methodological variation between data sources. For some 
disorders, we used natural history models, geospatial models, back-calculation 
models (models calculating incidence from population mortality rates and case 
fatality), or registration completeness models (models adjusting for incomplete 
registration with health-system access and other covariates). Disability weights for 
220 unique health states were used to capture the severity of health loss. YLDs by 
cause at age, sex, country, and year levels were adjusted for comorbidity with 
simulation methods. We included uncertainty estimates at all stages of the analysis. 
FINDINGS: 
Global prevalence for all ages combined in 2010 across the 1160 sequelae ranged 
from fewer than one case per 1 million people to 350,000 cases per 1 million people. 
Prevalence and severity of health loss were weakly correlated (correlation coefficient 
-0·37). In 2010, there were 777 million YLDs from all causes, up from 583 million in 
1990. The main contributors to global YLDs were mental and behavioural disorders, 
musculoskeletal disorders, and diabetes or endocrine diseases. The leading specific 
causes of YLDs were much the same in 2010 as they were in 1990: low back pain, 
major depressive disorder, iron-deficiency anaemia, neck pain, chronic obstructive 
pulmonary disease, anxiety disorders, migraine, diabetes, and falls. Age-specific 
prevalence of YLDs increased with age in all regions and has decreased slightly 
from 1990 to 2010. Regional patterns of the leading causes of YLDs were more 
similar compared with years of life lost due to premature mortality. Neglected tropical 
diseases, HIV/AIDS, tuberculosis, malaria, and anaemia were important causes of 




Rates of YLDs per 100,000 people have remained largely constant over time but rise 
steadily with age. Population growth and ageing have increased YLD numbers and 
crude rates over the past two decades. Prevalences of the most common causes of 
YLDs, such as mental and behavioural disorders and musculoskeletal disorders, 
have not decreased. Health systems will need to address the needs of the rising 
numbers of individuals with a range of disorders that largely cause disability but not 
mortality. Quantification of the burden of non-fatal health outcomes will be crucial to 
understand how well health systems are responding to these challenges. Effective 
and affordable strategies to deal with this rising burden are an urgent priority for 
health systems in most parts of the world. 
 
Lancet. 2012;380(9859):2224-60. 
A comparative risk assessment of burden of disease and injury attributable to 67 risk 
factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for 
the Global Burden of Disease Study 2010. 
Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, 
Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim 
AN,Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, 
Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce 
NG,Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, 
Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen 
JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis 
A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding 
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BACKGROUND: 
Quantification of the disease burden caused by different risks informs prevention by 
providing an account of health loss different to that provided by a disease-by-disease 
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analysis. No complete revision of global disease burden caused by risk factors has 
been done since a comparative risk assessment in 2000, and no previous analysis 
has assessed changes in burden attributable to risk factors over time. 
METHODS: 
We estimated deaths and disability-adjusted life years (DALYs; sum of years lived 
with disability [YLD] and years of life lost [YLL]) attributable to the independent 
effects of 67 risk factors and clusters of risk factors for 21 regions in 1990 and 2010. 
We estimated exposure distributions for each year, region, sex, and age group, and 
relative risks per unit of exposure by systematically reviewing and synthesising 
published and unpublished data. We used these estimates, together with estimates 
of cause-specific deaths and DALYs from the Global Burden of Disease Study 2010, 
to calculate the burden attributable to each risk factor exposure compared with the 
theoretical-minimum-risk exposure. We incorporated uncertainty in disease burden, 
relative risks, and exposures into our estimates of attributable burden. 
FINDINGS: 
In 2010, the three leading risk factors for global disease burden were high blood 
pressure (7·0% [95% uncertainty interval 6·2-7·7] of global DALYs), tobacco 
smoking including second-hand smoke (6·3% [5·5-7·0]), and alcohol use (5·5% [5·0-
5·9]). In 1990, the leading risks were childhood underweight (7·9% [6·8-9·4]), 
household air pollution from solid fuels (HAP; 7·0% [5·6-8·3]), and tobacco smoking 
including second-hand smoke (6·1% [5·4-6·8]). Dietary risk factors and physical 
inactivity collectively accounted for 10·0% (95% UI 9·2-10·8) of global DALYs in 
2010, with the most prominent dietary risks being diets low in fruits and those high in 
sodium. Several risks that primarily affect childhood communicable diseases, 
  
327 
including unimproved water and sanitation and childhood micronutrient deficiencies, 
fell in rank between 1990 and 2010, with unimproved water and sanitation 
accounting for 0·9% (0·4-1·6) of global DALYs in 2010. However, in most of sub-
Saharan Africa childhood underweight, HAP, and non-exclusive and discontinued 
breastfeeding were the leading risks in 2010, while HAP was the leading risk in south 
Asia. The leading risk factor in Eastern Europe, most of Latin America, and southern 
sub-Saharan Africa in 2010 was alcohol use; in most of Asia, North Africa and 
Middle East, and central Europe it was high blood pressure. Despite declines, 
tobacco smoking including second-hand smoke remained the leading risk in high-
income north America and western Europe. High body-mass index has increased 
globally and it is the leading risk in Australasia and southern Latin America, and also 
ranks high in other high-income regions, North Africa and Middle East, and Oceania. 
INTERPRETATION: 
Worldwide, the contribution of different risk factors to disease burden has changed 
substantially, with a shift away from risks for communicable diseases in children 
towards those for non-communicable diseases in adults. These changes are related 
to the ageing population, decreased mortality among children younger than 5 years, 
changes in cause-of-death composition, and changes in risk factor exposures. New 
evidence has led to changes in the magnitude of key risks including unimproved 
water and sanitation, vitamin A and zinc deficiencies, and ambient particulate matter 
pollution. The extent to which the epidemiological shift has occurred and what the 
leading risks currently are varies greatly across regions. In much of sub-Saharan 




Lancet. 2012;380(9859):2197-223.  
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 
1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. 
Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, 
Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal 
R,Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson 
C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basáñez MG, 
Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov 
B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F,Bolliger I, 
Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, 
Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello 
C,Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, 
Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson 
F,Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, 
Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro 
KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, 
Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt 
L,Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, 
Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, 
Ebel B,Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan 
SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fèvre EM, Finucane 
MM,Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Fransen M, 
Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari 
F,Gillum RF, Gmel G, Gonzalez-Medina D, Gosselin R, Grainger R, Grant B, 
  
329 
Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall 
W,Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen 
B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James 
SL,Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, 
Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye 
O,Koranteng A, Krishnamurthi R, Laden F, Lalloo R, Laslett LL, Lathlean T, Leasher 
JL, Lee YY, Leigh J, Levinson D, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE,Liu 
W, Loane M, Ohno SL, Lyons R, Mabweijano J, MacIntyre MF, Malekzadeh R, 
Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB,Marks R, 
Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, 
McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR,Meyer AC, 
Miglioli V, Miller M, Miller TR, Mitchell PB, Mock C, Mocumbi AO, Moffitt TE, Mokdad 
AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L,Mori R, Murdoch 
ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, 
Nevitt MC, Newton CR, Nolte S, Norman P, Norman R,O'Donnell M, O'Hanlon S, 
Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian 
JD, Rivero AP, Patten SB, Pearce N, Padilla RP,Perez-Ruiz F, Perico N, Pesudovs 
K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA 3rd, 
Popova S, Porrini E, Pourmalek F, Prince M,Pullan RL, Ramaiah KD, Ranganathan 
D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, 
Roberts T, Robinson C, De Leòn FR,Ronfani L, Room R, Rosenfeld LC, Rushton L, 
Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott 
JG, Segui-Gomez M, Shahraz S,Shepard DS, Shin H, Shivakoti R, Singh D, Singh 
GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, 
  
330 
Steer A, Steiner T, Stolk WA,Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli 
M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, 
Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga 
EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, 
Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, 
Weissman MM, White RA, Whiteford H, Wiebe N, Wiersma ST, Wilkinson JD, 
Williams HC, Williams SR, Witt E,Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, 
Zheng ZJ, Zonies D, Lopez AD, AlMazroa MA, Memish ZA. 
BACKGROUND: 
Measuring disease and injury burden in populations requires a composite metric that 
captures both premature mortality and the prevalence and severity of ill-health. The 
1990 Global Burden of Disease study proposed disability-adjusted life years (DALYs) 
to measure disease burden. No comprehensive update of disease burden worldwide 
incorporating a systematic reassessment of disease and injury-specific epidemiology 
has been done since the 1990 study. We aimed to calculate disease burden 
worldwide and for 21 regions for 1990, 2005, and 2010 with methods to enable 
meaningful comparisons over time. 
METHODS: 
We calculated DALYs as the sum of years of life lost (YLLs) and years lived with 
disability (YLDs). DALYs were calculated for 291 causes, 20 age groups, both sexes, 
and for 187 countries, and aggregated to regional and global estimates of disease 
burden for three points in time with strictly comparable definitions and methods. 
YLLs were calculated from age-sex-country-time-specific estimates of mortality by 
cause, with death by standardised lost life expectancy at each age. YLDs were 
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calculated as prevalence of 1160 disabling sequelae, by age, sex, and cause, and 
weighted by new disability weights for each health state. Neither YLLs nor YLDs 
were age-weighted or discounted. Uncertainty around cause-specific DALYs was 
calculated incorporating uncertainty in levels of all-cause mortality, cause-specific 
mortality, prevalence, and disability weights. 
FINDINGS: 
Global DALYs remained stable from 1990 (2·503 billion) to 2010 (2·490 billion). 
Crude DALYs per 1000 decreased by 23% (472 per 1000 to 361 per 1000). An 
important shift has occurred in DALY composition with the contribution of deaths and 
disability among children (younger than 5 years of age) declining from 41% of global 
DALYs in 1990 to 25% in 2010. YLLs typically account for about half of disease 
burden in more developed regions (high-income Asia Pacific, western Europe, high-
income North America, and Australasia), rising to over 80% of DALYs in sub-
Saharan Africa. In 1990, 47% of DALYs worldwide were from communicable, 
maternal, neonatal, and nutritional disorders, 43% from non-communicable diseases, 
and 10% from injuries. By 2010, this had shifted to 35%, 54%, and 11%, 
respectively. Ischaemic heart disease was the leading cause of DALYs worldwide in 
2010 (up from fourth rank in 1990, increasing by 29%), followed by lower respiratory 
infections (top rank in 1990; 44% decline in DALYs), stroke (fifth in 1990; 19% 
increase), diarrhoeal diseases (second in 1990; 51% decrease), and HIV/AIDS (33rd 
in 1990; 351% increase). Major depressive disorder increased from 15th to 11th rank 
(37% increase) and road injury from 12th to 10th rank (34% increase). Substantial 




Global disease burden has continued to shift away from communicable to non-
communicable diseases and from premature death to years lived with disability. In 
sub-Saharan Africa, however, many communicable, maternal, neonatal, and 
nutritional disorders remain the dominant causes of disease burden. The rising 
burden from mental and behavioural disorders, musculoskeletal disorders, and 
diabetes will impose new challenges on health systems. Regional heterogeneity 
highlights the importance of understanding local burden of disease and setting goals 
and targets for the post-2015 agenda taking such patterns into account. Because of 
improved definitions, methods, and data, these results for 1990 and 2010 supersede 
all previously published Global Burden of Disease results. 
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BACKGROUND: 
Measurement of the global burden of disease with disability-adjusted life-years 
(DALYs) requires disability weights that quantify health losses for all non-fatal 
consequences of disease and injury. There has been extensive debate about a 
range of conceptual and methodological issues concerning the definition and 
measurement of these weights. Our primary objective was a comprehensive re-
estimation of disability weights for the Global Burden of Disease Study 2010 through 
a large-scale empirical investigation in which judgments about health losses 
associated with many causes of disease and injury were elicited from the general 
public in diverse communities through a new, standardised approach. 
METHODS: 
We surveyed respondents in two ways: household surveys of adults aged 18 years 
or older (face-to-face interviews in Bangladesh, Indonesia, Peru, and Tanzania; 
telephone interviews in the USA) between Oct 28, 2009, and June 23, 2010; and an 
open-access web-based survey between July 26, 2010, and May 16, 2011. The 
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surveys used paired comparison questions, in which respondents considered two 
hypothetical individuals with different, randomly selected health states and indicated 
which person they regarded as healthier. The web survey added questions about 
population health equivalence, which compared the overall health benefits of 
different life-saving or disease-prevention programmes. We analysed paired 
comparison responses with probit regression analysis on all 220 unique states in the 
study. We used results from the population health equivalence responses to anchor 
the results from the paired comparisons on the disability weight scale from 0 
(implying no loss of health) to 1 (implying a health loss equivalent to death). 
Additionally, we compared new disability weights with those used in WHO's most 
recent update of the Global Burden of Disease Study for 2004. 
FINDINGS: 
13,902 individuals participated in household surveys and 16,328 in the web survey. 
Analysis of paired comparison responses indicated a high degree of consistency 
across surveys: correlations between individual survey results and results from 
analysis of the pooled dataset were 0·9 or higher in all surveys except in Bangladesh 
(r=0·75). Most of the 220 disability weights were located on the mild end of the 
severity scale, with 58 (26%) having weights below 0·05. Five (11%) states had 
weights below 0·01, such as mild anaemia, mild hearing or vision loss, and 
secondary infertility. The health states with the highest disability weights were acute 
schizophrenia (0·76) and severe multiple sclerosis (0·71). We identified a broad 
pattern of agreement between the old and new weights (r=0·70), particularly in the 
moderate-to-severe range. However, in the mild range below 0·2, many states had 




This study represents the most extensive empirical effort as yet to measure disability 
weights. By contrast with the popular hypothesis that disability assessments vary 
widely across samples with different cultural environments, we have reported strong 
evidence of highly consistent results. 
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OBJECTIVE: 
To assess the pain and functional disability levels corresponding to an indication for 
total joint replacement (TJR) in hip and knee osteoarthritis (OA). 
METHODS:  
DESIGN: 




Consecutive outpatients with definite hip or knee OA attending an orthopaedic 
outpatient clinic. Gold standard measure for recommendation for TJR: Surgeon's 
decision that TJR is justified. 
OUTCOME MEASURES: 
Pain (ICOAP: intermittent and constant osteoarthritis pain, 0-100) and functional 
impairment (HOOS-PS/KOOS-PS: Hip/Knee injury and Osteoarthritis Outcome 
Score Physical function Short-form, 0-100). 
ANALYSES: 
Comparison of patients with vs without surgeons' indication for TJR. Receiver 
Operating Characteristic (ROC) curve analyses and logistic regression were applied 
to determine cut points of pain and disability defining recommendation for TJR. 
RESULTS: 
In all, 1909 patients were included (1130 knee/779 hip OA). Mean age was 66.4 
[standard deviation (SD) 10.9] years, 58.1% were women; 628/1130 (55.6%) knee 
OA and 574/779 (73.7%) hip OA patients were recommended for TJR. Although 
patients recommended for TJR (yes vs no) had worse symptom levels [pain, 55.5 
(95% confidence interval 54.2, 56.8) vs. 44.9 (43.2, 46.6), and functional impairment, 
59.8 (58.7, 60.9) vs. 50.9 (49.3, 52.4), respectively, both P<0.0001], there was 
substantial overlap in symptom levels between groups, even when adjusting for 
radiographic joint status. Thus, it was not possible to determine cut points for pain 




Although symptom levels were higher in patients recommended for TJR, pain and 
functional disability alone did not discriminate between those who were and were not 
considered to need TJR by the orthopaedic surgeon. 
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The prevalence of osteoporosis is expected to increase with the ageing of the world's 
population. This article reviews the epidemiology, risk factors and health burden of 
osteoporosis. In the Global Burden of Disease (GBD) Study 2005, osteoporosis is 
studied as a risk factor for fracture by considering the bone-mineral-density (BMD) 
measurement as the continuous exposure variable. We have performed a systematic 
review seeking population-based studies with BMD data measured by dual-X-ray 
absorptiometry (DXA). The femoral neck was selected as the unique location and all 
values were converted into Hologic(®) to enable inclusion of worldwide data for 
analysis. Provisional results on mean BMD values for different world regions are 
shown in age breakdowns for males and females 50 years or over, as well as mean 
T-scores using the young, white, female reference of National Health and Nutrition 
Examination Survey (NHANES) III. Results show remarkable geographical 
differences and a time trend towards improvement of the BMD values in Asian and 
European populations. 
 
